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SUMMARY
i \  Using in situ hybridisation, Tau 1 and Tau 2 gene expression has 
been studied in adult and neonatal rats in the basal forebrain and 
hippocampal regions. Tau 1 mRNA levels are significantly higher in 
the neonatal (gestation day 17) rats, with Tau 2 mRNA levels being 
significantly higher in the adult rats (Chapter 3).
2\ Using in situ hybridisation, Tau 1 and Tau 2 gene expression in the 
basal forebrain and hippocampal regions has been studied in adult rats 
in response to intraperitoneal administration of the following 
compounds: ondansetron (lOOng/kg), MK801 (1 mg/kg), GYKI52466 
(30mg/kg), indomethacin (5mg/kg) and aniracetam (lOmg/kg). None 
of the compounds cause a significance change in either Taul or Tau 2 
mRNA levels after a 24 hour period (Chapter 3).
3\ Glial cell cultures have been used to study the distribution and 
expression of NADPH diaphorase expression in response to exposure 
of the cells to cytokines, excitatory amino acid agonists and proteases. 
The ghal cultures have been characterised by positive staining to ghal 
fibrillary acidic protein and NADPH diaphorase. Points 3-5 
summarise the work cairied out using these cultures (Chapter 4). 
Lipopoly s acchai ide (100|ig/ml) significantly increases NADPH 
diaphorase staining. A maximum induction is observed after a 6  hour 
time period. Interleukin-1 (0.25ng/ml) also significantly increases 
NADPH diaphorase staining, and again maximum induction occurs 
after a 6  hour time period. The lipopolysaccharide-induced increase in 
NADPH diaphorase staining remains unaltered following combined 
exposure of the cells to lipopolysaccharide ( 1 0 0 |Xg/ml ) and the 
calmodulin anatgonist W7 (400|xM).
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4\ The excitatory amino acid agonists glutamate (50|lM), AMP A 
(50|ulM) and NMDA (50|LiM and 100|lM) significantly increase 
NADPH diaphorase staining. This induction occurs after a 24 hour 
time period. The inhibitors APV (100|xM) and CNQX (lOOfxM) 
reduce the glutamate and AMPA-induced increase in NADPH 
diaphorase staining to near control values, again after a 24 hour time 
period. The glutamate-induced increase in NADPH diaphorase 
staining is reduced following combined exposure of the cells to 
glutamate (50p,M) and the calmodulin antagonist W7 (400jiM)
5\ Exposure of the cells to the proteases a-chymotiypsin (300ng/ml) 
and trypsin (500ng/ml) increase NADPH diaphorase staining. This 
induction occurs after a 24 hour time period.This increase is reduced 
to neai" control levels following combined exposure of the cells to the 
proteases and their respective inhibitors chymostatin (lOOpM) and 
trypsin inhibitor (Ijig/ml), again after a 24 hour time period.
6 \  Basal forebrain primaiy cultures have been used to study the 
distribution and expression of cytoskeletal proteins and NADPH 
diaphorase staining following exposure of the cells to nitric oxide, 
excitatory amino acid agonists and cytokines. The cells have been 
characterised by positive immunostaining to choline acetyitransferase 
(ChaT), neuron specific enolase, neurofilament and microtubule- 
associated protein 2 (MAP2). Points 6-10 summarise the work carried 
out using these cultures (Chapter 5).
A Nerve growth factor (200ng/ml) significantly increases ChaT and 
MAP2 immunoreactivity after a 4 day period, with no significant 
effect on tau immunostaining. MAP2 gene expression can also be 
induced following 24 hour exposure to nerve growth factor 
(200ng/ml). Exposure of the cultures to nerve growth factor 
(200ng/ml) also significantly increases NADPH diaphorase staining,
XU
xm
and neuron specific enolase immunostaining, after a 24 hour time 
period. Pretreatment with dexamethasone (l|xM) reduces the nerve 
growth factor-induced increase in MAP2 immunoreactivity to near 
control values, as does the nitric oxide scavenger haemoglobin 
(20|LiM). The calmodulin antagonist W7 (400|liM) reduces the nerve 
growth factor-induced increase in MAP2 immunoreactivity to near 
control values.
S\ Glutamate (50|liM) increases NADPH diaphorase staining in the 
neuronal cultures following exposure over a 24 hour time period. W7 
does not alter the glutamate-induced increase. The non-NMDA 
receptor agonist kainate (10|lM) significantly increases MAP2 
immunoreactivity and MAP2 gene expression after a 24 hour time 
period. The compound has no significant effects on tau 
immunoreactivity. The metabotropic receptor agonist ACPD does not 
alter tau or MAP2 immunoreactivity.
9\The nitric oxide releasing compounds SNP (50|aM), SNAP (50jlM) 
and SIN-1 (50|xM) significantly increase MAP2 immunoreactivity 
after a 24 hour time period. The compounds caused no significant 
effects on tau or NSE immunoreactivity. The increase in MAP2 
immunoreactivity is reduced to near control values following 
combined exposure of the cells to SNAP (50p.M) and haemoglobin 
(20jLiM), and, is mimicked by the cyclicGMP analogue 
SbromocyclicGMP (20[xM). Neither nerve growth factor (200ng/ml) 
or the nitric oxide releasers cause any detectable effect on neuronal 
cell morphology.
I
I0 \ Exposure of the cells to lipopolysaccharide (100|Llg/ml) and 
interleukin-1 (0.25ng/ml) causes no significant effect on amyloid 
precursor protein or cyclooxygenase immunoreactivity after a 24 hour 
time period.
11\ Studies of brain sections taken form two transgenic mice models 
models had enabled a preliminary investigation into the possible 
role(s) of amyloid precursor protein within the CNS. Complete 
removal of the amyloid precursor protein gene results in a dramatic 
onset of reactive gliosis in mice at 6  months of age compared to age 
matched control animals. At 13 months of age, the age matched 
control animals possess a significantly higher level of reactive 
astrocytes. The calcium-binding protein calbindin is significantly 
increased in the amyloid precursor protein-null mice at 13 months of 
age compared to age matched controls, and levels of synaptophysin 
and MAP2 remain unaltered in the null mice compared to age matched 
controls. A study of presenilin-1 expression and distribution in the null 
and wildtype animals reveals membrane bound immunoreactivity using 
an antibody directed against the N terminus. Immunoreactivity using 
an antibody directed against the C terminus reveals a cytoplasmic 
distribution. No difference in presenilin-1 levels occur in the null mice 
compared to the age matched controls in cortical and hippocampal 
regions. There is the possibility that the null mice at 6  months of age 
have an increase in cerebellar presenilin- 1  levels compared to age 
matched control animals. Animals with a mutated a-secretase site on 
amyloid precursor protein display a marked increase in reactive gliosis 
at 6  months of age compared to age matched control animals 
(Chapter 6).
12\ An initial study of postmortem brain tissue from Alzheimer’s 
Disease patient and age matched control reveals a dramatic increase in 
reactive gliosis and AT8  immunostaining within the diseased tissue. A 
significant level of colocalisation between plaques and tangles and 
presenilin-1 appears in some areas of diseased brain tissue (Chapter 
7).
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Chapter 1
INTRODUCTION
1
1.2 Neuropathology of Alzheimer's Disease
Alzheimer's Disease patients. Specifically, two microscopic deposits 
originally described by Alois Alzheimer in 1907 are observed: the 
neurofibrillary tangle and the senile plaque. As will be discussed in 
more detail in Section 1.3.1, the classic senile plaque of Alzheimer’s 
Disease is a complex lesion of the cortical neuropil containing several
1,1 Alzheimer's Disease
Alzheimer's Disease was first reported in 1907 by Alois 
Alzheimer (Alzheimer., 1907). It is now recognised as the fourth 
leading cause of death in the developed world with an estimated 17-25 
million sufferers world-wide. Its profound morbidity has stimulated 
research into therapeutic strategies aimed at alleviation and ultimately 
prevention of the disorder. At autopsy, the Alzheimer's Disease brain 
is characterised by a number of important pathological changes. First, 
there is a dramatic loss of neurons and synapses in many areas of the 
central nervous system. Researchers have found a loss of brain tissue 
in patients to be 30 times as fast as age matched controls. This tissue 
loss is thought to start in the regions involving higher cognitive 
function such as the hippocampus, and the disease can be clearly seen 
as a qualitatively different process from normal ageing (Simic et 
ah, 1997). Secondly, many neurotransmitters are reduced including 
acetylcholine, noradrenalin, serotonin, dopamine, glutamate and 
substance P (Davis et ah, 1980; Iversen et ah, 1983; Kowall and 
Beal.,1988). This dramatic and global reduction of many 
neurotransmitters and the profound tissue loss accounts for the broad 
clinical manifestations of the disease that include memory impairment, 
hallucinations, paranoia, restlessness, depression, aggression, aphasia, 
apraxia and personality disorders. Molecular and biochemical 
techniques as well as the recent development of animal models have 
contributed greatly in the search for understanding of the pathological 
processes in the disease. There is now strong reason to hope that 
drugs directed at the disease neuropathology will be able to greatly 
reduce or halt the cognitive decline and suffering of the Alzheimer's 
Disease patient.
Unique pathological lesions are found in the brains of
abnormal elements. It consists of a central deposit of extracellular 
amyloid fibrils (the core) surrounded by dystrophic neurites, activated 
microglia and fibrillary astrocytes. As will also be discussed in more 
detail in Section 1.5.2, the principal structural feature of tangles is the 
paired helical filament which is comprised mainly of abnormally 
phosphorylated isoforms of tau protein. Neurofibrillary tangle (NFT) 
formation and synaptic loss have been correlated with the degree of 
cognitive deficits in the disease (Arriagada et a l, 1992; DeKosky et 
al., 1990).
The regions most affected by neuron loss, synaptic dysfuntion 
and, neurofibrillary tangle (NFT) and plaque formation are the basal 
forebrain cholinergic system, amygdala, hippocampus and neocortex. 
Dysfunction and death of these neurons leads to reduction in synaptic 
inputs and deafferentation of targets predominantly in the amygdala, 
hippocampus and neocortex (Whitehouse et a l, 1982; Ai'nold et 
al, 1991; Terry et al.,1991). The basai nucleus of Meynert and the 
diagonal band nucleus provide the major source of cholinergic input to 
the cerebral cortex and hippocampus, and a reduction in the number 
of cholinergic neurons in these structures by two thirds has been 
reported (Arendt et a l ,1985; Nagai et a l, 1983; Lehman et a l ,1980).
The degeneration process in Alzheimer's Disease is a 
complicated pathway. Over the last ten years, many key experiments 
have helped to unfold some of the complexities underlying the disease, 
and there is much scope for further research.
1.3 The amyloid plaque
1.3.1 Introduction
The senile plaque first described by Alois Alzheimer was 
isolated by Glenner and coworkers (Glenner and Wong., 1984). They 
found it to be composed of a 4kDa peptide that aggregates into a 
fibrillar p-pleated structure, and named this peptide amyloid. Amyloid 
peptide (Ap) is a 40-42 amino acid residue protein. Aggregated Ap 
deposits appear green under polarised or fluorescent light after 
staining with Congo red. It is this classic staining that has come to 
characterise amyloid deposits. It has been known since 1968 that the 
density of senile plaques found in Alzheimer's Diseased brains 
correlates with the severity of clinical dementia (Blessed et al., 1968). 
Senile plaques are typically 50p.m in diameter and possess a central 
deposit of extracellular amyloid fibrils (the core) which is surrounded 
by dystrophic neurites, activated microglia and reactive astrocytes. 
Two types of plaque have been described. The classic senile or 
neuritic plaques consist of fibrillar, congophilic Ap deposits that are 
associated with dystrophic and degenerating neurites. Due to their p- 
pleated nature, these plaques stain with Congo red or thioflavin. The 
second type of plaque are the diffuse or preamyloid plaques. These 
consist of amorphous, noncongophilic AP deposits that are not 
associated with significant neuronal pathology.
Ap has been hypothesised to be causally related to Alzheimer's 
Disease. The 'Ap hypothesis' states that excess deposition of Ap in the 
brain somehow can lead to neurodegenerative changes and eventually 
to dementia. The evidence is as follows. First, Ap deposition is the 
earliest neuropathological marker in Alzheimer's Disease, and also in 
related disorders such as Down's Syndrome, where it can precede 
neurofibrillary tangle formation by two to three decades (Mann et al., 
1992). Ap deposition is relatively specific to Alzheimer's and related 
disorders (Selkoe et al., 1993). Ap is toxic to cultured neurons and 
cell lines (Mattson .,1992; Yankner et al., 1990). Finally, as is 
discussed in Section 1.4.6, mutations in the Ap precursor APP gene 
cause early onset familial Alzheimer's Disease. Collectively, these facts 
strongly implicate Ap deposition in the neuropathology of the disease. 
However, there has been much research into the time course of events
that occur in Alzheimer's Disease and a key question is which process 
triggers the Alzheimer's cascade of events. It has also been argued that 
only a small percentage of Alzheimer's Disease cases resulting from 
mutations of APP are attributable to excess Ap production (Cai et 
ah,1993; Felsenstein et al.,1993).
1.3.2 Ap production and aggregation
The production of Ap is discussed in detail in Section 1.4.4; AP 
has been shown to be a product of normal cellular metabolism and has 
been detected in media from a wide variety of cultured cells as well as 
in human cerebrospinal fluid (Haass et a l, 1992; Seubert et al., 1992; 
Shoji et al.,1992; Busciglio et al.,1993). It is possible that abnormal 
accumulation of Ap in Alzheimer’s Disease results from events that 
slow down its degradation and removal. The normal mechanism(s) of 
degradation is not known, although it is thought that proteolysis by 
extracellular enzymes and /or catabolism following cellular uptake are 
likely candidates. One possible reason that amyloid is so robust in 
plaques is that it is resistant to enzymatic or cellular degradation. In 
Alzheimer's Disease, an altered balance may occur, whereby the ratio 
of AP degradation to synthesis is altered as a result of enhanced AP 
release or decreased AP removal,
Ap aggregates to form insoluble, fibrillar extracellular deposits, 
the main constituent of plaques. Ap toxicity requires the peptide to be 
present in the form of an amyloid aggregate. Indeed, amyloid is a 
generic term used to describe a class of otherwise unrelated peptides 
which under physiological conditions aggregate to form insoluble 
filaments. Many studies have investigated the mechanisms of and 
factors affecting aggregation, and I will discuss some but not all of the 
work. Fibril formation has been described as a build up of a one­
dimensional crystal with non-uniform growth occurring in planes 
perpendicular to the axis of elongation (Lansbury et al., 1992), The C- 
terminus of the amyloid protein has been thought to be crucial to 
aggregation. Neuritic and cerebrovasculai’ plaques are composed of 
variants of Ap differing at their C-termini (Joachim et a l, 1988; Prelli 
et al.,1988). Neuritic plaques contain mainly P(l-42) (Roher et 
al., 1993). The following are some of the elements thought to effect A 
P aggregation. First, the aggregation rates and fibril morphologies of
1.3.3 Inflammatory mechanisms and Ap
Ap and related peptides in vitro are thought to be pH-dependent
(Terse et al.,1994). Secondly, metal ions have been studied. Ever
_since the observation that aluminium is present as aluminosilicates in 
plaques and tangles, (Candy et al., 1986), exposure to the metal has 
been considered a risk factor for the disease. Assays in vitro have 
demonstrated that aluminium can cause Ap(l-40) to aggregate 
(Kawahara et al., 1994). Finally, free radicals and other covalent 
modifications of Ap have been implicated in its aggregation process.
In addition to the classical neuronal pathology associated with 
Alzheimer's Disease, there is growing evidence that chronic 
inflammatory processes contribute to the pathogenesis of the disease. 
A variety of inflammatory proteins have been found in Alzheimer's 
post mortem tissue. Numerous immunohistochemical studies have 
identified proinflammatory cytokines such as interleukin- 1 and 
interleukin- 6  (Sheng et al.,1995), complement proteins such as C lq 
and C4 (Ishii et ai., 1992), and acute phase proteins such as a l -  
chymotrypsin (Abraham et al., 1988) in senile plaques. Evidence 
suggests that immobilised Ap can activate the classical complement 
cascade by an immunoglobulin-dependent pathway through binding to 
Clq, the first component of the C l complex(Rogers et al., 1992). 
Rogers and coworkers also suggested that the Ap-Clq binding 
interactions require aggregated rather than monomeric Ap.
Additional evidence to support a chronic inflammatoiy state 
associated with Alzheimer's Disease is the finding that there is an 
unexpectedly low prevalence of the disease in patients with 
rheumatoid arthritis (McGeer et al., 1992). This is discussed in more 
detail in Section 1 . 1 0 . 1 .
1.3.4 Proteins associated with Ap
Another possible explanation for the persistence of Ap within 
plaques is its association with other plaque components. Cells found in 
the vicinity of senile deposits release factors such as proteoglycans 
(Snow et al., 1988; Su et al., 1992), a-chymotiypsin (Pasternack et 
al.,1989) and apolipoprotein E (Strittmatter et al.,1994; Strittmatter et
"1
a l, 1995) that can bind to Ap. Interestingly, proteoglycans may be of 
particular relevance to Ap accumulation since these glycoconjucates 
aie an invariable feature of all amyloidogenic deposits (Snow et 
al., 1989). Recent work shows that AP can be catabolized by microglia 
and proteoglycans which co-localize with senile plaques and may slow 
down the degradation of AP (Shaffer et al, 1995).
1.4. Amyloid precursor protein
1.4.1 Introduction
Senile plaques can be found in the brain of normal elderly 
patients but accumulate greatly in subjects with Alzheimer's Disease. 
This extracellular' deposit is composed mainly of A(3. As mentioned 
previously, Ap is derived from a precursor, the amyloid precursor 
protein (APP). APP possesses the structure of a transmembrane 
protein, with the Ap sequence partly embedded in the membrane 
domain. The structural organisation of APP is shown in Figure 1.
1.4.2IsoformsofAPP
Several APP isoforms can be generated by alternative splicing of 
a single gene located on chromosome 21. The three major isoforms of 
APP are those of 695, 751 and 770 amino acids. The 751 and 770 
isoforms contain an N-terminal Kunitz protease inhibitor domain and 
are expressed in both neural and non-neural tissues (Kitaguchi et al ., 
1988; Ponte et a l, 1988; Tanzi et al, 1988). The 695 amino acid 
isoform is expressed at high levels in neurons, where it undergoes 
retrograde and anterograde axonal transport, and transcytosis (Koo et 
al,. 1990; Yamazaki et a l, 1995).
After synthesis, APP undergoes post-translational modifications 
that include signal peptide removal, N-glycosylation, sulphation of 
tyrosine residues, phosphorylation and proteolytic cleavage (Ghiso et 
al.,1989; Buxhaum et al.,1990; Oltersdorf et a l, 1990; Dyrks et al., 
1988). The cleavage processes aie discussed in further detail in 
section 1.4.4.
1.4.3 APP-like proteins
Two other mammalian proteins that are highly homologous to 
APP have been cloned: APLPl and APLP2 (Wasco et al., 1992; Slunt 
etal, 1994). This suggests that APP is a member of a multigene 
family.
.Several lines of evidence suggest that APP and its metabolism 
play an important role in the pathogenesis of Alzheimer's Disease, 
particularly the occurrence of familial forms of Alzheimer's Disease 
that are linked to mutations in the APP gene located on chromosome 
21, (Clark and Goate.,1993), and to a lesser extent, the fact that 
Down's Syndrome , which is due to trisomy 21, comprises 
Alzheimer's-like pathology including the deposition of A|3.Cells which 
produce a mutant from of APP (APPANL) , recently linked to familial 
Alzheimer's Disease, secrete six times more pA4 into the medium than 
wildtype cells (1993, Citron et a l, 1992). It has also been 
demonstrated that cells producing a mutant APP (mutant form of 
APP717 protein) release a larger proportion of the longer from of Ap 
(41 amino acids) which possesses a greater ability to form amyloid 
fibrils than the shorter form (Suzuki et a l, 1994). It has also been
shown that some forms of famihal Alzheimer's Disease are linked to a i:
variety of these genes and these are discussed in Section 1.9.
1.4.4 Ap generation from APP
APP is the only member of its gene family that contains the Ap 
domain and can thus give rise to the amyloidogenic derivative. The 
precise mechanism of AP generation has been the focus of many 
studies and it is thought that several pathways exist. The first pathway 
results in the generation of non-amyloidogenic products. As shown in 
Figure 1, several cleavages can occur in the vicinity of the Ap 
sequence. The breakdown elicited by a-secretase occurs within the A 
p sequence thus preventing the formation of amyloidogenic 
products.This enzyme generates an N-terminal fragment APP and its 
C-terminal counterpart of 10-1 IkDa which remains embedded in the 
membrane (Esch et a l, 1990;Anderson et a l, 1991; Sisodia et a l, 
1992; Seubert et a l, 1993). The 10-1 IkDa counterpart (sometimes 
referred to as plO) may undergo an additional cleavage leading to the 
formation of p3 and its complementary product p7 (Haass et a l, 1992; 
Busciglio et a l, 1993). Thus the a-secretase pathway precludes the 
formation of APP derivatives bearing potentially amyloidogenic 
properties. It should be noted at this stage that other minor non- 
amyloidogenic cleavages have been described such as that reported in 
monkey fibroblast CV-1 cells (Zhong et a l, 1994).
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All of the potentially amyloidogenic products generated from 
APP contain the full AP sequence. Two main pathways generate 
amyloidogenic products. The first involves a p secretase enzyme. This 
generates C-terminal products that contain the whole AP sequence 
near or at their N-terminus (Haass et al., 1992). The N-terminal 
fragment that derives from P secretase cleavage has been detected as a 
secretion product of human mixed brain cells (Seubert et al., 1993).
The second amyloidogenic-generating pathway involves y secretase, 
and results in the production of APP species lengthened at their C- 
terminus by Ap. This pathway has been demonstrated in neuronal 
PC I2 cells and in human kidney cells (Abderson et al., 1994).
However, this generation has been debated as a study performed with 
control and Alzheimer's Disease brains failed to detect such secretory 
soluble derivatives containing a complete C-terminal Ap sequence 
(Pasternack et al., 1992). The formation of Ap requires the sequential 
action of P and y secretases.
Several studies have looked at possible candidates for the 
secretases involved in Ap production. Cathepsins G and B have been 
postulated as P secretase candidates (Sahasrabudhe et al., 1993;
Dreyer et al., 1994). In addition, Sahasrabudhe and coworkers 
(Sahasrabudhe et al.,1994) also demonstrated that a-chymotrypsin 
could display P secretase-like activity. Schonlein and coworkers have 
reported on the purification and characterisation of a metalloprotease 
from human brain (Schonlein et al.,1994). The multicatalytic 
proteinase complex appears to display a p secretase-like activity 
(Ishiura et a l, 1989) but can also hydrolyze model peptides thought to 
behave as y secretase substrates (Mundy et a l, 1994).
Two more possible pathways of Ap generation exist. In the 
endosomal-lysosomal pathway, some cell surface APPs are 
reinternalised (Haass et a l, 1992), and cleaved at the N-terminus of 
the PA4 sequence by p secretase to produce potentially amyloidogenic 
C-terminal fragments (Golde et a l, 1992), and subsequently cleaved 
by X secretase to release soluble 4kDa Ap (Koo et a l, 1994). The 
identification of APP within clatlnin coated vehicles in PC 12 cells is 
consistent with utilisation of this pathway (Nordstedt et a l, 1993).
However, it is unclear whether a direct targeting pathway to the 
endosomal/lysosomal system without trafficking via the cell surface 
exists (Sinha et a l, 1992). It has recently been shown that signals
I
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within the cytoplasmic domain mediate APP internalisation (Koo et 
al., 1994) In addition to this reinternalised pathway, a pathway that 
targets APP from the trans-Golgi network directly to endosomes and 
lysosomes is thought to exist (Haass et al., 1993).
1.4.5 Physiological roles of APP
The physiological role of APP is not well understood, despite 
many studies. The secreted form of APP (APPs) can function as an 
autocrine factor to stimulate cell proliferation (Saitoh et al., 1989), 
and can promote cell-substratum adhesion possibly through an 
interaction with laminin (Kibbey et al., 1993). APPs also appears to 
mediate the neurite outgrowth response of PC 12 cells to nerve growth 
factor (Milward et al., 1992). APPs containing a region homologous 
to the Kunitz type protease inhibitor sequence are thought to have a 
role in the regulation of extracellular protease activity (Oltersdorf et 
al., 1989) and are endocytosed by the low density lipoprotein receptor 
protein (Kounnas et al., 1995). A possible in vivo function of APP has 
been suggested by the discovery that APP is a very potent inhibitor of 
the complexes involved in the regulation of the coagulation cascade 
(Smith et al., 1990, Van No strand et al., 1990a; Van Nostrand et 
al., 1990b). The regulation of APP binding to collagen typel by 
heparin and the mapping of the binding sites of APP to collagen typel 
has recently been demonstrated (Beher et al., 1996).
1.4.6 APP mutations
Many interesting studies have been caiiied out investigating the 
effects of mutation to the APP gene on the processing of Ap. Several 
familial forms of Alzheimer's Disease have been described that are 
linked to various mutations located on the APP gene, and these are 
discussed in Section 1.9. A vast literature covers the effects of APP 
mutations, most notably a Swedish kindred develops a Alzheimer’s 
Disease phenotype that results in over production of Ap and a 
decreased production of non amyloidogenic p3 (Citron et al.,1992). 
Several mutations thought to be responsible for early onset familial 
Alzheimer’s Disease have been identified on APP near the C terminal 
end of the AP sequence. However, these mutations are not thought to
11
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greatly alter the overall production of AP (Tanzi et ah, 199la; Tanzi et 
al., 1991b; Mullan and Crawford., 1993).
1.4.7 Transgenic models
Alzheimer's Disease is a uniquely human disease and for this 
reason the lack of an animal model has hampered research. Recently, 
several transgenic animal models with mutated APP have been 
developed and these are discussed in more detail in Chapter 6 .
■i
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Figure 1 The structural organisation of APP.
The drawing represents the structural organisation of APP7 5 1 .
Kunitz protease inhibitor (KPI) and Ap sequences are boxed. Dashed 
lines represent the transmembrane (TM).
Illustration taken from Checler., 1995, Figure 1 .
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1.5 Microtubule-Associated Proteins
1.5.1 Introduction
Brain microtubules contain a variety of microtubule-associated 
proteins (MAPs) and tubulin. The posttranslational modifications of 
both tubulin and MAPs are believed to be important in the regulation 
of assembly of microtubules (Goedert et al.,1993). MAPs are 
characterised by their ability to promote the assembly and stability of 
microtubules in axons and dendrites, suggesting a major role in the 
determination of neuronal morphology and plasticity. Microtubules 
undergo extensive growth and rearrangement in nerve cells, especially 
during periods of neurite outgrowth. Several brain MAPs have been 
identified that differ in their composition and activity. The two major 
MAPs are MAP2 and tau. MAP2 consists of high molecular weight 
species (MAP2a and MAP2b) and a lower molecular weight species 
(MAP2c). The family of low molecular weight MAPs is represented 
by six isoforms of tau. MAP2 is discussed in detail later. It is worth 
also mentioning two other structural MAPs iMAPlb and MAP4. 
MAP lb is believed to cross link microtubules (Noble et al.,1989). Glia 
also express MAPlb (Diaz-Nido et al.,1989). MAP4 is abundant in a 
variety of cells including oligodendrocytes (Paiysek et al.,1984) and 
contains microtubule binding domains homologous to those of MAP2 
and tau (Olmsted et al.,1986).
1.5.2 Tau Protein
Neurofibrillary tangles (NFTs) and senile plaques are the 
characteristic hallmaiks of Alzheimer's Disease. NFTs constitute the 
intraneuronal deposits. They aie found in the cell bodies and apical 
dendrites, and in the abnormal neurites that are associated with 
amyloid plaques. NFTs develop in those nerve cells that undergo 
degeneration in Alzheimer's Disease. These lesions contain abnoraial 
paired helical filaments (PHFs) as their main fibrous component. PHFs 
consist of two strands of subunits which twist around each other in a 
helical fashion. Their insolubility enables them to survive the deaths of 
the affected cells and remain as 'ghost tangles' that accumulate in the 
neuropil. These aie then engulfed by astrocytes and degraded. Using
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immunochemical and biochemical methods it has been shown that 
NFTs are composed of the microtubule-associated protein tau in an 
abnormal state of phosphorylation (Delacourte et al.,1986; Goedert et 
ah, 1988; Grundke-Iqbal et ah, 1986a; Grundke-Iqbal et al.,1986b; 
Kosik et al.,1986; Wischik et ah, 1988).
Tau is thought to be one of the earliest markers of Alzheimer's 
Disease. Tau protein in the disease is distinct from normal brain tau in 
the following ways: it is aggregated into PHFs which colocalise into 
NFTs. These can be visualised in postmortem tissue 
immunohistochemically. Tau in the disease is modified in several ways 
e.g. by phosphorylation, proteolysis and ubiquitination. During the 
disease process, abnormal tau is thought to spread in a characteristic 
spatial and temporal sequence, starting in selected neurons in the 
entorhinal region. It has recently been suggested that senile plaques 
contain a binding site for tau that is related to its interaction in 
promoting A(3 aggregation (Smith et al.,1995).
Tau proteins can bind to tubulin and have been shown to play a 
role in the stabilisation of microtubules in neurons (Matus., 1994). 
This abihty to interact with microtubules is modulated by their 
phosphorylation state as will be discussed later. Tau has been shown 
to be capable of influencing the following: net microtubule assembly, 
the rate of neurite elongation and neuritic stability (Esmaeli-Azad 
ertal.,1994). Tau has been shown to increase the rate of 
polymerisation of individual microtubules and slows their rate of 
depolymerisation (Drechel et al.,1992). Microtubules stabilised by tau, 
MAP2c or MAPlb are more stable in response to depolymerising 
agents (Takemura et al.,1992). Projections of certain MAPs may 
restrict the flexibility of microtubules (Matus., 1994), and projections 
of certain MAPs from the microtubule surface may promote bundling 
(Kanai et al.,1989).
1.5.2.1 Isoforms of Tau protein
Tau is present throughout the nervous system (Binder et 
al.,1985). Early studies reported that tau in the adult brain consisted 
of four to six polypeptides (Cleveland et al.,1977) , while in the 
foetus, only one tau protein band was found (Couchie et al.,1985). In 
1988, Goedert and colleagues identified a 352-amino acid residue of
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human tau (Goedert et al.,1988). At this point, all previously reported 
tau sequences contained, in their carboxy-terminal halves, a 
characteristic region of three tandem repeats of 31 or 32 amino acids, 
each displaying a Pro-Gly-Gly-Gly motif. It was proposed that these 
repeat regions represented the tubulin-binding region of tau (Lee et 
al.,1991). Goedert and colleagues then isolated cDNA clones 
encoding an isoform of tau differing from the previously reported tau 
sequences by the presence of an additional repeat of 31 amino acids 
giving four rather than three repeat regions in its carboxy-terminal half 
(Goedert et al.,1989). Goedert and colleagues developed probes 
derived from cDNA clones encoding the three (named tau type 1 ) and 
four (named tau type 2) repeat tau isoforms. They found mRNA 
recognised by both types of probe in all areas of the human adult brain 
examined. However, type 1 was abundant in the fetal brain, with type 
2 virtually undetectable. Type 1 and type 2 mRNAs were detected in 
pyramidal cells in the cerebral cortex. In the hippocampus, typel 
mRNA was found in pyramidal and granule cells while type 2 was 
detected in most but not all of the pyramidal cells and absent from the 
granule cells. These results proved that the expression of tau protein 
mRNA is both stage and cell specific.
In further studies, Goedert and colleagues reported the 
sequences of additional isoforms of human tau protein, which differed 
from the previous forms by the presence of either zero, one or two 
insertions of 29 amino acids in their amino-terminal region. Full length 
cDNA clones showed that the insertions occurred in combination with 
the three and four tandem repeat regions (Goedert et al.,1989). 
Together with the two isoforms previously described, this gave a total 
of six human tau isoforms ranging between 352 and 441 amino acids 
in length, and derived from a single gene by alternative splicing 
(Goedert et al, 1989). The present nomenclature for the six isoforms 
of human tau is as follows; three (t3, t3S, t3L) or four (t:4, t4S, t4L) 
tandem repeat regions and the presence of zero (t3 and x4), one (t3S 
and t4S) or two (x3L and x4L) N-terminal 29 amino acid inserts 
(Singh et al.,1996). All six isoforms have been reported to be present 
in a hyperphosphoiylated state in PHFs (Grundke-Iqbal et al.,1986; 
Kopke et al.,1993; Goedert et al.,1992).
The functional significance of having six different isoforms is 
still unclear. Differences in the distribution between white and grey
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matter and ability to aggregate (Butler et al.,1986) have been Y
reported. The molecular geneity of tau is thought to be due to both
mRNA processing and post-translational modifcation (Butler at 
al.,1986). 3
1.5.2.2 Tau Localisation
In the normal brain, tau is localised in the axons and is thus 
more abundant in white matter than in grey matter (Matus et al.,1981; 
Binder et al.,1985). In Alzheimer's Disease, and under conditions of 
neurodegenerative disorder, phosphorylated tau-species are also found 
in the somatodendritic compartment (Kowall et al.,1987). In a recent 
study, Janke and colleagues found tau isoforms differing in their 
tubulin binding characteristics are differentially distributed in 
subcellular neuronal compartments (Janke et al.,1996).
1.5.2.3 Tau Phosphorylation
The phosphorylation state of tau changes during 
neurodevelopment and highly phosphorylated tau accumulates in the 
PHFs of Alzheimer's Disease. Normal fetal tau is also phosphorylated 
and shares common epitopes with PHF tau (Goedert et al.,1989; 
Kosik et al.,1989). Tau has been shown to be abnormally 
phosphorylated and aggregated into PHFs in affected neurons 
(Grundke-Iqbal et al., 1986a and 1986b; Iqbal et al.,1989; Lee et al 
1991). The abnormal phosphorylation of tau results in the loss of its 
microtubule assembly and stability activity (Iqbal et al.,1986; Alonso 
et al.,1994). Abnormal phosphorylation of tau also results in PHF 
resistance to proteolysis (Grundke-Iqbal et al.,1988). It is thought that 
in Alzheimer’s Disease, a reactivation of the fetal state of tau protein 
occurs in selected neurons (Kondratick and Vandre., 1996).
Phosphorylation Sites:
Studies have identified a number of specific phosphorylation 
sites in normal human fetal and adult tau as well as in PHF-tau 
isolated from postmortem brain samples (Hasagewa et al.,1992; 
Watanabe et al.,1993). These initial studies showed that the following 
residues are phosphorylated in PHF tau and fetal tau, but not in
normal adult tau: Thr-181, Ser-199, Ser-202, Thr-231, Ser-235, Ser- 
236, Ser-396 and Ser-404. In another set of studies, with the 
exception of Ser-202 and Ser-396, these sites were found to be 
partially phosphorylated in normal adult tau (Goedert et al.,1994).
Goedert and colleagues also showed that in PHF tau these sites are 
abnormally phosphorylated, and is hyperphosphorylated. 
Hyperphosphorylated tau , i.e that which is fully phosphoiylated at 
Ser-202 and Ser-396, is also known as A6 8  (Goedert et al.,1993). It 
has been shown that many of the sites are phosphorylated in tau 
proteins in the fetal brain, but that fetal tau proteins are preferentially 
dephosphorylated shortly after birth and remain dephosphorylated 
even when fetal tau is converted into adult tau (Kanemaru et al.,1992 
and Bramblett et al.,1993). In developing rat brain, it has been shown 
that fetal tau is phosphorylated from embryonic day 18 until postnatal 
day 11. After this time, the level and phosphorylation state of tau 
dramatically decreases and five adult isoforms appear (Mawal-Dewan 
et al.,1994). It should be noted that since these and other studies 
investigating phosphorylation sites in human brain tau are done using 
postmortem brain slices, there is the risk that rapid dephosphorylation 
of tau by phosphatases that remain active during the postmortem
interval may have occurred. It is now thought that 21 different :phosphorylation sites exist in PHF tau (Morishima-Kawashima et 
al.,1995).
A clear difference in distribution between tau proteins 
phosphorylated to different states has been seen in cultured rat 
neurons. Tau proteins phosphorylated at Ser-202 (recognised by the 
antibody AT8 ) were found concentrated in the axonal portion that is 
close to the cell body, while tau proteins that carry an epitope that 
contains dephosphorylated Ser-202 (recognised by an antibody to 
Taul), are enriched in the distal axon and the growth cone (Rebhan et 
al.,1995). It should be noted at this stage that the rat brain is
■especially useful for studies on the regulation of tau phosphoiylation 
during development, because regions of the tau molecule are 1 0 0 % 
conserved between rats and humans, and because the development of 
human and rat tau isoforms are very similar (Brion et al.,1993 and 
Kosik et al.,1989).
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Phosphatases/ldnases
The finding that PHF-tau is hyperphosphorylated almost equally 
at Ser/Thr-Pro and Ser/Thr-nonPro sites suggests that proline- 
directed protein kinases, (PDPKs), and non-proline-directed protein 
kinases,(non-PDPKs), are involved in the hyperphosphorylation 
process (Morishima-Kawashima et al.,1995). Several kinases have 
been shown to phosphorylate tau in vitro, and other studies have 
shown that protein phosphatases are able to dephosphorylate tau in 
vitro. An understanding of how the phosphorylation and 
dephosphorylation of tau is regulated will provide important insights 
into the pathogenesis of NFTs.
The PDPKs glycogen synthase kinase 3 a  and 3(3 have been 
shown to phosphorylate tau at Ser 202 and Ser-396 (Latimer et 
al.,1995; Lovestone et al.,1994), and these findings have implicated 
glycogen synthase kinase (GSK), a neuronal kinase, as being 
important in the regulation of normal cytoskeletal structure and 
function and possibly in the neurodegeneration of Alzheimer's 
Disease. It has recently been demonstrated that, in intact mammalian 
cells, tau highly phosphorylated in the presence of GSK loses the 
property of microtubule stabilisation. This suggests that regulation of 
tau phosphorylation by this enzyme may be important in cytoskeletal 
modulation during neurodevelopment, and this effect may be lost in 
neurodegeneration (Lovestone et al.,1996). Other kinases shown to 
phosphorylate tau at various sites are the PDPKs MAP kinase, cdk5 
and cdk2 kinases. (Goedert et al.,1994 ). The non-PDPKs shown to 
phosphoiylate tau include A-kinase, CaM kinase 2 and CK-1 (Singh et 
al.,1995; Singh et al.,1996). It has recently been suggested that in tau 
hyperphosphorylation in Alzheimer’s Disease brain, cdk5-catalyzed 
phosphorylation may serve to upregulate the activities of c-kinase and 
CK-1 (Sengupta et al.,1997).
Arendt and colleagues have shown that chronic infusion into rat 
brain of okadaic acid, a specific inhibitor of serine/threonine protein 
phosphatases 1 and 2A, results in memory impairment accompanied 
by a PHF-like phosphorylation of tau preen and the formation of Aj3- 
containing structures in the grey and white matters (Arendt et 
al.,1995). It has been suggested that a defect in protein phosphatase 
could be the cause of the abnormal hypeiphosphoiylation of tau. 
Gong and coworkers found that Alzheimer's Disease phosphorylated
t
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tau in brain extracts was mainly dephosphorylated by protein 
phosphatase 2A and 2B and to a lesser extent by protein phosphatase 
1 , and that this tau phosphatase activity was significantly reduced in 
the disease (Gong et al.,1995). It has recently been shown that in 
neurons, phosphorylase Idnase may be one of the kinases that 
participate in the phosphorylation of tau (Paudel.,1997).
It has been suggested that the different tau isoforms may be 
present at different states of phosphorylation in PHFs (Singh et 
al.,1996). It is still unknown whether the 6  tau isoforms possess all of 
the 2 1  possible phosphorylation sites, and how differently 
phosphorylated isoforms are aggregated to form the PHF structure.
Implications
The path of events in Alzheimer's Disease is still unclear, i.e. 
whether tau is first hyperphosphorylated, which induces its 
dissociation from microtubules and leads to their collapse, or whether 
microtubule collapse initiates a newly dissociated tau which then 
becomes hypeiphosphoiylated. An imbalance between kinases and 
phosphatases could result in the hyperphosphorylation of tau protein. 
As discussed earlier, phosphorylation of tau has been shown to 
prevent proper association of the protein with microtubule. However, 
it has also been shown that rapid hyperphosphorylation of tau occurs 
after colchicine-induced microtubule collapse (Mattson et al.,1990). 
The full cycle of events remains to be elucidated.
1.5.3 MAP2
MAP2 and tau contain common sequences in tubulin binding 
sites, and interact with the C terminal of tubulin that is on the surface 
of the tubules (Serrano et al.,1984). As well as MAP2 and tau, three 
other structural MAPs exist. These are MAP la and lb, and MAP4, 
which is an isoform of MAP2c (Lewis et al.,1988; Doll et al.,1993; 
Kindler et al.,1990). These variants arise by alternative splicing from 
the same gene (Kindler et al.,1990; Goedert et al.,1991). MAP2c 
consists of the N and C terminal domains of MAP (2a/b) joined 
together and lacking the intervening sequence. The C-terminal 
segment contains a proline-rich region followed by three or four 
conserved micro tubule binding regions. MAP2c is expressed in
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developing mammalian brain and is down regulated during brain 
maturation. It has recently been shown that MAP2c is involved in 
functionally specific interactions with microtubules and microfilaments 
(Cunningham et al.,1997). MAP(2a/b) is more prominent in the adult 
brain (Riederer and Matus., 1985). MAP2c has a widespread 
distribution in the brain being found in neuronal cell bodies, dendrite, 
axons and glial cells (Tucker et al.,1990). In contrast, MAP2(a/b) is 
selectively localised in the dendrites and neuronal cell bodies (Caceres 
et al.,1984; Huber et al.,1984). In addition to its well known 
association with microtubules, MAP2 is also colocalised with actin, 
microfilaments, membrane organelles and dendritic spines (Caceres et 
al.,1983; Morales et al.,1989). Recently a novel low molecular weight 
isoform of MAP2c has been discovered. It has been detected in cell 
cultures containing glial cells but the specific cell types that express it 
have yet to be elucidated (Ferhat et al.,1994; Doll et al.,1993). In this 
study MAP2(a/b) is refered to as MAP2.
1.5.3.1 MAP2 Phosphorylation
MAP2 is phosphorylated by MAP kinase. Part of the 
phosphorylation occurs at the C-terminal of the molecule, which 
contains the microtubule binding domain. Phosphoiylation of MAP2 
has been shown to cause microtubule disassembly (Burns et al.,1988; 
Murphy et al.,1983). Completely dephosphorylated MAP2 cannot 
interact with microtubules and phosphorylation also controls the 
association of MAP2 with actin microfilaments (Brugg et al.,1991; 
Selden et al.,1983). MAP2c is more highly phosphorylated in the 
developing rat brain, whereas MAP2b is more extensively 
phosphorylated in the adult brain (Sanchez et al.,1995).
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1,6 Nitric Oxide
1.6.1 Introduction
Nitric oxide (NO) was first recognised as a messenger molecule 
in the CNS in 1988 (Garthwaite et al.,1988). It is the unstable 
intercellular molecule that had been hypothesised a year earlier 
(Garthwaite J. and Garthwaite G.,1987) to mediate the increased 
levels of cyclicGMP (cGMP) following activation of glutamate 
receptor subtypes, particularly those of the NMDA subtype. As will 
be discussed in more detail later, the enzyme responsible for 
synthesising NO, nitric oxide synthase (NOS), has been purified, 
cloned and expressed (Bredt et al.,1991).
1.6.2 Nitric Oxide Functions
NO has been shown to have many diverse roles. It is an 
important biological messenger involved in vasomotor control, 
vascular homeostatis, and important neuronal and immunological 
functions (Moncada and Higgins., 1993). Besides its role as 
endothelial-derived relaxing factor (Furchgott.,1990; Moncada et 
al.,1991) and a mediator of macrophage cytotoxicity (Hibbs et 
al.,1987; Marietta et al.,1989), NO appears to be a neuronal 
messenger in the brain and peripheral nervous system, and has been 
found to satisfy many criteria of a neurotransmitter (Garthwaite., 1991; 
Snyder and Bredt., 1991). NO is a free radical that binds to the iron- 
sulphur centres of enzymes and by doing this interferes with the 
function of these enzymes. NO also reacts with oxygen, superoxide 
and transition metals, and each of the products of these reactions 
supports further reactions at other sites (Stamler.,1994). The reaction 
with superoxide anions forms peroxinitrite anions that decompose to 
yield highly damaging hydroxyl free radicals and nitrogen dioxide 
(Beckman et al.,1990). NO is a relatively stable compound that can 
easily cross cell membranes and has the potential to travel significant 
distances in tissue before reacting with a target. In neuronal cultures, 
acute exposure to high concentrations of NO by over activating 
NMDA receptors or, by addition of NO-releasing compounds such as 
SNP and SNAP, results in neuronal cell death (Dawson et al.,1993;
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Dawson and Snyder., 1994). During focal cerebral ischaemia, 
concentrations of NO may rise very rapidly to levels toxic to neurons 
(Malinski et al.,1993). NO is responsible for endothelial relaxing 
factor activity regulating blood pressure. As mentioned previously, 
stimulation of NMDA receptors has been shown to induce the release 
of NO which then diffuses to neighbouring cells and amongst other 
reactions activates guanylate cyclase to raise intracellular cGMP 
content (Garthwaite et al.,1988; Knowles et al.,1989). NO has been 
reported to be involved in the induction and maintenance of LTP 
particularly in the dentate gyms (Bohme et al.,1991; Izumi et al.,1992;
Mizutani et al.,1993). In cell lines , NO has been shown to modulate
:gene expression (Haby et al.,1994; Peunova et al., 1993), and in 
hippocampal granule cells NO alters proenkephalin and prodynorphin 
gene expression (Johnston and Morris., 1994).
1.6.3 NADPH diaphorase
As mentioned previously, NO is produced by NOS, an enzyme 
that is thought to be present in discrete populations of neurons but not 
in resting glial cells (Bredt et al.,1991). NOS can be demonstrated 
conveniently by the histochemical technique for nicotinamide adenine 
dinucleotide phosphate diaphorase (NADPH diaphorase) staining, and 
has been shown to be identical to NADPH diaphorase, NOS is 
localised to the same discrete neuronal populations in the brain that 
stain for NADPH diaphorase (Dawson et al.,1991; Hope et al.,1991).
Dawson and coworkers illustrated NOS catalytic activity to be similar 
to NADPH diaphorase staining using human kidney cells transfected 
with NOS cDNA, and showed NOS and NADPH diaphorase staining 
in the same proportions as in neurons (Dawson et al.,1991). Despite 
the important roles of NO, a relatively small population of neurons in 
the brain (except in the cerebellum) contain a high level of NOS. As 
discussed later, non-neuronal sources of NO exist in the brain, as 
illustrated by the fact that cultured astrocytes express a form of NOS.
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L6.4 Nitric oxide and Alzheimer's Disease
Until recently, little reseai'ch has focused on a possible role for 
microglial cells in A^-mediated neuronal degeneration in Alzheimer's 
Disease. The differences in the morphology of diffuse plaques, which 
lack reactive glial cells, and the neuritic plaques surrounded by 
reactive ghal cells favours some from of glial involvement in neuritic 
plaque development. It has been shown that microglia are induced to 
release NO by A|3 alone and by the synergistic action of A|3 and 
interferon-% (Goodwin et al.,1995). It is possible that Ap-induced 
activation of microglia, and subsequent NO release is one mechanism 
of neurotoxicity in Alzheimer's Disease. An increased number of 
NADPH-diaphorase stained neurons within the substantia innominata 
of Alzheimer's Disease patients has been observed and this further 
suggests a role for NO in the neurodegeneration in the disease 
(Benzing and Mufson.,1995). A loss of nitric oxide responsive soluble 
guanylyl cyclase activity in the temporal cortex of Alzheimer's Disease 
patients has been reported (Bonkale et al.,1995). It is still not clear 
whether this loss reflects changes in pathology or specific signal 
transduction abnormality. Recent evidence suggests that an imbalance 
of NO and oxygen radicals may mediate the AP-induced endothelial 
damage on endothelial cells and contribute to the pathology of the 
normal ageing process, as well as the cell damage in Alzheimer’s 
Disease (Sutton et al.,1997).
L6.5
Nitric oxide synthase
The enzymes of the nitric oxide synthase (NOS) family share the 
capability for synthesising NO during the conversion of L-ai'ginine to 
L-citrulline. NOS exists in two principal isoforms, constitutive and 
inducible, which differ in their calcium dependency and rate of 
expression. Constitutive NOS is calcium/calmodulin-dependent and 
produces NO for short periods in response to receptor stimulation. 
Neuronal (nNOS) and endothelial (eNOS) are both constitutive. 
Inducible NOS is calcium independent and induced by a variety of 
cytokines, inhibited by glucocorticoids, and once expressed 
synthesises NO for extended periods. Macrophage (mNOS) is
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inducible, and is localised to macrophages throughout the body but 
also occurs in the brain as glial NOS (gNOS), microglial cells being 
modified macrophages.
nNOS is localised to neurons throughout the peripheral and 
central nervous system. Dinerman and co workers found both eNOS 
and nNOS to occur throughout the brain in a wide range of neuronal 
cell types. Both were found in the cerebellum and olfactory bulb in the 
same call populations. However in the hippocampus, eNOS was found 
to be more concentrated in the pyramidal cells than in any other brain 
area, with nNOS being restricted to occasional interneurons 
(Dinerman et al.,1994).
The identification of NOS as the enzyme responsible for the 
neuronal NADPH diaphorase histochemical reaction (Hope et 
al.,1991), together with the development of antibodies to the purified 
NOS (Bredt et al.,1990) have made possible detailed anatomical 
localisation of the neurons generating NO. The cerebellum is thought 
to contain the highest levels of NOS activity and cGMP (Greenberg et 
al.,1982) in the brain. In the cerebellar cortex, NADPH diaphorase 
histochemistry indicate that NOS is present in basket and granule 
cells, but not in the Purkinje cells (Vincent and Hope., 1992). In the 
striatum, NADPH diaphorase histochemistry has shown NOS to be 
selectively localised in the population of medium-sized, aspiny 
interneurons that also contain somatostatin and neuropeptide Y 
(Vincent et al.,1983). NOS synthase appears to be absent from the 
cholinergic interneurons (Vincent and Hope .,1992). In the cerebral 
cortex and hippocampus, NOS appears to be present in the 
populations of interneurons but absent from the principal cells. The 
pyramidal cells of the cerebral cortex do not contain NOS (Vincent 
and Hope .,1992). As in the striatum, the cortex has a small 
population of NOS containing interneurons that express somatostain 
and neuropeptide Y (Vincent et al.,1983). The hippocampus contains 
interneurons that stain positively for NADPH diaphorase in the 
pyramidal cell layer, although the pyramidal cells themselves are not 
stained (Vincent and Kimura .,1992). In the dentate gyrus, positively 
stained cells are found in the molecular' layer, and in particular just 
beneath the granule layer (Vincent and Hope., 1992). The cell groups 
identified as NOS-containing thus make useful models for studying the 
role of NO in the nervous system.
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Astrocytes are known to possess a variety of similar properties 
to macrophages including the capacity to synthesise histocompatibility 
agents and cytokines (Robbins et al.,1987). Microglial cells present in 
the brain exhibit macrophage-like properties and these observations 
led to the study of NOS types in glial cells. Galea and coworkers 
found cultured CNS glial cells to express an inducible form of NOS 
similar to that found in macrophages (Galea et al.,1992). This iNOS 
was expressed following exposure of the ghal cultures to the 
endotoxin lipopolysaccharide (LPS), and shared many properties with 
inducible mNOS: both are cytoplasmic, dependent upon NADPH and 
FAD for full activity, are calcium-independent and competitively 
inhibited by N^-monomethyl-L-arginine. It was suggested that iNOS 
in glia may, by generating NO, contribute to the neuronal damage 
associated with cerebral ischaemia. Whereas cNOS activity can be 
tightly regulated by changes in intracellular calcium levels (Bredt et 
al.,1991), the activity of iNOS is calcium-independent and thus once 
expressed the enzyme can produce NO for extended intervals resulting 
in potentially toxic levels (Stuehr and Nathan., 1989).
The initial events in the LPS-induced activation of iNOS in 
macrophages have been shown to involve tyrosine kinase (Weinstein 
et al.,1992; Glaser et al.,1993). A role for the involvement of tyrosine 
phosphorylation events during the early process of iNOS induction 
has also been demonstrated in cultured glial cells (Feinstein et 
al.,1994).
Glial NO can be toxic to neurons (Choi et al.,1993) and to 
oligodendrocytes (Mitrovic et al.,1994). An important question is 
what determines whether a glial cell can be induced and if the 
expression of NOS can be regulated by endogenous and /or 
exogenous factors at the level of transcription, translation and/or post­
translational modification. Inactivation of endotoxin-induced NOS 
transcription has been reported in astrocytes pretreated with 
deactivating cytokines (Simmons and Murphy., 1993), and NO itself 
has been shown to interfere with the transcriptional induction of NOS 
(Park et al.,1994). Park and coworkers found that the magnitude and 
duration of NO production from activated astrocytes in culture may 
be determined by signals from adjacent neurons and microglial cells 
(Park et al.,1994).
I
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Another important finding was the discovery that cultured 
astrocytes express a constitutive form of NOS thought to be similar to 
endothelial and neuronal NOS, as well as an inducible form of NOS 
(Ma et al.,1994). In order to serve some important physiological roles 
of NO such as maintaining the normal mitogenic state of astrocytes, 
both constitutive and inducible forms are present.
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1.7 Microglia
1.7.1 Introduction
Neuroglia comprise the largest class of non-neuronal cells. 
Neuroglia can be further categorised as microglia or macroglia, and 
macroglia are further subdivided into oligodendrocytes and astrocytes 
(Frederickson., 1992). Astrocytes constitute the main macroglial cell 
in the CNS, and were hypothesised at the beginning of the century to 
be important in brain function. Astrocytes in the mature brain can be 
divided into two broad categories; they are either fibrous, filament- 
containing cells found mainly in the bundles of nerve fibres or, are 
protoplasmic with less fibrous material and located in the grey matter 
surrounding nerve bodies, axons and synapses (Duffy, 1983). A 
further category of glial cell exists: reactive glia, and this is discussed 
in section 1.7.2. The cell filaments aie composed of glial fibriUaiy 
acidic protein (GFAP) and this is used as a marker for astroglia 
(Bignami and Dahl, 1974). Astrocytes have multiple functions 
including the mechanical support of other CNS components, 
neurotransmitter metabolism and participation in repair and 
regeneration (Duffy, 1983; Pfeiffer et al.,1977). Microglia are sources 
of growth factors such as transforming growth factor-p, platelet- 
derived growth factor and basic fibroblast growth factor. This 
suggests that these cells provide a trophic support system (Shimojo et 
al.,1991). Secretion of nerve growth factor by activated brain 
macrophages has also been reported (Mallat et al.,1989).
Glia have well established roles in the nervous system, including 
the regulation of external potassium and the uptake of the excitatory 
amino acids aspartate and glutamate which are released by neurons 
into the extracellular space (Nicholls et al.,1990). Recent evidence 
suggests that glutamate acting at metabotropic receptors expressed by 
astrocytes could modulate glial activity evoked by neurotransmitters, 
and thus influence the ongoing modulation of neurons by astrocytes 
(Haak et al.,1997).
Cultured astroglia provide a convenient, enriched population of 
astroglia for study. Cell cultures have well-known advantages as 
experimental models, and provide readily observable systems that in 
many cases retain biological properties which parallel those in vivo.
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The greatest source of culture model systems to explore CNS function 
and dysfunction is fetal brain material from rodents. For studies of 
human adult CNS disorders however, these models have 
disadvantages; their fetal origin and their derivation from another 
species. As fetal material, the molecular and genetic machinery of the 
cells would be expected to be devoted to growth and development 
and may have little or no susceptibility to the CNS disorder under 
investigation. Astroglial cultures prepared from fetal material do not 
mature in culture to the degree that occurs in vivo.
1.7.2 Reactive Gliosis
Extensive evidence indicates that microglia aie involved in brain 
function especially in neuropathological conditions (McGeer et 
al.,1993). Resting microglia are activated in response to injury, 
infection and inflammation of the nervous system, whereupon they 
enlarge and extend numerous processes which become packed with 
intermediate filaments (Bignami and Dahl., 1976; Duffy., 1983). This 
phenomenon is known as reactive gliosis. Reactive gliosis is seen in 
AIDS dementia, prion-associated encephalopathies, acute traumatic 
brain injury and Alzheimer's Disease (Gajdusek.,1990; Beach et 
al.,1989; Delacourte et al.,1990). The transition of astrocytes from the 
resting to the activated state seen in reactive gliosis is associated with 
an increased expression of new molecules not normally detected in 
resting astroglia, as well as the upregulation of other factors. It 
remains controversial whether these changes are detrimental or 
beneficial (Reier et al.,1989). It is possible that the increase in 
cytoskeletal proteins within the reactive astrocytes could help assist 
wound repair by stabilising the surrounding tissue (Reier., 1986). 
However, it has also been suggested that the glial scar may form a 
barrier that could hinder regenerative processes such as neurite 
outgrowth (Reier et al.,1983).
A role for reactive astrocytes in tissue regeneration and repair is 
also supported by their molecular profile. In vivo astrocytes express 
extracellular matrix molecules such as laminin, proteoglycans and 
adhesion proteins (Ard and Bunge., 1988). In vitro they are also able 
to secrete glycosaminoglycans (Johnston-Green et al.,1991). 
Caggiano and colleagues demonstrated the involvement of eicosanoids
29
and nitric oxide in the induction of reactive gliosis (Caggiano and 
Kraig.,1996).
Several studies have investigated the neuroprotective of 
astrocytes relevant to the pathogenesis of neurodegenerative diseases.
The release of basic fibroblast growth factor and IL - 6  from astrocytes 
has been shown to protect hippocampal neurons against glutamate 
toxicity and protect neurons against hypoxia respectively (Mattson et 
al.,1990; Maeda et al.,1994).
1.7.3 Microglia and Alzheimer’s Disease
As has been discussed earlier, Ap plaques are associated with a 
number of other proteins including immune process compounds.
Reactive astrocytes have also been found in association with amyloid 
plaques (Selkoe.,1991), raising the possibility that microglia could be 
involved in senile plaque formation. MacKenzie and colleagues 
reasserted a specific role for microglia in the formation of neuritic 
plaques from diffuse plaques (MacKenzie et al.,1995). They found no 
association between microglial cells and diffuse plaques but a strong 
association between microglial cells and the formation of neuritic 
plaques. The initial event in the formation of senile plaques is thought 
to be the deposition of AP protein, and cultured microglia have been 
shown to synthesise APP and metabolize it in a way favouring the 
formation of Ap (Bauer et al.,1991; Haass et al.,1991). Alternatively, 
it has been suggested that microglia could take up APP from another 
source such as degenerating neurons and convert it to Ap (Cummings 
et al.,1991). Finally, the presence of pre-established amyloid deposits 
could cause microglia to become activated (MacKenzie et al.,1995).
Studies to date investigating the association between microgha 
and senile plaques in Alzheimer's Disease have found a generalised 
increase in microglia in affected areas of the cortex, and accumulation 
of microglia around senile plaques (Coria et al.,1993; Itagaki et 
al.,1989). Pike and colleagues demonstrated that aggregated Ap 
peptides induce a reactive phenotype in cultured astrocytes that is 
paralleled by the selective localisation of reactive astrocytes in 
Alzheimer's Disease (Pike et al.,1994). They suggested that Ap itself 
could be a potent stimulus to astrocytes and may significantly 
contribute to the reactive gliosis characterisitc of Alzheimer's Disease.
kÛ
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1.7.4 Other compounds involved in microglial function
Nerve growth factor (NGF) is a neurotrophic protein required 
for the development and survival of several populations of neurons. In 
the CNS, NGF is synthesised by certain neurons, but during brain 
development and under different pathological conditions, there is an 
increased production of NGF by astrocytes (Bakhit et al.,1991). 
However, little is known about how this synthesis process is 
upregulated. It is possible that several NGF-inducing agents act 
through different pathways. One of them is the signalling network 
involving the activation of protein kinase C (PKC). It has recently 
been suggested that phosphatidylcholine-hydrolising phospholipase C 
induces the synthesis of NGF by ghal cells in both a PKC-dependent 
and PKC-independent manner (Laviada et al.,1995).
Neurotrophin involvement in the development and growth of 
the CNS has been studied extensively. Neurotrophins participate in 
multiple developmental processes ranging from survival of neurons 
(Levi-Montalcini and Angeletti.,1968; Theonen and Barde.,1980; 
Henderson et al.,1993), to proliferation of oligodendrocyte precursors 
(Barres et al.,1994) and axon growth (Zhang et al.,1994). Microglia 
have been shown to be sources of trophic factors known to support 
development and normal function of the CNS (Elkabes et al.,1996). 
Microglia are responsive to neurotrophins; both brain derived 
neurotrophic factor and neurotrophin-3 induce proliferation and 
phagocytic activity of microglia in vitro (Elkabes et al.,1996).
A role for the neurotrophic cytokine interleukin-1 (IL-1) as a 
mediator of astrocyte activaiton and growth was first demonstrated by 
Giulian and colleagues (Guilian and Lachman.,1985). LI-1 has been 
shown to induce proliferation of astrocytes cultured from neonatal rat 
brains, and when injected into the brain to induce reactive gliosis 
(Guilian and Lachman.,1985). Evidence also reports induction of 
tumour necrosis factor mRNA and IL-1 in astrocytes following 
treatment with interferon y and LPS (Chung and Benveniste., 1990). 
IL-1 is thought to play a role in the pathogenesis of certain human 
CNS diseases (Lee et al.,1995). High levels of IL-1 are present in the 
cerebral tissue of Alzheimer's Disease brains (Griffin et al.,1989). The 
elevated level of IL-1 is thought to be due to overexpression by
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activated microglia in the tissue, particularly by those microglia 
associated with senile plaques (Griffin et al.,1995). Sheng and 
colleagues reported a positive correlation between the regional 
distribution of IL-1 positive microglia and tau positive plaques in 
Alzheimer's Disease patients (Sheng et al.,1995). This further supports 
a role for IL-1 in the formation of plaques and in the pathogenesis of 
Alzheimer's Disease.
•i:
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1.8 Cholinergic system and Alzheimer’s Disease
Over the past two decades, evidence has accumulated suggesting that 
central cholinergic systems are important in the regulation of learning, memory 
and cognition (Baitus et al.,1985; Bartus and Johnston.,1976). Degeneration of 
cholinergic neurons in the CNS is one of the critical components contributing 
to cognitive impaiiiuents in Alzheimer's Disease. Neuropathological changes in 
the disease involve cell loss and degeneration in the neocortex and many 
neurotransmitter systems, particularly the cholinergic system, are especially 
vulnerable. The basal nucleus of Meyneit and the diagonal band of Broca 
provide the major source of cholinergic input to the cerebral cortex and the 
hippocampus (Divac.,1975; Lehman et al.,1980; Mesulam and Van 
Hoesen.,1976). A reduction in number of the cholinergic neurons by almost 
two thirds has been reported in Alzheimer’s Disease brain tissue (Nagai et 
ah, 1983). However, Pearson and colleagues reported a shrinkage rather than a 
loss of these neurons in Alzheimer's Disease brain tissue (Pearson et ah, 1985). 
This result agreed with results from lesioning studies (Sofroniew et al., 1987). It 
is possible that cholinergic neurons projecting from the basal nucleus of 
Meynert to the neocortex are atrophied rather than lost in Alzheimer’s Disease 
(Allen et ah, 1988).
Several biochemical markers of presynaptic cholinergic nerve endings 
such as choline acetyltransferase show severe depletion in Alzheimer's Disease 
(Jope et al., 1994). In contrast to this, receptor binding methods have shown 
that postsynaptic muscarinic receptors are retained in Alzheimer's Disease 
(Davies and Yerth.,1977; Svensson et al., 1992). These findings led to the 
attempt to ti'eat Alzheimer's Disease patients with cholinergic agonists.
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1.9 Genetics of Alzheimer’s Disease
1.9.1 Introduction
Identification of the underlying causes and means of prevention 
constitute the current objectives of epidemiological research on 
Alzheimer's Disease. The major new development in this area is the 
recognition of genes that predispose to the disease. Genetic autosomal 
dominant forms of Alzheimer's Disease, called familial Alzheimer's 
Disease (FAD), result in the relatively early onset of the disease. 
Studies have led to the discovery of four genes linked to the 
development of early onset FAD. The first is the APP gene on 
chromosome 21 (Checler et ah, 1993), and mutations in this gene have 
been discussed in Section 1.4.6. The second of these genes is the 
apolipoprotein E gene located on chromosome 14 (Corder et 
al.,1993). Two novel genes have recently been identified: presenilin 1 
(PS 1/S 182) on chromosome 14 (Sherrington et al.,1995; Alzheimer’s 
Disease collaborative group.,1995), and presenilin 2 (PS2/STM2) on 
chromosome 1 (Rogaev et al., Levy-Lehad et al., 1995). The normal 
biological role (s)of the presenilins are unknown, however it has been 
suggested that they participate in intracellular transport (Sherrington 
et al., 1995).
1.9.2 Risk Factors for Alzheimer’s Disease
As has been previously discussed, the main risk factors of the 
disease are: increased production of soluble Ap and its precursor, 
failure to remove amyloid deposition, and point mutations of the APP 
gene. Some of the factors that could cause these are discussed below.
Apolipoprotein E (ApoE), a 34kDa lipoprotein, is a major 
lipoprotein in the central nervous system, and it plays an important 
role in hippocampal response to injury, dendritic remodelling and 
synaptogenisis (Piorier et al., 1994). ApoE is encoded from three 
alleles (e2, e3, £4) giving six genotypes in humans. Several 
investigations have shown that a specific apoE isoform, Apo 84 allele, 
is a risk factor for both early and late onset Alzheimer's Disease 
(Schmechel et al.,1993; Strittmatter et a l ,1995). The coexistence of 
ApoE and Ap has been detected in both senile plaques and
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neurofibrillary tangles in the brain of Alzheimer's Disease patients
(Namba et ah, 1991). Recent evidence suggests that the combination
of the herpes simplex virus 1 and carriage of the ApoE e4 allele
increase the risk of Alzheimer’s Disease and together are damaging to J
the nervous system (Itahaki et al., 1997).
Head injury has been identified as the main envnonmental risk 
factor for Alzheimer's Disease, and may act as a risk factor by causing 
acute deposition of AP (Roberts et al., 1994).
Smoking is thought to be protective against the development of 
Alzheimer's Disease via the effects of nicotine on nicotinic receptors,
Ap toxicity and induction of antioxidant systems (Brenner et 
al.,1993).
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1.10 Clinical treatments for Alzheimer’s Disease and other drugs 
related to the disease and tan protein expression.
1.10.2 Clinical treatments for Alzheimer’s Disease.
Pharmacological treatment of patients with Alzheimer's Disease 
is becoming more important and a vast number of drugs have been 
researched in a variety of countries. There is presently no treatment 
that will arrest the progression of Alzheimer's Disease. However, it 
has been shown that in the vast majority of clinical trials, the 
cholinesterase inhibitor tacrine (tetrahydroaminoacridine) is able to 
induce very beneficial effects in cognition and memory. The number of
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1.10.1 Inverse association of non-steroidal anti-inflammatory 
drugs and Alzheimer’s Disease.
Postmortem analysis of Alzheimer's Disease brain tissue has 
shown the presence of reactive glial cells densely embedded around 
amyloid plaques (McGeer et al., 1992). Postmortem tissue also 
revealed the presence of several immunoprotective proteins that are 
normally absent or expressed at very low levels in the normal brain 
(McGeer et ah, 1989). These observations indicate a possible immune- 
mediated process in Alzheimer's Disease and first suggested a role for 
anti-inflammatoiy agents in treatment of the disorder. Clinical trials of 
indomethacin in Alzheimer's Disease showed a small improvement in 
those treated with the drug (Rogers et al., 1993). These findings 
suggested an inverse relationship between anti-inflammatory 
compounds and Alzheimer's Disease and this was further supported by 
the observation that there is a low prevalence of the disease among 
patients with rheumatoid arthiitis (Broe et al., 1990; McGeer et 
al., 1990). Studies have suggested that non-steroidal anti-inflammatory 
drugs act as a protective factor for Alzheimer's Disease (Henderson et 
al., 1992; Rich et ah, 1995).
drugs investigated as possible candidates for alleviation of the disease 
is vast and below is a summary of the main groups of drugs.
Three main classes of drug have been reseaiched; cholinesterase 
inhibitors, nootropics and neuroprotective agents. Tacrine, velnacrine 
and eptastigimine are cholinesterase inhibitors. A major defect in 
neurotransmission in Alzheimer's Disease results from loss of 
cholinergic function. Reduced choline acetyltransferase activity is seen 
in postmortem Alzheimer's tissue (Sims and Bowen., 1983). Tacrine, a 
centrally active, reversible cholinesterase inhibitor, has been reported 
to improve psychometric test performance and to improve global 
assessment in Alzheimer's Disease patients(Davis et al., 1992).
However, some negative results were also seen (Gauthier et al., 1990).
Aniracetam, oxiracetam, and piracetam and pramiracitam are 
nootropics with potential for the treatment of Alzheimer's Disease.
The term nootropic was derived by Giurgea in 1972 to describe 
compounds that enhance learning and memory. Aniracetam has been 
shown to improve the condition of elderly patients suffering from 
slight to moderate mental deterioration (Canonico et al., 1991).
Aniracetam has been shown to modulate the AMPA receptor (Martin 
et al., 1993). However, aniracetam has been reported to be a less than 
ideal dmg; the effect on AMPA receptors may be only weak and most 
of the drug may be broken down in the stomach (Service., 1994).
The following neuroprotective agents have been tried at clinical 
trials for the treatment of Alzheimer's Disease:selegiline, acetyl-L- 
carnitine, gangliosides, idebenone and nimodipine. A major problem in 
the treatment of the disease is the lack of substantial knowledge about 
the actual availability of these drugs in the CNS. Inadequate 
concentrations in the brain can potentially decrease the clinical 
usefulness of new and existing drugs. Different methods to overcome 
this problem have been developed but they also have their side effects 
and problems. Another aspect of treatment which has been 
investigated is combination therapy, and given the complex nature 
pathogenesis of Alzheimer's Disease, this therapeutic approach may be 
the best option.
Recent research has focused on immune mechanisms in the 
pathogenesis of Alzheimer's Disease. A large number of immune 
system proteins have been found to be associated with the disease 
lesions (Toomama et al., 1990; Rogers et al., 1988). For the near
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future, consideration of iramune-directed therapy of the disease may 
be another option.
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Project Aim:
Neuronal and glial cell cultures are viable models with which to 
study the eflfects o f various compounds on the expression and 
regulation o f cytoskeletal proteins. One o f the main neuropathological 
markers o f Alzheimer's Disease is the presence o f tangles, the main 
constituent o f which are paired helical filaments composed o f the 
microtubule associated protein tau in an abnormal state o f 
phosphorylation. The aim o f the current work has been to investigate 
a possible relationship between nerve growth factor, nitric oxide 
synthase activity and the expression o f microtubule associated 
proteins in neuronal and glial cultures. Evidence has established a 
relationship between nerve growth factor, nitric oxide and microtubule 
associated protein expression in PC12 cells and other cell lines 
(Peunova et a l, 1995; Haby et a l, 1994), however, the effect o f nitric 
oxide on cell morphology and protein expression has been less well 
documented in neuronal cells.
Another main neuropathological marker o f Alzheimeris Disease 
is the presence o f senile plaques composed primarily o f amyloid 
protein. The development o f two transgenic mouse fines in which the 
amyloid precursor protdn gene has been ablated (Zheng et a!., 1995) 
or alterW (Moechars et a l,1996) has provided the second main aim o f 
the project: to investigate the relationship between the amyloid 
precursor protein and raoiphological and synaptic markers.
Chapter 2
M ETHODS.
- a
I2.1 Cell Culture
2.1.1 .'Dissociated primary neuronal culture
Ï
Basal forebrain neurons were cultured using a modification of 
the methods of Hartikka and Hefti (1988). Timed pregnant Wistar rats 
were killed with an overdose of sagatal injected intraperitonealy on 
gestation day 17 (E l7). Embryos were removed and placed in 
Dulbecco's Minimum Essential Medium.The basal forebrain region 
was dissected under a microscope. The localisation of the basal 
forebrain was from the description of fetal brain anatomy by Inagaki et 
al (1982). Dissected pieces of basal forebrain tissue were transferred 
into a culture dish containing Minimum Essential Medium. The tissue 
pieces were minced and washed three times in Minhnum Essential 
Medium. Cells were dissociated in 10ml of a 0.67% trypsin solution 
made up in sterile saline, at 37 for 15 minutes. The trypsin was 
inactivated with 1.5ml heat inactivated fetal calf serum (ECS).
Following trypsinisation the cells were washed three times in 
Minimum Essential Medium and spun at 500g in a DAMONMEC 
centrifuge for three minutes per wash. The cells were then 
resuspended in Dulbecco's Modified Eagles Medium (DMEM) 
supplemented with the following: 5% horse serum, 0.5% FCS, 100 
units/ml penicillin, lOOjig/ml streptomycin and 2mM L-glutamine. The 
tissue was triturated in supplemented DMEM using a pasteur pipette 
and cells were plated at a density of 180 x 1 0  ^ cells per 1 ml (see 
section 2 . 1 b) onto 8 -well multichamber glass slides previously coated 
with poly-D-lysine (4jxg/ml). The cultures were grown in a humidified 
incubator supplied with 95% oxygen and 5% carbon dioxide. After 24 
hours, the medium was replaced with neurobasal medium 
supplemented with B27 and penicillin-streptomycin. This was 
necessary to obtain serum-free conditions. Cells were used within 3 
days of seeding.
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2.1.1b: Cell counting using trypan blue staining
In order to control the number of cells plated, the cell density 
was determined using trypan blue. This method also enables the 
amount of cell damage caused by dissociation to be investigated. The 
method was essentially identical to that of Banker and Goslin (1991 ). 
One drop of eell suspension was mixed with an equal volume of a 
0.08% tiypan blue solution dissolved in HBSS solution. This mixture
was placed onto a haemocytometer, and the number of live and dead 
cells in one small grid was counted.
For the experiments involving investigation of neurite structure, 
cells were diluted to a density of 1 1 0  x 1 0  cells per 1 ml.
2.1.2: Glial cell culture
The method for rat ghal culture was adapted from Keller et al 
(1985). Two day old rat pups were killed with an overdose of sagatal 
injected intraperitonealy, and their brains removed and placed in 
saline. The meningeal layer was removed under a dissection 
microscope, and the cortical tissue removed from the cerebrum. 
Generally, the tissue from two pups was pooled. The tissue was 
minced and washed three times in sterile saline before trypsinisation in 
a 0.25% trypsin/EDTA solution at 37®C for 15 minutes. The trypsin 
was inactivated with 2ml FCS, and the cells then spun at 500g for 
three minutes and the trypsin decanted off. The cells were then rinsed 
in F-12 DMEM nutrient mixture supplemented with the following: 
20% FCS, 100 units/ml penicillin, lOOpg/ml streptomycin, 3mM L- 
glutamine and 0.25% amphotericin B. Each rinse was followed by 
centrifugation at 500g for three minutes. The cells were then triturated 
in F-12 DMEM nutrient mixture using a pasteur pipette, and then 
dispersed by passing through a 20-gauge needle into 5ml culture 
flasks. Once seeded onto the flasks, the cultures were incubated for 48 
hours in a humidified incubator supplied with 95% oxygen and 5% 
carbon dioxide. At this stage it was essential to minimise movement of 
the cells in order to prevent cell clumps. After 48 hours the medium 
was replaced with F-12 DMEM nutrient mixture similar to previously 
but containing only 5% FCS. The medium was replaced every two 
days thereafter. One week after seeding, the cells underwent a process
41
■I
Prior to inrmunohistochemistry,cultures were fixed for 15 
minutes in an ice cold 4% formaldehyde solution. The cultures were 
rinsed three times in 0.1 M phosphate-buffered saline (PBS) for 10 
minutes and incubated at room temperature for 60 minutes in O.IM 
PBS containing 20% normal goat (polyclonal antibodies) or horse 
(monoclonal antibodies) semm (NS). The cultures were then 
incubated for 1 2  hours at 4®C with specific antibodies against in 
O.IM PBS with 1% NS, and 0.5% Triton-X. (details of antibody 
concentrations are in Materials section). After rinsing in PBS three 
times for 5 minutes per rinse, the cultures were incubated with 
biotinylated secondary antibody for 60 minutes, rinsed in O.IM PBS 
twice for 10 minutes, and then incubated with ABC-conjugated horse 
radish peroxidase for 60 minutes in accordance with manufacturers 
instructions. The peroxidase was visualised with 0.1% 
diaminobenzidine made up in O.IM phosphate buffer ph 7.2 containing 
0.02% hydrogen peroxide and 0.05% nickel chloride. Slides were then 
dehydrated in a graded series of alcohols (70%, 90%, 100%%) and 
mounted with coverslips using DPX.
of seeondaiy culture. This was done in order to eliminate neuronal and 
oligodendroglial contamination,and to expand the exisiting ghal cell 
population. Cells were trypsinised in a 0.25% trypsin/EDTA solution 
for three minutes at 37^C. The culture flasks were then shaken firmly 
to dislodge the attached cells. The trypsin solution was inactivated 
with 2ml FCS and the cells centrifuged at 500g for three minutes. The 
cells were then washed in F-12 DMEM-5% FCS and dispersed in 24 
ml F-12 DMEM-5% FCS before being seeding onto 24 well plastic 
culture plates containing glass coverslips. After 24 hours, the plates 
were shaken gently and the medium replaced. The cells were then 
ready for treatment.
2.2 Immunohistochemistry
2.2.1: Antibody reaction
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2.2.2: NADPH diaphorase staining
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NADPH-diaphorase staining was performed according to the 
method of Valtschanoff et al (1992). Tissue culture slides or glass 
coverslips were fixed for 15 minutes in a 0 .2 % glutamldehyde solution 
in O.IM phosphate buffer, pH 7.2. Slides were then pre-incubated in 
O.IM phosphate buffer eontaining 0.3% Triton-X-100 for 10 
minutes,then transferred to a freshly prepared buffer-Triton solution 
containing 0.5mg/ml NADPH and a few drops of a 0.2mg/ml nitro 
blue tétrazolium solution. After incubation at room temperature on a 
shaker for 10 minutes slides were transferred to an oven at 37 for 
between 4 and 12 hours. Slides were then rinsed in O.IM phosphate 
buffer,dehydrated in a graded series of alcohols and coverslipped with 
DPX mounting medium. Since the reaction product is slighty soluble 
in ethanol, rinses in alcohol were short. Within each experiment, all 
slides received identical dehydration procedures.
2.3 In situ hybridisation
2.3.1: Oligonucleotide Probes
Oligonucleotide probes of unique sequence were synthesised on 
an Applied Biosystems DNA synthesiser. The probe sequences were
as stated in the Materials section.
2.3.2: Cryostat sections
In situ hybridisation was performed according to the method of 
Wisden and Morris (1992). After treatment, brains were removed and 
fast-frozen on dry ice. 2 0 |xm cryostat sections were cut at the levels of 
the basal forebrain and hippocampus. The sections were mounted onto 
sterile slides previously baked at 180 and coated in a 0 .0 1 % 
solution of poly-L-lysine. The sections were then dried at room 
temperature and fixed in a 4% formaldehyde solution for 15 minutes. 
The sections were then transferred into a Ix phosphate buffered saline 
solution (PBS) for 2 minutes and dehydrated in a graded series of 
alcohols (70%,90%, 100%) for 2 minutes each. Sections were stored 
in 1 0 0 % alcohol.
O.Spmol oligonucleotide probes(45-mer) were 3'-end labelled 
with lOpmol of the isotope 5-[a-^^ S]dATP,specific activity 1300 
Ci/mmol.The specific activity of the probes was 1.0 xlO^ dpm/|Lig.
For the reaction solution, the following were mixed in an 
eppendorf tube:
2.2 |al diethylpyrocarbonate(DEPC) treated water 
1.25 1 1 1 5x reaction buffer(contains IM potassium 
cacodylate, 125mm Tris/HCl, 1.25mg ml-1 bovine serum
albumin,pH6 .6 )
l.Ojil of oligonucleotide at a concentration of 0.3 pmol |il “1
1.6 111 [a-35 S] dATP (1300 Ci/mmol)
0.5 111 TdT.
The reagents were mixed carefully using a pipette and incubated 
in a water bath at 32 for 3-5 hours. The reaction was stopped by 
addition of 40 pi DEPC-treated water.Sephadex G-25 spin columns
-ft
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were prepared using 1ml syringes plugged with glass wool. The 
syringes were filled with a 1:1 solution of Sephadex G-25 powder and 
Tris/EDTA buffer. This was spun at 500g for 1 minute to obtain the 
column. 50pl of the reaction mixture was added to the column and 
spun at 500g for 1 minute to remove unincorporated nucleotides. The 
eluate was collected in a sterile eppendorf tube. 2  pi of the eluate was 
analysed by liquid scintillation counting. The counts were in the range 
of 150 000 to 300 000 dpm /2 pi. 2 pi of IM dithiothreitol solution 
made in DEPC-treated water was added to preserve the probe from 
oxidation. The probes were stored at -20°C until use.
Sections were removed from 100% ethanol and allowed to diy 
at room temperature. Following this sections could be hybridised with 
selected probe at 42 overnight. In a sterile eppendorf tube the 
radiolabelled probes were diluted 1 : 1 0 0  in hybridisation buffer. 2  pi 
IM DTT was added to the mixture which was then vortexed 
thoroughly. 1 2 0  pi of probe/hybridisation buffer was applied to each 
slide,and slides were then gently covered with parafilm. Air bubbles 
were removed using blunt ended forceps. A small piece of tissue was 
saturated with 4xSSC and placed along side the slides in a sealed 
petridish to maintain humidity. Slides were incubated overnight at 
420C.
After overnight incubation, slides were transferred into coplin 
jars containing 250ml of prewai’med IxSSC at 55 *^ 0. The parafilm 
was gently removed using forceps,and the slides were then washed 
twice in fresh IxSSC for 30 minutes at 55 with constant agitation. 
Following this,the slides were transferred into O.l.xSSC at room 
temperature for 1 0  minutes and then dehydrated in graded alcohols 
(70%, 90%, 100%) for 2 minutes each before air drying.
The sections were then exposed to autoradiographic film at 
room temperature. Dry slides were attached to paper with tape and 
exposed to the film for between 4 days to 1 week depending on the 
probes used and the efficiency of their labelling. Under safe light 
conditions films were developed for 5 minutes in D19, rinsed in water 
for 2 minutes, fixed in Unifix for 4 minutes and rinsed in water for 20 
minutes.
After film developing, slides were dipped in K5 liquid 
photographic emulsion. Slides were dipped under safe light in a 
filtered 1:1 solution of emulsion: distilled water eontaining 0.5%
■
glycerol prewarmed to 45 ^C. Slides were allowed to dry before being 
transferred to light-tight slide boxes containing fresh silica gel. The 
boxes were stored at 4 until time of development,usually 5x the 
duration on film.
Exposed boxes were allowed to come to room temperature.
Under safe light, the slides were transferred to glass racks and 
immersed into 250ml D19 developer at 19^C for 8  minutes. Slides 
were then rinsed in water and immersed into 250ml of freshly 
prepared 30% sodium thiosulphate solution for 4 minutes. The slides 
were then rinsed in water for 15 minutes and then counterstained in 
0.2% neutral red solution for 3 minutes and dehydrated in graded 
alcohols (70%,90%, 100%) for 2 minutes. Finally slides were 
transferred into histoclear for 1 0  minutes and mounted with glass 
coverslips using DPX mounting medium.
2.3.3: Cell cultures
The method used for in situ hybridisation of cell cultures was 
essentially identical to that described for in situ hybridisation of the 
cryostat sections.
2.4 Experimental design
2.4.1:'In vitro' experimental design
All basal forebrain cultures were treated with drugs for 24 hours 
or as specified at 37 °C. The drugs were delivered directly to the 
bathing medium in 1 0  |il volumes,assuming that the total volume of 
each chaiuber on the 8 -well multichamber slides was 0.4ml. Drug 
solutions were administered in 10|il of Hanks Balanced Salt Solution 
(HBSS), controls received 10|xl of HBSS. After the desired time 
period, the cells were fixed in a 4% formaldehyde solution,rinsed in 
IxPBS,dehydrated in ethanol and processed for in situ hybridisation or 
staining as previously described. In all experiments, at least one well 
per slide received vehicle treatment for comparison with the other 
treatment on the same slide.
f
•r:.
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2.4,2Pin vivo ' experimental design
Male Wistar rats weighing between 150 and 200g were injected 
intraperitonealy with drug dissolved in physiological saline solution or 
vehicle. At 24 hours postinjection, the rats were killed with an 
overdose of Sagatal injected intraperitonealy. The brains were 
removed and 2 0 fxm-thick cryostat sections were cut and processed for 
in situ hybridisation as described previously.
3
2.5 Haemoglobin solution preparation
■i
This method was identical to Martin et al (1985). Haemoglobin 
needs sodium dithionite excess to convert met-Hb (Fe 3+ Hb) to oxy- 
Hb (Fe2+ Hb(02) 4). Dialysis tubing was boiled in distilled water for 
15-20 minutes then rinsed in distilled water. 1290mg of Hb was 
dissolved in 20ml distilled to give a ImM solution. 34.82mg of sodium 
dithionite was dissolved in 1 0 0 |Xl of distilled water and added to the 
Hb solution. The combined solution was was then poured into the 
dialysis tubing and air bubbles carefully removed, the tubing was 
placed in distilled water for between 2 and 4 horns. The final ImM Hb 
solution was then aliquoted and frozen, to be used within 2  weeks.
2.6 Transgenic models
2.6.1 APP-deficient mice
The production of transgenic mice was performed by Zheng et 
al (1995) as follows: APP-deficient mice were produced by 
homologous recombinaton in embryonic stem cells (Zheng et al 1995). 
To produce mice homozygous for the disrupted gene, cross-matings 
between heterozygous mice were set up. This resulted in 34% wild 
type (+/+), 36% heterozygous (+/-) and 24% were homozygous for 
the mutated APP allele (-/-). The present work studied these 
transgenic mice at 13 months of age. At 13 months, the mice were 
killed by sagatal overdose followed by transcardial perfusion with 
10% formalin solution. After 48 hours, the brains were removed.
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parafin wax embedded and dehydrated through a graded series of 
alcohols. lOjim sections were cut on a vibratome and mounted onto 
slides. Sections were taken for immunohistochemistry using specific 
antibodies against the following: MAP2, synaptophysin, GFAP, APP, 
calbindin, (see Materials section), as described in Section 2.8.
2.6.2 APP/RK mice
The functional significance of the a-secretase processing of 
APP was investigated by Moechars and coworkers (Moechars et 
al.,1996). A mutant APP was created that is pailially defective in 
secretion from three cell types : COS cells, MDCK cells and primary 
neurons. Expression of this a-secretase mutant in mouse brain 
(APP/RK mice) resulted in behavioural disturbances, seizures and 
premature death. The neuropathological changes observed included 
apoptosis, necrosis and reactive gliosis in the hippocampus, cortex 
and amygdala (Moechars et al.,1996).
The current study looked at GFAP immunoreactivity in the 
cortical layers of APP/RK and wildtype mice. The staining method 
was as described in Section 2.8
2.7 Human postmortem Alzheimer’s tissue
Postmortem samples were obtained from Cambridge Brain Bank 
Laboratories. The control and disease brain tissue had been carefully 
matched on the basis of age and sex. The diseased tissue was obtained 
from patients whose cause of death had been detennined as 
Alzheimer’s Disease. Brains were fixed by long-term storage in 10% 
buffered formalin solution. 1 0 pm sections were cut and taken for 
immunohistochemistry using specific antibodies against the following: 
MAP2, synaptophysin, GFAP, 6F3D, AT8 , S182-C20 and S182-N19 
as described in Section 2.8. Double labelling was carried out using the 
method described in Section 2.9.
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2. 8 Immunohistochemistry of tissue sections 2.6 and 2.7.
2.9 Double Labelling
The method is essentially identical to that described in Section
2.2.1 with the following alterations: To remove wax from the sections 
and rehydrate, sections were passed through xylene, a series of 
alcohols (100%, 90%, 70%) and tap water for 2 minutes each. 
Sections to be treated with antibodies to APP and P amyloid were 
incubated in 80% formie acid solution for 10 minutes. All sections 
were incubated in a 0.3% hydrogen peroxide solution for 30 minutes. 
O.IM PBS contained 5% NS and 0.3% Triton-X throughout.
Tissue sections were passed through xylene and a graded series 
of alcohols for 2 minutes each. Sections were then incubated for 30 
minutes in a 0.3% hydrogen peroxide solution. Sections were then 
rinsed three times in O.IM PBS for 10 minutes and incubated for 60 
minutes in monoclonal antibody in O.IM PBS containing 5% normal 
horse semm and 0.3% Triton-X. The sections were then incubated 
for 12 hours at 4 oC in the monoclonal antibody in O.IM PBS 
containing 5% NS and 0.3% Triton-X. Following secondary antibody 
treatment and peroxidase visualisation, sections were rinsed in distilled 
water for 10 minutes, and then incubated in 0.3% hydrogen peroxide 
solution for 1 hour. A further 10 minute wash in distilled water was 
then followed by overnight storage in fresh distilled water. Sections 
were then processed with the polyclonal antibody. The method for this 
was identical omitting the hour long incubation in 0.3% hydrogen 
peroxide and using a different visualisation system.
2.10 Radiolabelliiig
Forebrain and cerebellar section from APP-null and wildtype 
mice were proeessed for radiolabelling using an antirabbit ^^S 
secondary antibody to calbindin. The primary calbinidn polyclonal 
antibody was at a concentration of 1:1000. The steps for the reaction 
were identical to the process described in Section 2.8 with the
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following changes. The ^^S-labelled secondai’y antibody was applied 
at a concentration of O.lpCi/ml as described by Blanchai'd and 
coworkers for 1 hour (Blanchard et al.,1993). Tissue sections were 
then washed thoroughly in distilled water for 3x 5 minutes, and 
dehydrated thiough a graded series of alcohols (70%, 95% and 100%) 
and xylene. Sections were then washed in 100% ethanol and allowed 
to dry. The sections were then exposed to autoradiographic film (p 
max hyperfilm-Amersham) at room temperature. Dry slides were 
attached to paper with tape and exposed to film for three days. Under 
safe light conditions, films were developed for 5 minutes in D19, 
rinsed in water, fixed in Unifix for 5 minutes and rinsed thoroughly in 
water
2\ Chapters 4 and 5: to quantify any diug-induced changes in cultured 
cell immunoreactivity, mean relative optical density levels per well 
were measured using the NIH ‘Image’ 1.52 system. For a single well, 
a total of between 8  to 1 2  cell mean optical density levels per well 
were taken, and the measurements repeated. Background level was 
assessed by measurement of optical density over an area devoid of 
cells, and this measurement was subtracted from all values.
Slides dipped in liquid photographic emulsion had measurements of 
mean number of pixels occupied by silver grains per unit aiea 
assessed.
2.11 Image and statistical Analysis
Image analysis quantification of the results was divided into 
three categories as follows:
1\ Chapter 3 results: to quantify any drug-induced changes in the 
levels of Tau 1 or Tau 2 mRNA , cell silver grain densities in the basal 
forebrain and hippocampal CAl areas were measured using the NIH 
‘Image’1.52 Macintosh image analysis system following dipping of 
slides in liquid photographic emulsion. For each region, a total of ten 
measurements of mean number of pixels occupied by silver grains per 
unit area were taken.
50
3\ Chapter 6: to quantify changes in immunoreactivity in transgenic or 
wildtype mice, mean optical density values per unit area were 
measured using the MCID 2 system. Background level was assessed 
by measurement of optical density over an area devoid of cells, and 
this measurement was subtracted from all values.
Statistical analysis was as follows:
1\ For glial and neuronal cell culture experiments where multiwell 
chambers, and thus multiple treatments compared to control values, 
wre used: analysis of variance ANOVA (one-way stacked) was 
performed on the data (Minitab). The Dunnett’s and Tukey’s posthoc 
tests were then used to assess statistical significance of any drug 
induced changes, and any differences between specific pairs of 
treatment respectively.
2\ For the in vivo work, and a relatively simple experimental design 
where one set of control animals was compared to one set of treated 
animals, the parametric test, the Student’s t test, was used.
3\ For the transgenic work ,where one set of wildtype animals was 
compared to one set of transgenic animals, and an uneven distribution 
was apparent, the non-parametrie Mann Whitney U test was chosen.
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MATERIALS
Antibodies
APP 22c 11 2.5mg/ml, rabbit polyclonal Boehringer Mannheim
AT8 1 :1 0 ,0 0 0 , mouse monoelonal Boerhinger Mannheim
pA4 (6F3D) 1 :1 0 0 , human monoelonal DAKO
COX2 1 :1 0 ,0 0 0 , mouse monoelonal Transduction
Laboratories
calbindin 1 :1 0 0 0 , rabbit polyclonal MRC Labs
ChaT 1:500, mouse monoclonal Sigma
GFAP 1 :1 0 0 0 , rabbit polyclonal DAKO
MAP2 1 : 1 0 0 , mouse monoclonal Boehringer Mannheim
NSE 1 :1 0 0 0 , mouse monoclonal AFFINITI
synaptophysin 1 : 1 0 0 , mouse monoclonal SIGMA
S182-N19 1:50, goat polyclonal Santa Cruz Biotech.
S182-C20 1 :1 0 0 , goat polyclonal Santa Cruz Biotech.
tau 1:500, mouse monoelonal Sigma
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LPS, sodium dithionite, amphotericin B, Hb, indomethacin, PGE2, 
SNP, W7, SNAP, SIN-1. SIGMA
n
%
Drugs
• poly-L-lysine, pe iy-D-lysine, nickel chloride, nitro blue tétrazolium, 
hydrogen peroxide, p nicotinamide adenine dinucleotide, glycerol, 
diaminobenzidine, SbromocyclicGMP, DMSG, DEPC, kainate, 
NMDA, DTT, EDTA, copper sulphate, ammonium sulphate, glycine.
• sodium chloride, sodium dihydrogen orthophosphate, jodium  
hydrogen phosphate, sodium thiosulphate, sodium citrate, ethanol, 
sodium acetate, coverslips. BDH
• paraformaldehyde, acetic acid, sodium pyrophosphate. ALDRICH 
CHEMICAL CO.
• dextran sulphate, terminal deoxynucleotidyltransferase buffer.
BOERINGER MANNHEIM.
• [a-” S]dATP. Df/POAT.
• Dulbecco’s modified Eagle’s medium, Dulbecco’s modified Eagles Imedium nutrient mixture F 12, B27 supplement, heat inactivated 
fetal calf serum, Hank’s balanced salt solution, trypsin, trypsin- |
EDTA, penicillin-streptomycin, noimal horse semm. GIBCO.
• ABC complex, mormal goat serum. VECTOR LABORATORIES.
• MK801 ondansetron, aniracetam. RESEARCH BIOCHEMICALS.
• APV, AMPA, ACPD, CNQX. TOCRIS NEURAMIN.
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• neutral red. GURR.
•  GYKI. Gift from Prof Stone, University o f Glasgow. 
Chemicals
• film, emulsion. KODAK.
•  DPX mountant. BDH.
• histoclear. NATIONAL DIAGNOSTICS
• sephadex G25 medium. PHARMACIA
• analytical grade alcohol. AN  ALAR
•  Triton-X-100, formic acid. SIGMA
• silica gel. F/50iV5
Solutions
Hybridisation
buffer
50% deionised formamide, 0 .0 2 % polyadenylic acid, 10% 4x st; 
saline citrate solution, 5% 0.5M sodium phosphate, 1% sodium 
pyrophosphate and 10% dexti an sulphate. Made up in DEPC-tr 
water.
I X standard 0 .15M sodium chloride, 0.015M sodium citrate, pH 7.0. 
saline citrate 
solution (SSC)
I x P B S
DEPC water
Tris-EDTA
buffer
I M D D T
3.8g NaCl, 4.05ml IM disodium hydrogen phosphate, 0.95ml 
sodium dihydi'ogen phosphate, made up to 500ml with distilled 
1ml DEPC per litre of deionised water
lOmM Tris, ImM EDTA in DEPC water
3.09g DTT in 20ml 0.0IM sodium acetate, pH 5.2
300 ml methanol, 3ml hydrogen peroxidehydrogen 
peroxide
acid-alcohol 0.5% HCl, 70% ethanol
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haematoxylin 
Neutral Red
100% solution (Sigma) 
0.2%, 1ml GAA
Koelle Medium 500mg copper sulphate, 750mg glycine moxed in 750ml of disti 
water. Add: 74ml of 0.2M acetic acid and 176ml of 0.2M sodiu: 
acetate. Buffer solution to pH 5.0 with sodium hydroxide. Store 
fridge.
sulphide
solution
In fume hood mix: 10ml of IM acetic acid, 40ml of distilled wai 
a few drops of ammonium sulphide.
Oligonucleotide probes
MAP2
taul
tau2
complementary to the region coding for the 
N-terminal 15 amino acids common to all 
MAP2 isoforms (Kindler et al 1990).
complementary to the nucleotide encoding 
bases 752 to 909 excluding 796 to 987 
complementary to the nucleotide encoding 
bases 796 to 788
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Chapter 3
Tau gene expression
Introduction
As has been discussed in Chapter 1 section 1.5.2.1, the six 
isoforms of tau can be divided into Tau 1 and Tau 2. In the present 
study, radiolabelled oligonucleotide probes were used to investigate 
the effects of various compounds related to cognition and/or possible 
tau modulation on Tau 1 and Tau 2 mRNA expression in adult rats. 
The basal levels of expression of Tau 1 and Tau2 mRNA in adult and 
neonatal rats was also investigated. In parallel with these experiments, 
tau immunoreactivity and gene expression levels were studied in vitro 
in primary neuronal basal forebrain cultures, and these results are 
discussed in Chapter 5.
In the present study, the following compounds were 
administered intraperitoneally to adult rats:
3.1 Ondansetron
Ondansetron is a 5HT-3 receptor antagonist which along with 
its well documented anti-emetic properties, has been shown to have 
cognitive enhancing properties, for example by reversing the 
scopolamine-induced deficit in the mouse dark-light box (Barnes et 
al., 1990). The compound at a dose of Img/kg has recently been 
shown to ameliorate the performance deficits of the anticholinergic 
drug scopolamine in mice (Roychoudhury and Kulkarni., 1997). The 
action of ondansetron in this and other behavioural paradigms has led 
to the suggestion that the drug may be of some clinical importance in 
the treatment of cognitive impairment such as in age-associated 
memory impairment in non-disease states (Crook and Lakin.,1991). 
However, initial clinical trials with the drug have failed to show any 
ability to improve cognition (Hall and Ceuoens.,1990).
3.2 MK801
MK801 is a non-competitive N-methyl-D-aspartate (NMDA) 
receptor antagonist that binds with high affinity to the phencyclidine 
binding site (Clineschmidt et al., 1982). It has been described as both a 
neuroprotective agent (Gill et al., 1988; Sato et al., 1988), and a
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neurotoxin (Olney et al., 1989). It protects against ischaemic damage 
(Gill et al., 1988) and is a potent anticonvulsant (Sato et al.,1988). In 
cell culture, glutamate has been shown to increase tau 
immunoreactivity (Sindou et al., 1992; Couratier et al., 1995). The 
effects of glutamate and other excitatory amino acids on cytoskeletal 
protein immunoreactivity in cell culture is discussed in Chapter 5. In 
parallel with those results, the use of MK801 enabled investigation of 
NMD A receptor response to tau gene expression in vivo. MK801 is 
lipid soluble and thus able to cross the blood brain barrier. Some of 
the behavioural effects induced by the drug are similar to those of 
phencyclidine, for example, dysphasia and hallucinations.
3.3 GYKI52466
Excessive activation of glutamate receptors is thought to play a 
cmcial role in the pathogenesis of a number of neurological disorders 
including epilepsy and ischaemia (Choi et al., 1988; Rothman and 
Olney., 1986). Consequently, glutamate antagonists may be useful as 
therapeutic agents in such disorders. The selective protective effects 
of the benzodiazepine compound GYKI52466, and the quinoxaline- 
dione compound NBQX have been reported in the four vessel 
occlusion model of transient global ischaemia in rats (Le Peillet et 
al., 1992). Cerebroprotection by GYKI52466 is thought to be due to 
blockade of the action of glutamate on postsynaptic non-NMDA 
receptors; evidence suggests that GYKI52466 is a potent antagonist 
at AMPA and kainate receptors with little or no action at NMDA 
receptors (Ouarduoz and Durand., 1991; Moncada et al., 1991). 
Further evidence suggests that that one possible mechanism by which 
GYKI52466 produces neuroprotection following transient ischaemia 
is by prevention of an increase in extracellular glutamate concentration 
(Arvin et al., 1992).
Glutamate toxicity has been shown to induce a concentration- 
dependent increase in tau immunoreactivity in primary neuronal 
cultures (Mattson., 1990; Sindou et al., 1992). The use of
GYKI52466 in the present work was to investigate any possible 
effects of non-NMDA receptor action on tau gene expression in vivo.
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3.4 Indomethacin
Non steroidal anti-inflammatory drugs (NSAIDS) are among the 
most widely used therapeutic agents. As has been discussed in 1.10.1, 
there has recently been evidence suggesting an inverse relationship 
between NSAID use and onset of Alzheimer’s Disease. NSAIDs aie 
thought to reduce the risk of developing the disease (Breitner et 
al.,1994; McGeer et al., 1992; Rich et al.,1995). NSAIDs inhibit 
cyclooxygenase, the enzyme responsible for the production of 
prostaglandins. Ideally, NSAIDs would selectively inhibit the inducible 
isoform of cyclooxygenase; inhibition of the constitutive form causes 
the side effects such as gastric and renal damage, and skin reactions. 
Previous work with indomethacin has used an intraperitoneal dose of 
5mg/kg (Bret-Dibat et a l, 1994). The plasma half life of the drug is 
short, around 30 mins in adult humans. A dose of 20mg/kg has been 
shown to result in 30% mortality in adult rats (Beyer., 1978). In the 
present study, adult rats were exposed to 5mg/kg indomethacin to 
investigate any possible effects of the NSAID on Tau 1 of Tau2 gene 
expression.
3.5 Aniracetam
Aniracetam is a member of the nootropic class of drug, and has 
been shown to improve the condition of elderly patients suffering from 
slight to moderate mental deterioration (Canonico et al., 1991). It is 
thought that aniracetam may enhance the efficacy but not the potency 
of AMPA-induced calcium influx in cerebellai" granule cells ((Gouliaev 
and Senning .,1994). Previous work has used doses of between 10 and 
300mg/kg intraperitoneally in rats (Consolo et al., 1990; Chopin et 
al.,1992), and for the present work a dose of lOmg/mg was chosen.
3.6 In situ hybridisation measurements
As discussed in Chapter 2 section 2.3, the method for in situ 
hybridisation in this section of work and also that in Chapter 5, was as 
described by Morris (1989; 1992). The specificity of the hybridisation 
protocol is suggested by various pieces of evidence. First, the high 
stringency conditions employed prevent the hybridisation of the
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probes to any other sequences in the tissue. The unique and well 
documented pattern of Tau 1 and Tau2 gene expression in neonatal 
and adult tissue indicates that these probes are specific. The frequent 
use of the probes in our laboratory indicates that the hybridisation 
conditions used allow specific localization of the mRNA sequences to 
which the probes are complimentary. However, it is worth mentioning 
the control systems normally employed for in situ hybridisation to 
prove that hybridisation signals detected represent the authentic 
complementary mRNA. The controls include hybridisation with a 
labelled sense oligonucleotide, pretreatment of tissue sections with 
RNAse A, Northern blots, and the competitive inhibition of the 
hybridisation signal by excess unlabelled oligonucleotide.
Results analysis was performed by taking careful measurements 
of the number of pixels occupied by silver grains in defined areas of 
the basal forebrain and hippocampal CAl regions. Between ten and 
fifteen similarly sized areas in each region were marked out. The 
number of pixels occupied by silver grains within each measured, 
ensuring that all of the basal forebrain and hippocampal CAl regions 
were accounted for, and that no overlap between marked areas had 
occurred.
Results
3.7 Tau gene expression in the basal forebrain and hippocampal 
regions in adult and neonatal rats.
Following sectioning of the brain regions, slides were taken for 
in situ hybridisation using probes for Taul and Tau2 mRNA. It can be 
seen that levels of Taul are significantly higher in the neonatal rats in 
both the CAl and hippocampal regions [Fig. 3.1.1]. Levels of Tau2 
were significantly higher in the CAl and basal forebrain regions in the 
adult.
3.8 Ejfect o f a single drug treatment on tau gene expression.
Following intraperitoneal injection of ondansetron (lOOng/kg, 
n=4 ), MK801 (Img/kg, n=4), GYKI52466 (30mg/kg, n=4 ), 
indomethacin (5mg/kg, n=3 ), and aniracetam (lOmg/kg, n=4 ) or 
vehicle (0.9% saline), Taul and Tau2 levels were compared in treated 
and control animals in the basal forebrain and CAl regions. As can be 
seen in Fig. 3.2.1, neither Taul or Tau2 mRNA levels were 
significantly altered by a single dose of ondansetron after 24 hours, 
p>0.05 by Student’s t test. Fig. 3.2.2 illustrates that a single dose of 
MK801 did not significantly alter Taul or Tau2 levels, again p>0.05 
by Student’s t test. Similarly, a single dose of GYKI53488, 
indomethacin and aniracetam did not significantly alter Taul or Tau 
levels as illustrated in Figs 3.2.3, 3.2.4 and 3.2.5, p>0.05 by Student’s 
t test.
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Figure 3.1.1 : Comparison of tau gene expression in the basal
forebrain and CAl hippocampal regions of adult and neonatal rats.
The brains were removed from adult and neonatal (E l7) rats, and 
sections prepared for in situ hybridisation.
Results obtained from autoradiographic films are expressed as mean 
relative optical density levels ± SEM.
Statistical analysis was carried out using the Student’s t-test.
* p<0.05.
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Figure 3.2.1 : Effect of a single dose of ondansetron on tau gene
expression in adult rats.
Adult rats were intraperitoneally injected with vehicle (0.9% saline) or 
ondansetron (lOOng/kg). After a time period of 24 hours, animals 
were killed, their brains removed, and sections processed for in situ 
hybridisation.
Results obtained from autoradiographic film are expressed as a 
percentage change of control values.
Statistical analysis was carried out using the one sample t-test. No 
significant changes were observed.
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Figure 3.2.2 : Effect of a single dose of MK8Q1 on tau gene
expression in adult rats.
Adult rats were intraperitoneally injected with vehicle (0.9% saline) or 
MK801 (Img/kg). After a time period of 24 hours, animals were 
killed, their brains removed and sections processed for in situ 
hybridisation.
Results obtained from autoradiographic film are expressed as a 
percentage change of control values.
Statistical analysis was carried out using the one sample t-test. No 
significant changes were observed.
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Figure 3.2.3 : Effect of a single dose of GYK153488 on tau gene
expression in adult rats.
Adult rats were injected intraperitoneally with vehicle (0.9% saline) or 
GYKI53488 (30mg/kg). After a time period of 24 hours, the animals 
were killed, their brains removed, and sections processed for in situ 
hybridisation.
Results obtained from autoradiographic film are expressed as a 
percentage change of control values.
Statistical analysis was carried out using the one sample t-test. No 
significant changes were observed.
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Figure 3.2.4 : Effect of a single dose of indomethacin on tau gene
expression in adult rats.
Adult rats were injected intraperitoneally with vehicle (0.9% saline) or 
indomethacin (5mg/kg). After a time period of 24 hours, the animals 
were killed, their brains removed, and sections processed for in situ 
hybridisation.
Results obtained from autoradiographic film are expressed as a 
percentage change of control values.
Statistical analysis was carried out using the one sample t-test. No 
significant changes were observed.
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Figure 3.2.5: Effect of a single dose of aniracetam on tau gene
expression in adult rats.
Adult rats were injected intraperitoneally with vehicle (0.9% saline) or 
indomethacin (lOmg/kg). After a time period of 24 hours, the animals 
were killed, their brains removed, and sections processed for in situ 
hybridisation.
Results obtained from autoradiographic film are expressed as a 
percentagechange of control values.
Statistical analysis was carried out using the one sample t-test. No 
significant changes were observed.
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Discussion
3.9 Tau gene expression in the basal forebrain and CAl hippocampal
regions in adult and neonatal rats.
Goedert and colleagues have demonstrated the existence of six 
isoforms of human tau protein ranging from 352 to 441 amino acids in 
length (Goedert et al.,1989a; Goedert et al.,1989b). Type 1 and Type 
2 tau proteins mRNAs are thought to be developmentally regulated. 
Type 1 mRNA encoding the three repeat isoforms are expressed 
throughout life, whereas Type 2 transcripts encoding the extra amino 
acids were absent from the human fetal brain but expressed in the 
adult brain throughout life. This indicated that tau is a nervous system 
specific protein, and that tau mRNA is subject to developmentally 
regulated alternative splicing (Goedert et al., 1989a). A developmental 
change in mRNA levels for the microtubule associated protein MAP2 
has been reported in the rat brain (Garner and Matus.,1988). The 
levels of transcripts encoding the three and four repeat isoforms of 
human tau have been shown to be unaltered in the cerebral cortex of 
Alzheimer's Disease patients (Goedert et al., 1989b; Goedert et 
al., 1989a). Multiple tau isoforms are found in neurofibrillary tangles, 
and it is unhkely that the overexpression of Type 1 or Type 2 protein 
mRNAs causes the formation of paired helical filaments (Goedert et 
al., 1989b).
A comparison of Type 1 and Type 2 tau protein in neonatal and 
adult rat brain agrees with previous evidence; Type 1 mRNA is high in 
the neonatal brain, while Type 2 is abundant in the adult. The juvenile 
tau consists of a single major component and the transition from this 
simple pattern to the more complex pattern of 4-6 bands is thought to 
begin ai’ound postnatal day 15 and be completed by postnatal day 35 
(Couchie and Nunez., 1985). The neonatal rats used in the present 
work were at gestation day 17, so as expected very little Type 2 tau 
was seen. Detailed development studies on tau in the human brain 
have not been cai’ried out so it is possible that the pattern of 
expression in embryonic human brain may be similar to that seen in the 
rat brain. It is thought that stage and cell specific expression of at least 
some types of tau occurs in the human brain (Goedert et al., 1989a).
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GYKI52466:
The effects of benzodiazepines on the CNS include reduced 
anxiety and aggression, and sedation. Approximately 40 minutes after 
treatment, the rats displayed marked sedation, suggesting that the 
drug has reached its target site.
Indomethacin:
No behavioural effects were seen following treatment with 
indomethacin, although with NSAIDS behavioural side effects aren’t
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3.10 Ejfect o f single dose intraperitoneal injections on tau gene
expression in adult rats.
None of the drugs used had any effect on tau expression in 
either the hippocampus or basal forebrain. It is important to discuss a 
number of considerations that should be made regarding the 
experimental procedures. First, whether the drugs reached the target
sites, and secondly, whether the time points and concentrations used 
were effective. It would be of interest to repeat the experiments using 
different time points up to 24 hours. A more stringent experimental 
procedure would apply a range of concentrations.
Ondansetron:
No visible behavioural effects were observed, and given that no 
change in Taul or Tau2 mRNA levels occurred, it is debatable as to 
whether the drug reached the target sites.
MK801.
Following the intraperitoneal injections of the drug, the rats 
displayed a transient sedation phase for approximately 30 minutes. 
This would suggest that the drug had reached its target, and MK801 
is lipid soluble, and thus able to cross the blood brain banier. Taul 
and Tau2 mRNA levels are thus unlikely to be affected by this dosage.
I
normally apparent. No changes in Taul or Tau2 mRNA levels were 
seen, however, perhaps a more thorough experiment would have 
made use of different time points and doses.
Aniracetam:
The actions of aniracetam in the brain have been debated. The 
compound is thought to be far from ideal as a drug; its effect on 
AMPA receptors is thought to be weak and short term, with little of 
the drug reaching the brain as it is broken down by enzymes and acids 
in the stomach (Service .,1994), In light of this, perhaps a larger dose 
of the drug should have been used, and a shorter time point 
investigated.
Summary
Using in situ hybridisation, the expression of Tau 1 and Tau 2 
mRNA in neonatal and adult rats, and, in adult rats in response to 
intraperitoneal drug injections has been investigated. In agreement 
with the literature, Tau 1 mRNA levels were higher in the neonatal 
brain, and Tau 2 mRNA levels higher in the adult brain. Both Tau 1 
and Tau 2 mRNA levels remained unaltered following intraperitoneal 
injection of the listed compounds. The results of these experiments, 
with the conditions mentioned, suggest that expression of the tau gene 
does not show a great deal of plasticity. However, it is possible that a 
shift in expression of one of the other splice variants of tau may go 
undetected just compar ing typel and type2 tau mRNA levels.
Leading on from these experiments, tau protein and mRNA 
expression has been investigated in vitro using primary dissociated 
neuronal cultures, and these results are discussed in Chapter 5. In 
view of the fact that in the neuronal cell culture experiments, cellular 
levels of the cytoskeletal protein MAP2 change after exposure to 
excitatory amino acids and nitric oxide releasers with no change in 
tau, perhaps it would be of interest to repeat these experiments using 
radiolabelled oligonucleotide probes to monitor MAP2 mRNA levels.
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Chapter 4
Regulation and expression of 
NADPH diaphorase 
immunostaining in 
glial cultures.
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Introduction
This section of work made use of glial cell cultures. As 
described in Chapter 2, section 2.1.2, the method of cell culture is 
based on that of McCarthy and De Vellis (1980). As discussed in the 
following introductions, excitatory amino acids, interleukin and 
proteases have been shown to have possible involvement in the 
neuropathology of Alzheimer’s Disease. The aim of the present work 
was to investigate the effects of these compounds on NADPH 
diaphorase immunostaining in glial cells in culture.
4.1 Excitatory Amino Acids 
Introduction
Excitatory amino acids (EAAs), such as glutamate and 
aspartate, are the major excitatory neurotransmitters in vertebrates, 
lonotropic BAA receptors have been classified into three major 
subtypes based on their differential sensitivity to a-amino-3-hydroxy- 
5-methylisoxazole-4-propionate (AMPA), kainate and N-methyl-D- 
aspartate (NMDA) as selective agonists. Glutamate binds with high 
affinity to all three subtypes of receptor. More recently, a novel class 
of EAA receptors was discovered; the metabotropic receptors. These 
receptors are linked to either stimulation of inositol phospholipid 
hydrolysis or to inhibition of phospholipase C activation. NMDA, 
AMPA and kainate receptors can be further subdivided into non- 
NMDA (AMPA and kainate), and NMDA receptors. The ion channel 
activated by the NMDA receptor has two distinguishing 
characteristics: it is permeable to both sodium and calcium and is 
blocked by magnesium in a voltage-dependent manner. Via an influx 
of calcium through the channel, cGMP synthesis is stimulated. This 
stimulation is blocked by magnesium and the selective NMDA 
receptor antagonist D-(-)-2-amino-5-phosphonovaleric acid (APV).
In the present study, the following compounds have been used 
to investigate the effects of NMDA and non-NMDA-receptor induced 
changes in NADPH diaphorase immunoreactivity in glial cell cultures: 
glutamate, AMPA, an AMPA antagonist- CNQX, NMDA and the 
selective NMDA receptor antagonist APV.
EAAs and Neurodegeneration
Besides its role as the major excitatory neurotransmitter in the 
mammalian nervous system, glutamate has been shown to cause 
degeneration. Lucas and Newhouse first demonstrated the abihty of 
systemically injected glutamate to cause degeneration in the retina 40 
years ago (Lucas and Newhouse.,1957). Olney showed that 
exogenous glutamate causes CNS lesions 12 years later 
(Olney., 1969). These findings led to the 'excitotoxic' hypothesis of 
glutamate's action (Olney et al., 1971). Excessive release, abnormal 
leakage or impaired uptake of glutamate or, altered glutamate 
receptor sensitivity have all been postulated as possible causes of 
death in many neuropathological disorders such as Huntington's 
disease, ischaemia, epilepsy and Alzheimer's Disease.
In addition to the well-established cholinergic deficits, other 
neurotiansmitters are also affected in Alzheimer's Disease such as 
biogenic amines, amino acids and neuropeptides (Hardy et 
al.,1985;Gottfries.,1990). In Alzheimer's Disease, cortical and 
liippocampal pyramidal neurons, which are particularly affected by 
neurofibrillary tangles and neuronal degeneration, use glutamate as a 
neurotransmitter (Maragos et al., 1987). Loss of glutaminergic 
terminals and reduction of glutamate content in these structures have 
been reported (Cross et al., 1986; Procter et al., 1988; Lowe et 
al., 1990). A decrease in gluatamic acid levels has been described in 
the outer molecular layer of the dentate gyrus , the major target of the 
entorhinal projection to the hippocampus, and in the neocortex in 
Alzheimer’s Disease (Hyman et al., 1987; Hyman et al., 1984). The 
anatomical distribution of glutamate metabotropic binding sites in 
comparison to AMPA and kainate binding has been studied in the 
hippocampal region of Alzheimer’s Disease brains, and significantly 
reduced levels of glutamate metabotropic and AMPA binding sites in 
the diseased tissue were observed in the CAl region (Dewar et 
al., 1991). Taken together these data suggest a role for EAAs in the 
pathogenesis of Alzheimer's Disease (Maragos et al., 1987). 
Discrepant changes in the concentration of several amino acids have 
been reported in postmortem tissue from Alzheimer's Disease patients. 
Whether these changes correlate with a modification of the 
neurotransmission of these amino acids remains to be seen. Increased
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levels of glutamine and glycine have been observed, and reduced 
glutamate and taurine contents. (Alom et a l ,1991; Pomara et 
al., 1992). Conflicting data for aspartate levels in the cortex of 
Alzheimer's Disease patients has been reported (Sasaki et al., 1986;
Lowe et a l, 1990). The decrease in glutamate levels seen in cortical 
projections with decreased choline acetyltransferase levels suggests a 
regulation of glutaminergic cortical neurons by the chilinergic 
teiminals, and evidence supports a role for glutamate in cortical 
cholinergic terminals (Szerb and Fine., 1989).
A key link between glutamate receptor activation and 
subsequent neurodegeneration is thought to be agonist-triggered 
calcium entry. Small subsets of neurons have been found to possess 
clacium-permeable AMPA/kainate receptor-gated channels and 
evidence suggests that some of these neurons are sensitive to calcium- 
dependent AMPA/kainate receptor mediated injury (Ozawa et 
a l ,1991; Brorson et al.,1992; Weiss et a l ,1994). Yin and colleagues 
demonstrated kainate injury to cultured basal forebrain cholinergic 
neurons to be calcium dependent (Yin et a l, 1994). The heightened 
vulnerability of basal forebrain neurons to kainate toxicity may reflect 
rapid calcium entiy through calcium-permeable AMPA/kainate 
channels, and there is the possibility that AMPA/kainate receptor- 
mediated injury may contribute to Alzheimer's Disease 
neuropathology (Yin et a l, 1994).
Astrocytes perform two functions important for maintaining 
glutamate concentrations in the extracellulai' space at nontoxic levels.
The first is high-affinity glutamate uptake, the second is the 
conversion of glutamate to glutamine by glutamine synthase.
Structural analysis has shown that astrocytes aie associated with 
glutaminergic synapses and that the fine astrocytic processes of these 
regions are enriched in glutaminergic synthase (Derouiche and 
Frotscher.,1991). Removal of astrocyes from mixed clutures has been 
shown to lead to neuronal death in the presence of high glutamate 
concentrations (Sugiyama et a l, 1989; Rosenberg et al., 1992).
Astrocytes play a crucial role in the maintenance of the CNS, and 
injuiy to astrocytes may promote neurodegeneration directly or 
indirectly in diseases such as Alzheimer's Disease. Ap has been shown 
to increase the secretion of basic fibroblast growth factor and 
interleukin-1 from astrocytes (Aiaujo and Cotman.,1992).
à
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Overproduction of these components can result in increased APP and 
other plaque components thus promoting plaque development.
Evidence has shown that calcium-mediated glutamate toxicity in 
primary neuronal cultures induces a concentration-dependent increase 
in tau immunoreactivity (Mattson., 1990; Sindou et al., 1992). 
Glutamate has been shown to induce a shift from the lowest to the 
highest molecular weight tau isoform and an acidification of tau 
proteins (Sautiere et al., 1992). NMDA has been found to induce a 
significant increase in tau immunoreactivity in rat embryonic neurons, 
and this is directly related to the onset of neuronal death (Couratier et 
al., 1995). This immunoreactivity modification is thought to appear 
under both fast and slow NMDA-receptor mediated toxicity, under 
magnesium-free conditions and is prevented by NMDA receptor 
agonists (Couratier et al., 1995). As mentioned earlier, acute NMDA 
toxicity is associated with an excessive influx of calcium into neurons;
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in both hippocampal and cerebellai’ slices NMDA toxicity is abolished i
when calcium is omitted from the medium (Choi., 1987). Another
potential mechanism underlying NMDA toxicity is the production of 
NO (Dawson et al.,1992). Direct evidence for the involvement of NO 
in NMDA toxicity was illustiated in a study showing that inhibition of 
NOS reduces toxicity (Moncada and Higgins., 1991). Calcium can 
activate extralysosomal proteases, such as calpains, which are 
involved in cytoskeletal remodelling. It has been shown that calpains 
can induce proteolysis of tau protein (Johnson et al., 1989). Couratier 
and colleagues showed that modifications in tau immunoreactivity are 
related to neuronal depolarisation ,and that both glutamate and 
sodium-channel coactivation are together needed to, produce changes 
in tau immunoreactivity (Couratier et al., 1995).
4.2 Nitric Oxide Toxicity
As mentioned previously, NO has been implicated in the 
neurotoxicity associated with glutamate receptor stimulation (Dawson 
et al., 1990), and this observation has led to speculation that glutamate 
receptor stimulation and thus NO may be involved in the pathology of 
neurodegenerative diseases such as Alzheimer’s Disease (Meldrum and 
Garthwaite.,1990). Mitochondrial damage has also been suggested to 
be important in the pathology of Alzheimer's Disease (Beal et
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al., 1993). Increasing evidence suggests that the NO derivative 
peroxynitrite anion (ONNO-), formed from a reaction between 
superoxide anion (02-) and NO, may be responsible for the 
neurotoxic effects of NO (Lipton et ah, 1993; Radi et ah,1991). 
Bolanos and colleagues suggested that ONOO- may be the agent 
responsible for the mitochondrial damage seen in astrocytes following 
induction of NOS (Bolanos et ah, 1994). It has recently been shown 
that neurons are much more vulnerable to damage following exposure 
to ONOO- than astrocyes, and that ONNO- synthesised and released 
by astrocytes under trauma may diffuse to neuronal target cells with 
damaging consequences (Bolanos et ah, 1995). This mechanism may 
explain the the neurotoxicity associated with NO and mitochondrial 
dysfunction in neurodegenerative diseases.
The use of the calmodulin antagonist W7 in the present work 
has enabled an investigation into the possible type of NOS involved in 
any compound-induced change in NADPH diaphorase 
immunostaining.
4.3 Proteases
Proteases are thought to be involved in the neuropathology of 
Alzheimer's Disease. Serine proteases such as activated complement 
factors have been found in plaques (Carrell et ah, 1986) and, the serine 
protease inhibitor a  1 -antichymotrypsin domain is located within APP 
(McGrogan et ah,1988). As discussed in Chapter 1 Section 1.4.4, 
studies of the proteolysis of Ap revealed three distinct pathways. 
Candidates for the proteases involved in the generation of soluble and 
potentially amyloidogenic Ap have been researched. An imbalance 
between proteases and their inhibitors may play a role in the 
neuropathology of Alzheimer's Disease.
Thrombin, a serine protease of the blood coagulation system, 
has been shown to have profound effects on cellular activation in 
vitro. It is mitogenic for fibroblasts and astrocytes (Cavanaugh et 
ah, 1990), inhibits neurite outgrowth of neuronal cells (Grand et 
ah, 1989) and reverses the stellation of astrocytes (Cavanaugh et 
ah, 1990). Thrombin has also been shown to regulate a number of 
cellular events in the nervous system (Dihanich et ah, 1991), and it is 
thought that a balance between thrombin and thrombin-like proteinase
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on astrocyte surfaces may be crucial for normal astrocyte function 
(Cavanaugh et ah, 1990). The levels of NGF secreted by primary 
astrocytes are enhanced when cells are cultured in the presence of a~ 
thrombin (Neveu et ah, 1993). It is thought that prothrombin 
synthesised in the brain could constitute an important source of 
protease able to modulate the expression of NGF. A synergistic effect 
of nitric oxide synthase and a serine protease has been observed in 
endothelial cell cultures (Stamler et al., 1992). Serine proteases and 
their inhibitors have been found in amyloid fibrils (Gollin et al., 1992), 
and are thought to have an important role in the neuropathology of 
Alzheimer’s Disease.
The present work used the following proteases and inhibitors : 
a-chymotrypsin and its inhibitor chymostatin, trypsin and trypsin 
inhibitor.
4.4 LPS and IL-1
Microglial cells, the brain resident macrophages, are thought to 
be involved in most inflammatory and degenerative diseases in the 
CNS. Like peripheral macrophages, they can be stimulated by 
lipopolysacchaiide to release NO and prostanoids (Chao et al., 1992; 
Lee et al., 1995). The relationship between LPS and iNOS in glial cells 
has previously been discussed in detail.
A role for interleukin-1 (IL-1) as a mediator of astrocyte 
activation and growth was first demonstrated by Giulian and 
coworkers (Giulian and Lachman.,1985). It was shown to induce 
proliferation of astrocytes cultured from neonatal rat brains, and when 
injected into the brain to induce reactive gliosis and enhanced 
immunoreactivity for GFAP protein. The cytokine is produced by 
astrocytes and microglia (Giulian et al., 1986), and has been shown to 
cause the induction of the inducible form of NOS (iNOS) in astrocytes 
(Lee et al., 1993). Conflicting evidence has emerged concerning the 
precise role of IL-1. It is now thought that the pattern of astrocyte 
activation in response to IL-1 is that of a stress response rather than a 
response to a growth factor (Dinarello.,1994). It is still thought to be 
a key candidate in the induction of reactive gliosis (Lee et al., 1995). 
Other cytokines such as interferon-% are thought to act as priming 
signals for astrocytes (Lee et al., 1995). Thus, regulation of the IL-1
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system may underlie many of the common pathological processes 
involving reactive gliosis. APP mRNA was found to be enhanced by 
IL-1 in primary neuronal cultures, and thus may have a role in the 
neuronal mechanism related to Ap deposition (Forloni et ah, 1992).
As both LPS and IL-1 are well documented inducers of iNOS in 
cultured glial cells, these compounds were chosen as positive controls 
in the present work, and used to illustrate an increase in NADPH 
diaphorase immunostaining.
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Results
4.5 Characterisation o f glial cultures.
In cells cultured from the basal forebrain region of postnatal rats 
(P2), a high proportion of the cells were identified as glial cells on the 
basis of their large flat epithelial-like morphology and characteristic 
positive immunostaining for glial acidic fibrillary protein (GFAP), 
revealing large unstained nuclei [Fig. 4.1a]. The glial cells were 
typically 100p.m in diameter. A small proportion of neuronal cells was 
present, clearly distinguishable from the glial cells on the basis of their 
morphology. To reduce contamination by neuronal cells, the culture 
flasks were stirred between platings to dislodge the neuronal cells 
which proved to be less robust than the glial cells. The identity of the 
neuronal cells was confirmed by in situ hybridisation using an 
oligonucleotide probe specific for microtubule-associated protein 2  
(MAP2) mRNA which is found only in neuronal cell types. After one 
week in culture, the cells were shaken on an orbital shaker to dislodge 
oligodendrocytes.
The cultured glial cells stained positive for NADPH diaphorase 
[Fig. 4.1b]. Processes with stellate-like morphology could be seen 
with the staining. These flat structures were long (lOOjim) and had 
swellings along their length.
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Figure 4.1 Characterisation of rat glial culture cells.
Cells were processed for immunocytochemistry using antisera against:
A GFAP Photograph illustrates ghal cell body at high magnification.
Cells were also processed for:
b\ NADPH diaphorase staining Photograph illustrates gUal cell body at low nMgnih..*:».
Scale bar represents:
A 5pm.
B 1 0 0 pm.
B
4.6 Effect o f excitatory amino acids on NADPH diaphorase levels in
glial cultures.
Cultures were treated with 50jO.M glutamate, 50{LtM AMP A or 
50/100|xM NMDA made up in HBSS and incorporated directly into 
the culture medium. Control wells recieved HBSS alone. Cells were 
exposed to the drugs for a time period of 24 hours. Cells were also 
treated with 50pM glutamate along with lOOjaM of the inhibitor APV 
for 24 hours, and 50|U,M AMPA plus lOOpM of the inhibitor CNQX, 
also for a time period of 24 hours.
Analysis of variance revealed that treatment with the excitatory 
amino acids glutamate and AMPA had resulted in a significant 
increase in NOS levels [Figs 4.2.1, F (4, 186 ) = 55.84, p<0.001, 
p<0.05, n = 7 cultures]. NMDA treatment also resulted in a significant 
increase in NOS levels [Fig. 4.2.2, F (2,140) = 25.17, p<0.001, 
p<0.05, n = 6  cultures].
Treatment of the cultures with the inhibitors APV(100p.M) and 
CNQX(100p.M) reduced the glutamate and AMPA-induced increases 
in NADPH diaphorase activity to near control levels. The values 
resulting from simultaneous treatment with glutamate and APV, and 
AMPA and CNQX for a time period of 24 hours are significantly 
different from those obtained by agonist alone [Fig. 4.2.1, p<0.05 by 
Tukey’s pairwise test.].
In order to further investigate the involvement of NOS and 
identify the type of NOS present in the glial cells and increased in the 
presence of the excitatory amino acids, cultures were exposed to 
glutamate (50|iM) for 24 hours, W7 (400|iM) for 4 hours prior to 
fixation, and the two compounds simultaneously. As shown 
previously, 50p.M glutamate caused an increase in NADPH 
diaphorase activity. Analysis of variance revealed that Treatment with 
400|iM W7 had reduced the glutamate-induced increase to near 
control levels [Fig. 4.2.3, F (2, 30) = 30.32, p<0.001, p<0.05 in 
Tukey’s pairwise test, n = 6  cultures].
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Figure 4.2.1 Effect of excitatory amino acids on NADPH diaphorase
levels in postnatal rat glial culture.
postnatal day 2 (P2) gtial cultures were treated with 50pM glutamate, 
50pM AMPA, coadministration of 50pM glutamate with lOOpM 
APV, orcoadministration of 50|xM AMPA with lOOjxM CNQX in 
HBSS for 24 hours. Control wells received HBSS alone.
Cells were then taken for NADPH diaphorase staining.
Results are expressed as percentages of control optical density levels 
±SEM. Significance was determined by one-way ANOVA followed 
by post-hoc Dunnett's test, and post-hoc Tukey's pairwise test. 
*p<0.05.
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Figure 4.2.2 Effect of excitatory amino acids on NADPH diaphorase
levels in poi'%atal rat glial culture.
A.ftjiatal (Pz^) rat glial cultures were treated with 50p,M and 100|iM 
NMDA, and coadministration of 50pM NMDA plus lOOpM APV, all 
in HBSS for 24 hours. Control wells received HBSS alone.
Cells were then taken for NADPH diaphorase staining.
Results are expressed as percentages of control optical density levels 
±SEM. Significance was determined by one-way ANOVA followed 
by post-hoc Dunnett's test. * p<0.05.
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Figure 4.2.3 Effect of glutamate and W7 on NADPH diaphorase
levels inp ed^atal rat glial culture.
fW riatal ( f i )  rat glial cultures were treated with 50|xM glutamate 
for 24 hours , 400jLiM W7 for 4 hours, or coadministration of the two 
in HBSS. Control wells received HBSS alone.
Cells were then taken for NADPH diaphorase staining.
Results are expressed as percentages of control optical density levels 
±SEM. Significance was determined by one-way ANOVA followed 
by post-hoc Dunnett's test and post-hoc Tukey's pairwise test. 
*p<0.05.
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4.7 Ejfect o f LPS and W7 on NADPH diaphorase activity in glial 
cultures.
Cell cultures were treated with lOOpg/ml of the endotoxin 
lipopolysaccharide ( LPS) for 24 hours and 400|iM of the calcium 
scavenger W7 for 4 hours, or vehicle for 24 hours. Drugs were 
dissolved in HBSS and incorporated into the culture medium, while 
control wells recieved HBSS alone. Following this time period, 
cultures were taken for NADPH diaphorase staining. Treatment with 
W7 alone did not significantly alter NADPH diaphorase levels [Fig.
4.3.1]. Analysis of variance revealed that treatment with LPS had 
significantly increased NOS levels , while treatment with both LPS 
and W7 did not alter the increase in NADPH diaphorase levels seen 
after treatment with LPS alone [Fig. 4.3.1, F (3, 63) = 20.19, 
p<0.001, p<0.05, n = 7 cultures, p >0.05 by Tukey’s pairwise test.].
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Figure 4.3 Effect of LPS and W7 on NADPH diaphorase levels in
f  ':'^ t a l  rat glial culture.
(^o^ihatal (p% ) rat glial cultures were treated with lOOpg/ml LPS for 
24 hours , 400|iM W7 for 4 hours, or coadministration of the two in 
HBSS. Control wells received HBSS alone.
Cells were then taken for NADPH diaphorase staining.
Results are expressed as percentages of control optical density levels 
+SEM. Significance was determined by one-way ANOVA followed 
by post-hoc Dunnett's test, and post-hoc Tukey’s pairwise test. 
*p<0.05.
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4,8 Time course o f LPS and interleukin-1 effect on NADPH 
diaphorase levels in glial cultures.
Cultures were treated with 100|Xg/ml LPS made up in HBSS 
and incorporated into the medium, or HBSS alone, for 2, 6  and 24 
hours. The exposure to lOOpg/ml LPS was significantly different 
from the vehicle by analysis of variance, and the maximum increase in 
NADPH diaphorase activity occured after a time period of 6  hours.
No further increase in levels was observed between 6  and 24 hours 
[Fig. 4.4.1, ANOVA: F (3, 80) = 30.27, p<0.001, p<0.05, n = 6  
cultures, p>0.05 by Tukey’s pairwise test].
.r-;rA similar pattern of results occured after exposure to 0.25ng/ml 
IL-1 over 2, 6  and 24 hours. Again, the dmg was made up in HBSS 
and incoiporated into the medium while vehicle wells recieved HBSS 
alone. The maximum increase in NOS levels occured after 6  hours 
[Fig. 4.4.2, ANOVA: F (3,80) = 40.17, p>0.001, p<0.05, n = 6  
cultures, p>0.05 by Tukey’s pairwise test].
t|
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Figure 4,4.1 : Effect of LPS on NOS levels in >^»<4natal rat glial
culture - time course.
Cultures were treated with 100|ig/ml LPS for time periods of 2, 6  and 
24 hours.
Cells were then taken for NADPH diaphorase staining.
Results are expressed as percentages of control optical density levels 
± SEM. Significance was determined by one-way ANOVA, followed 
by post-hoc Dunnett’s test, and post-hoc Tukey’s pairwise test. 
^'p<0.05.
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Figure 4.4.2 : Effect of IL-1 on NOS levels inpo^Hiatal rat glial
culture - time course.
Cultures were treated with 0.25ng/ml EL-1 for time periods of 2, 6  and 
24 hours.
Cells were then taken for NADPH diaphorase staining.
Results are expressed as percentages of control optical density levels 
± SEM. Significance was determined by one-way ANOVA, followed 
by post-hoc Dunnett’s test, and post-hoc Tukey’s pairwise test. 
p<0.05.
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4.9 Ejfect o f protease and inhibitors on NADPH diaphorase activity 
in glial cultures.
The cultures were treated with proteases alone, or protease and 
inhibitors for a time period of 24 hours. Once again, the compounds 
were made up in HBSS and incorporated directly into the medium, 
while the vehicle wells recieved HBSS alone. Exposure to 500ng/ml 
trypsin resulted in a significant increase in NADPH diaphorase 
activity, as did exposure to 300ng/ml a-chymotrypsin [Figs 4.5.1 and
4.5.2]. Exposure to 300ng/ml of a-chymotiypsin together with 
lOOiiM chymostatin reduced the a-chymotrypsin-induced increase in 
NADPH diaphorase activity to near control values [Fig.4.5.2, F (3, 
80) = 25.14, p<0.001, p<0.05; p<0.05 by Tukey’s pairwise test, n = 6  
cultures].
Exposure to 500ng/ml trypsin simultaneously with ipg/ml 
trypsin inhibitor resulted in a reduction to near control values [Fig.
4,5.2, F (3, 80) = 19.99, p<0.001, p<0.05; p<0.05 by Tukey’s 
pairwise test, n = 6  cultures].
$
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Figure 4.5.1 : Effect of proteases and inhibitors on NADPH
diaphorase levels in AoAatal rat glial culture.
Cultures were treated with 300ng/mla-chymotrypsin, 100|iM 
chymostatin, co administration of the two or vehicle. All compounds 
were administered in HBSS for 24 hours. Vehicle wells recieved 
HBSS alone.
Cultures were taken for NADPH diaphorase staining.
Results are expressed as a percentage of control optical density levels 
± SEM. Significance was determined by one-way ANOVA followed 
by post-hoc Dunnett’s test and post-hoc Tukey’s pairwise test.
* p<0.05.
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Figure 4.5.2 : Effect of proteases and inhibitors on NADPH
diaphorase levels in|icnrtAatal rat glial culture.
Cultures were treated with 500ng/ml trypsin, Ipg/ml trypsin inhibitor, 
coadministration of the two or vehicle. All compounds were 
administered in HBSS for 24 hours. Vehicle wells recieved HBSS 
alone.
Cultures were taken for NADPH diaphorase staining.
Results are expressed as a percentage of control optical density levels 
± SEM. Significance was determined by one-way ANOVA followed 
by post-hoc Dunnett’s test and post-hoc Tukey’s pairwise test.
* p<0.05.
200
150
'm
CD"d1cOo 100
CDo
ou-4->h 50oo
4—Io
c o n t r o l
I I I IISQOnjg/ml t r y p s i n
H~Hi 5 0 0 n g / m l  t r y p s i n  + 1 / r g / m l  t r y p s i n  i n h i b i t o r  
^ ^ 1 / i . g / m l  t r y p s i n  i n h i b i t o r
D a t a  a r e  m e a n  ± SEM, n  = 6 c u l t u r e s .
ANOVA a s  fo llows: F[3,  80] -  19.99, p < 0 .0 0 1 .
* In D u n n e t t ’s P < 0 .0 5  c o m p a r e d  to  c o n t r o l  v a lu e .  
In T u k e y ’s p a i r w i s e  p< 0 ,0 5 .
I
IDiscussion
4,10 Glial cell classification
Glial cells can be divided into the following divisions: 
astrocytes, oligodendrocytes and microglial. Two discrete populations 
of astrocytes can de distinguished from one another in culture, based 
on morphological, biochemical and developmental criteria (Raff et 
ah, 1983.). Type 1 (protoplasmic) astrocytes are flattened and 
epithelial-like when grown in media containing serum. Under the same 
conditions. Type 2 (fibrous) astrocytes have rounded somata and long 
processes (Raff et al., 1983). Cultured protoplasmic astrocytes can be 
rapidly induced to become stellate, which more closely resembles their 
appearance in vivo, by treatment with agents that increase intracellular 
cyclic AMP levels such as p adrenergic agonists and forskolin 
(Narumi et al., 1978; Bridoux et al.,1986). Serum withdrawal from 
media is thought to cause astrocytes to convert to stellate morphology 
(rounded somata from which long processes extend), (Lim et 
al., 1973). It has been suggested that the ability of serum to inhibit 
neurite outgrowth in a mouse neuroblastoma cell line is due to semm- 
derived thrombin (Gurwitz and Cunningham., 1988).
The cells cultured in the present work are Type 1 astrocytes: the 
cells displayed flat epithelial-like morphology and rounded somata 
were not present. The method of astrocyte cell culture was that of 
McCarthy and de Vellis (1980). The use of one to two day old rat 
pups,and no younger, ensures the absence of viable neurons in the cell 
suspension obtained form the cerebral cortices. The length of the 
initial culture period was kept at between 7 and 9 days. Periods 
shorter than this are thought to be insufficient to obtain successful 
maturation of astrocytes (McCarthy and de Vellis., 1980). Following 
this method, after 7 to 9 days in culture, Type 1 astrocytes were 
separated from oligodendrocytes and Type 2 astrocytes by shaking on 
an orbital shaker leaving a Type 1 astrocytic culture. It should be 
noted that while the cultures appeared 90% Type 1 astrocytic, there 
was a small contamination of microglia, fibroblasts, oligodendrocytes 
and vascular cells.
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4.11 Ejfect o f LPS and W7 on NADPH diaphorase activity in glial
cultures.
Treatment of the cultures with lOOjxg/ml of the endotoxin LPS 
for 24 hours caused a dramatic increase in NADPH diaphorase levels. 
As mentioned previously, neuronal NADPH diaphorase has been 
shown to be a nitric oxide synthase (Hope et al., 1991). It is important 
here to discuss whether this increase in NADPH diaphorase activity 
induced by exposure to LPS is an increase in NOS levels, and to 
investigate the type of NOS involved; neuronal, endothelial or 
inducible. LPS has previously been shown to cause the induction of a 
calcium-independent NOS in primary glial cultures (Galea et al.,1992; 
Simmons and Murphy., 1992). Galea and coworkers found the 
response to LPS to be dose-dependent and maximally effected after 
48 hours. Simmons and coworkers exposed the cultures to a higher 
concentration of LPS (IO|ig/ml compared to 500ng/ml), and found 
maximal induction after 12 hours. This induction was found to be 
completely abolished by the protein synthesis inhibitor cycloheximide. 
Cultures were exposed to LPS for 24 hours in this set of experiments, 
and other time points are discussed in Section 4.13. While the 
concentration used in the present work is considerably higher than in 
previous studies, 1 0 0 |a.g/ml treatment proved to induce the cleaiest 
NADPH diaphorase staining. Although a vast literature supports the 
idea that LPS induces glial NOS in the cultures, and it is more than 
likely that to be this same type of iNOS in the present work, the NOS 
type responsible was further investigated using the calmodulin 
antagonist W7.
The fact that combined exposure of cell cultures to LPS and W7 
did not alter the LPS-induced increase in NOS levels indicates that the 
type of NOS activated by exposure to LPS is calmodulin-independent. 
In light of recent evidence, W7 appears to no longer be a 
distinguishing factor between neuronal and inducible NOS; both 
enzymes are calmodulin-dependent. LPS has been shown to cause 
induction of an inducible NOS in glial cells through activation of 
tyrosine kinase, as illustrated by abolishition with the tyrosine kinase 
inhibitor genistein (Feinstein et al.,1994). The initial events in the LPS 
activation of macrophages has also been shown to involve tyrosine 
kinase (Weinstein et al.,1992). iNOS in macrophages and hepatocytes
8 0
have been shown to tightly bind calmodulin like a subunit component 
without the need for a rise in intracellular calcium (Cho et al.,1992; 
Evans et al.,1992). It now appears that a similar system occurs with 
iNOS in glial cells: iNOS tightly binds calmodulin and produces NO 
even when calcium levels are low or absent (Kitamura et al.,1996; 
Ruan et al.,1996). LPS is thought to induce iNOS in glial cells by the 
de novo synthesis of iNOS proteins, as illustrated using the protein 
synthesis inhibitor cycloheximide (Kitamura et al.,1996). It appears 
that the current work suggests a calmodulin-independent NOS to be 
activated in the glial cells by LPS, differing from the idea that iNOS is 
calmodulin-dependent. Recent work has suggested the presence of 
differential expression and/or structural diversities of the iNOS gene 
(Park et al.,1996). Thus, it is possible that exposure of the glial cells 
to LPS resulted in the induction of an inducible yet calmodulin- 
independent form of NO that may be structurally different to other 
forms of iNOS. It is possible that structurally different forms of NOS 
differ in their calmodulin-dependency. A further experiment to 
establish whether iNOS is induced by LPS would have involved the 
use of the iNOS inhibitor dexamethasone. As is discussed in the next 
section of work, where glutamate exposure results in the increase of a 
calmodulin-dependent form of NOS, the glial cultures do appear to 
possess more than one type of NOS enzyme.
4,12 Ejfect o f excitatory amino acids on NADPH diaphorase activity 
in glial cultures.
Exposure of the glial cultures to glutamate, AMPA and NMDA 
resulted in an increase in NOS levels. This increase was reduced to 
near control levels following combined exposure to the EAAs with 
their respective selective antagonists. Thus, it would appear that both 
non-NMDA and NMDA receptors aie involved in the induction of 
NOS in the cultured glial cells. To investigate the type of NOS 
involved, the calmodulin antagonist W7 was applied to the cultures. In 
contrast to the LPS results discussed in section 4.11, W7 reduced the 
glutamate-induced increase in NOS levels to near control values, 
suggesting that the NOS involved here is calmodulin-dependent.
A key link between glutamate receptor activation and 
subsequent neurodegeneration is thought to be agonist-triggered
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calcium entry. In neocortical cultures, the widespread damage induced 
by brief activation of NMDA-type glutamate receptors is calcium 
dependent and is thought to be triggered by the highly calcium- 
permeable NMDA receptor-gated channel (Choi., 1988; Mac Dermott 
et al.,1986). With non-NMDA receptors (AMPA or kainate), which 
gate with low calcium permeability, much longer exposure durations 
are required to induce widespread cortical neurodegeneration (Koh et 
al.,1990). There has been a prevailing view that since glutamate 
causes neuronal death under the discussed conditions, any changes 
observed in glial cells are a consequence of neuronal damage (Hertz 
and Schousboe .,1986)
It would appear that in the present results, the type of NOS 
induced in glial cells by the excitatory amino acid glutamate differs 
from that induced by LPS, in that it appears to be calmodulin 
dependent. Morphological examination of the cells reveals that the 
same cell populations are being stained by NADPH diaphorase in both 
sets of experiments. The glutamate-induced induction of NOS is much 
larger than that caused by LPS exposure, and W7 blocked this larger 
increase illustrating the effectiveness of the compound in the present 
cell culture conditions. Perhaps it is not surprising that LPS and 
glutamate cause induction of what appear to be different types of 
NOS with different calmodulin dependencies: the two compounds act 
by differing pathways and perhaps the differing patterns of action 
trigger differential expression of the iNOS gene, structural diversity of 
the gene has been suggested (Park et al.,1996). LPS is thought to act 
via a cytokine receptor resulting in induction of iNOS via tyrosine 
kinase activation (Kitamura et al.,1996) and, as mentioned above, 
glutamate through the NMDA receptor causes induction of iNOS via 
an influx of calcium. As mentioned previously, calmodulin dependency 
is no longer a disguising factor between neuronal and inducible forms 
of NOS. Thus, it is possible that the glutamate-induced calmodulin- 
dependent NOS could be neuronal or iNOS. As discussed in section 
4.11, the LPS-stimulated NOS is more than likely to be iNOS: a vast 
literature has shown this to be the case. The finding that glutamate 
raises the level of a type of NOS differing in calmodulin dependency 
from that seen following exposure to LPS perhaps strengthens the 
argument that glial cells posses several types of NOS differing in 
calmodulin dependency. Further experiments using specific
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radiolabelled oligonucleotide probes to iNOS and neuronal NOS 
would clarify the type of enzyme present in the cultured cells. Also, 
use of calcium chelators such as EOT A would distinguish between the 
two forms of the enzyme: low calcium concentration would block the 
activity of neuronal NOS, while not altering the activity of iNOS.
4.13 Time course o f LPS and IL-1 on NADPH diaphorase activity in 
glial cultures.
Exposure of glial cultures to lOOpg/ml LPS or 0.25ng/ml IL-1 
provided interesting results. As previously mentioned, Galea and 
coworkers found the response to LPS to be maximally induced after 
48 hours in primary astrocyte cultures (Galea et al.,1992), while 
Simmons and colleagues, using a higher concentration of LPS, found 
maximal induction after 12 hours and maintained for 36 hours 
(Simmons and Murphy., 1992), again in primary astrocyte cultures. 
However, in the present study, the maximal induction following 
exposure to LPS or IL-1 occurred after 6  hours, with no further 
increase after 24 hour exposure, although it should be noted that 24 
hours was the maximum time point studied. Possibihties for the type 
of NOS enzyme involved have been discussed in section 4.11. Thus it 
appears that the glial cells studied in the present work show induction 
of NOS in perhaps a shorter time course than previously illustrated. 
The present shorter time course of induction of NOS agrees with 
recent work where a rapid induction of NOS gene expression has been 
shown to occur in the heart during endotoxemia (Bateson et al.,1996). 
The resulting release of NO is thought to depress cardiac contractile 
function. Bateson and coworkers looked at the time courses of change 
in iNOS mRNA levels and enzyme activity in the left ventricular wall 
of rats following injection of LPS. Within 30 minutes of LPS 
treatment, a rapid increase in iNOS mRNA occurred which peaked 
after 3 hours and dropped to near baseline levels after 12 hours. 
Enzyme activity peaked after 6  hours and dropped to baseline levels 
after 24 hours. Bateson and coworkers concluded that the LPS- 
induced rapid stimulation of iNOS activity in the rat heart occurs via 
an increase in expression of the iNOS gene. It is thought that iNOS 
transcription is regulated by activation of the immune system regulator 
nuclear factor kappa B (Goldiing et al.,1995). As has been discussed
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there is evidence for the presence of structurally different forms of 
iNOS. It is possible that in the glial cells, induction of an inducible 
form of NOS, structurally different to previous forms of the enzyme in 
its calmodulin-dependency, could be induced on a faster scale than 
other forms of the enzyme. The mechanisms behind this are not clear, 
and further experiments covering a more expansive range of time 
points would perhaps give a clearer picture.
4.14 Effects o f proteases and inhibitors on NADPH diaphorase 
activity in glial cultures.
The results of several studies support the idea that an imbalance 
between brain proteases and their inhibitors may play a role in 
Alzheimer's Disease. Levels of active protease nexin-1 (a proteinase 
inhibitor) are decreased in Alzheimer's Disease hippocampus to 
around 15% of the levels in age matched controls (Wagner et 
al.,1988). Further, amyloid deposits of Alzheimer's brain contain a-1 
antichymotrypsin (Abraham et al.,1988), and the amyloid precursor 
shows sequence homology to Kunitz serine protease inhibitors 
(Kitaguchi et al.,1988). Cavanaugh and coworkers suggested that a 
correct balance between thrombin and protease nexin- 1  on astrocyte 
surface may be crucial to normal astrocyte function (Cavanaugh et 
al.,1990). Further evidence of protease involvement in the pathology 
of Alzheimer’s Disease is as follows. NOS activity has been found to 
be elevated in brain microvessels in Alzheimer's Disease (Dorheim et 
al.,1994). a-1 antichymotiypsin is a glial-derived protein associated 
with senile plaques in Alzheimer's Disease (Abraham et al.,1988). 
Both aal-antitrypsin and a  1-antichymotrypsin may be functionally 
involved in the pathogeneis of the lesions of Alzheimer’s Disease, and 
the cells thought to be producing both compounds are astrocytes 
(Gollin et al.,1992). Recent data suggest that a-1 antichymotrypsin 
interaction with Ap(l-40) inhibits fibril formation but does not affect 
the amyloid peptide toxicity, and that toxicity of A(3 can develop 
without fibril formation (Aksenova et al.,1996). a-1 antichymotrypsin 
is capable of accelerating the rate of polymerisation of amyloid fibrils 
thus enhancing plaque deposition (Ma et al.,1994; Eriksson et 
al.,1995), and is thought to be an important factor in the pathology of 
the disease.
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IThe current work clearly demonstrates that the proteases 
chymotrypsin and trypsin significantly increase NADPH diaphorase 
levels, with respective inhibitors reducing the levels to near baseline 
levels. The glial cells stained by the NADPH diaphorase appear to be 
morphologically of the same population as in previous experiments.
At this stage it is not possible to speculate the type of NOS involved.
For an understanding of the possible type of NOS involved in the 
protease-induced increase in NADPH diaphorase immunostaining, 
these experiments should have been repeated using W7, ■i'ïdexamethasone and radiolabelled oligonucleotide probes.
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„ ISummary
Cultured ghal cells have been characterised by positive staining 
to GFAP, and used to investigate NOS activity in response to 
cytokine, endotoxin, excitatory amino acid agonists and proteases.
The ghal cells appear to possess several types of NOS differing in 
their calmodulin dependency, and it is possible that the cells respond 
to different compounds by induction of structurally different forms of 
the NOS enzyme.
Following on from this investigation of NOS activity in glial 
cells, it was of interest to investigate NOS activity, and cytoskeletal 
protein expression, in primary dissociated neuronal cholinergic cells in 
culture.
Î
IÏ
, |
Chapter 5
Regulation and expression of 
cytoskeletal protein and NADPH 
diaphorase immunostaining in 
basal forebrain neuronal cultures
Introduction
This section of the work made use of primary neuronal basal 
forebrain cultures. As discussed in section 2.1.1, the method of cell 
culture was based on the method of Hartika and Hefti (1988). The 
cultured cells were characterised by immunolabelling for neuron 
specific enolase, neurofilament, MAP2 and choline acetyl transferase. 
The cell culture model was then used to investigate changes in 
cytoskeletal protein immunoreactivity, and NADPH diaphorase levels 
in the cells in response to exposure to the following compounds: nerve 
growth factor, nitric oxide-releasing compounds and excitatory amino 
acid agonists.
5.1 Neuron Specific Enolase
In order to characterise the cell cultures, a specific marker for 
neuronal cells was required. Enolases are glycolytic enzymes that 
convert 2 -phosphoglycerate into phosphoenolpyruvate. There are 
three homodimeric enolase enzymes in mammalians composed of the 
subunits a a , PP and yy (Schmechel and Marangos.,1982; Zomzely- 
neurath.,1983). In the adult mammalian nervous system two of the 
isozymes have been found. The non-neuronal enolase (NNE) a a  
dimer is expressed in glial cells (Schmechel et al., 1978). The yy form is 
specifically localised to neurons and termed neuron specific enolase 
(NSE) (Moore and McGregor., 1965; Schmechel et al., 1980). The 
third isozyme, pp, is found in muscle tissue. NSE is also found in 
peripheral neuroendocrine tissue, and a variety of tumours including 
melanoma and carcinoids. Recently, NSE has become of interest to 
neurologists as an indicator of brain damage,
Several studies have shown NSE to be exclusively present in 
neurons with the highest concentration in CNS neurons. The highest 
levels of NSE are found in the cortex and caudate putamen, the 
enzyme being absent in other cells in the brain such as ghal cells 
(Cicero et al.,1970: Pickel et al.,1976). NSE is soluble and present in 
the cerebrospinal fluid (CSF). An elevated level of NSE in the CSF 
been researched as a marker of neuronal damage (Hardemark et 
al.,1989). CSF levels of NSE had been shown to be reduced in 
Alzheimer's Disease (Cutler et al.,1986).
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5.2 Nerve Growth Factor
Nerve growth factor (NGF) is a member of the polypeptide 
gene family, the neurotrophins, which also includes brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 and neurotrophin-4/5 
(Barde et al., 1982; Ip et al.,1992). NGF, BDNF and NT-3 are present 
in the hippocampus and the cerebral cortex (Leibrock et al.,1989). 
Considerable evidence indicates that NGF is necessary for the survival 
and function of cholinergic neurons projecting from the basal
forebrain to the hippocampus and frontal cortex (Thoenen and 
Barde.,1980; Levi-Montalcini and Angeletti.,1986). As the 
degeneration of these pathways occurs in the neuropathology of 
Alzheimer's Disease, and several studies have shown a decrease in 
NGF receptor function and retrograde transport in Alzheimer's 
Disease, (Kerwin et al.,1991; Kerwin et al.,1992; Mufson et al.,1995), 
the potential of NGF as a possible therapeutic agent has been 
researched (Saffran.,1992). Evidence shows that in the central 
nervous system, NGF is produced by certain neurons (Gall et 
al.,1991), astrocytes (Furukawa et al.,1986) and microglia (Mallet et 
al.,1989).
Numerous studies have illustrated the protective effects of NGF. 
It has been shown to prevent apoptopic cell death in injured central 
cholinergic neurons (Wilcox et al.,1995), to protect striatal cholinergic 
neurons against quinolinic acid excitotoxicity in the rat neostriatum 
(Perez-Navarro et al.,1994), and to act as a trophic factor on intact 
and injured basal forebrain cholinergic neurons (Koliatsos et al.,1994). 
In addition to its function as a neurotrophin, NGF has also been 
shown to act as a mediator of microglial function.
Two cell surface NGF receptors have been characterised on the 
basis of binding affinity and signal transduction properties: the rapidly 
dissociating p^^ low affinity NGF receptor (Johnson et al.,1986), and 
the slowing dissociating pl"^^ TrkA tyrosine kinase receptor (Kaplan 
et al.,1991). The function of the low affinity receptor in still unclear’, 
while several lines of evidence show that the activation of the p^'^^ 
TrkA receptor is necessary to elicit NGF responses (Green et 
al.,1986; Hempstead et al.,1992; Ibanez et al.,1992).
The rat pheochromocytoma PC 12 cell line is an NGF- 
responsive model system that has been useful for studying the
et al.,1991). The function of the low affinity receptor in still unclear, 
while several lines of evidence show that the activation of the p i40 
TrkA receptor is necessary to elicit NGF responses (Green et 
al.,1986; Hempstead et al.,1992; Ibanez et al.,1992).
The rat pheochromocytoma PCI2 cell line is an NGF- 
responsive model system that has been useful for studying the 
mechanisms of NGF actions (Greene and Tischler.,1976). PC I2 cells 
proliferate in semm-containing medium, and when exposed to NGF, 
withdraw from the cell cycle and gradually adopt the many 
characteristics of mature sympathetic neurons (Greene and 
Tischler.,1982). The most diamatic aspect of this is the extension of 
long axon-like neurites. The processes involved in this neurite 
extension have been extensively researched, and the expression of 
microtubule-associated proteins and protein kinases monitored. The 
induction of MAPI and tan in response to NGF has been shown to 
promote microtubule assembly and these factors are regulators of 
neurite outgrowth in PC12 cells (Drubin et al.,1985; Sano et al.,1990; 
Teng et al.,1993). Mechanisms behind neurite outgrowth have been 
less extensively studied in primary dissociated cultures, and it was of 
interest to investigate cytoskeletal protein expression, cell morphology 
and neurite outgrowth in response to NGF in basal forebrain neuronal 
cells.
S,3 Cyclooxygenases
Cyclooxygenase catalyses the first two steps in the biosynthesis 
of prostanoids from ai achidonic acid (the formation of prostaglandin 
G2  and its subsequent reduction to prostaglandin H 2 ), and is the 
target of non-steroidal anti-inflammatory drugs (NSAIDS) such as 
indomethacin. Administration of NSAIDs is thought to retard the 
onset of Alzheimer's Disease ( Rich et al.,1995 ). Two isoforms exist: 
constitutive (Coxl) and inducible (Cox2). Most currently available 
NSAIDs inhibit both isoforms but it is thought that selective Cox2 
inhibition may reduce unwanted side effects such as gastric and renal 
damage. It is thought that prostanoids produced by the Coxl isoform 
are involved in the maintenance of cellular physiology, whereas those 
produced by Cox2 are involved in the inflanunatory process (Simmons 
et al.,1992; Mitchell et al.,1993).
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The mechanism underlying the inverse relationship between 
NSAIDS and onset of Alzheimer’s Disease has not been established, 
and an attractive possibility is that it involves a prevention of 
development of plaques and tangles. In parallel with the in vivo work 
looking at the effect of indomethacin treatment on tau gene 
expression, the cell cultures were treated with prostaglandins, and any 
changes in APP and C0X2 expression noted.
1
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Results
5.4 Characterisation o f basal forebrain neuronal cultures.
In cells cultured from the basal forebrain region of embryonic 
rats (E l7), a large proportion of the cells can be clearly characterised 
as cholinergic neuronal cells. The cells were typically around 25|am in 
diameter with many extensive neurites. Neurite length was on average 
10-15p.m. The final plating dilution of the cultures proved to be vital 
to the maintenance of the cells. A dilution giving an even distribution 
of cells with a significant degree of cell-cell contact provided the 
optimum cell survival. Cells and neurite characteristics were easier to 
analyse if the cells were not clumped together. The dilutions used are 
discussed in the methods chapter. Cells showed positive
immunostaining for choline acetyltransferase (ChaT), a marker for 
cholinergic cells [Fig. 5.1a]. Positive immunostaining was also seen 
for the microtubule-associated protein MAP2, which is found only in 
neuronal cell types [Fig. 5.1b]. The glycolytic enzyme neuron specific 
enolase (NSE) also stained positively in the cultures, further
chaiacterising them as neuronal cells [Fig. 5.1c]. Positive
immunostaining was also seen with neurofilament [Fig. 5 .Id]. The
high survival rate of the cells, and the use of multiple well plates for 
cell growth, made the neuronal cell cultures a useful and productive 
experimental model.
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Figure 5.1 : Characterisation of neuronal basal forebrain cultures.
Cells were processed for immunocytochemistry using antisera against 
the following:
A choline acetyltransferase 
B MAP2
C neuron specific enolase 
0  neurofilament
Scale bar represents 25|im.
A B
D
-  Y
y
>
5.5 NGF effects on ChaT, tau and MAP2 expression in neuronal 
cultures.
Cells were treated with nerve growth factor (NGF) at a 
concentration of 200ng/ml for 4 days. The NGF was made up in the 
culture growing medium and added directly to the culture at each 
medium change over the 4 day time period. Control wells received 
medium alone. As can be seen in Fig. 5.2.1, exposure to NGF resulted 
in a dramatic increase in ChAT and MAP2 immunoreacti vity, with no 
significant change in tau immunoreactivity.
As the effect of NGF on MAP2 was so dramatic, and the ChaT 
immunostaining was for cell characterisation purposes, it was decided 
to further investigate the MAP2 result. Cells were exposed to 
200ng/ml NGF for time periods of 24 hours, 4 days and 1 week. 
Again, the NGF was made up in the culture medium, and added each 
time the medium was changed. Control wells received medium alone. 
The maximum rise in MAP2 immunostaining induced by NGF 
occurred after 4 days, with no further increase seen after 1 week [Fig.
5.2.2, F(3.80) = 20.17, p<0.001, p<0.05, n = 6  cultures]. The same 
experiment was repeated by in situ hybridisation using an 
oligonucleotide probe specific for MAP2 mRNA. Exposure to NGF 
resulted in an increase in MAP2 gene expression which continued to 
rise following 4 days and 1 week treatment as shown in Fig. 5.2.3 
[F(3, 80) = 15.41, p<0.001, p<0.05, n = 4 cultures].
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Figure 5.2.1 : Effect of NGF on MAP2. tau and ChaT 
immunoreactivity in neuronal basal forebrain cultures.
NGF was added to the cultures at a concentration of 200ng/ml for 4 
days. Control wells received culture medium alone. After processing 
for immnunostaining with antisera against MAP2, tau and ChaT, 
optical density levels were measured.
Results are expressed as a percentage of control optical density level ± 
SEM.
Significance was measured by Mann Whitney U test. *** p<0.001.
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Figure 5.2.2 : Effect of NGF on MAP2 immunoreactivity in neuronal
basal forebrain cultures - time course.
Cultures were treated with 200ng/ml NGF for time periods of 24 
hours, 4 days and 1 week. Control wells recieved culture medium 
alone.Cells were then processed for immunostaining using antisera 
against MAP2.
Results are expressed as a percentage of control optical density levels 
±SEM .
Significance was measured using one-way ANOVA and post-hoc 
Dunnett’s test. * p<0.05.
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Figure 5.2.3 : Effect of NGF on MAP2 mRNA levels in neuronal
basal forebrain cultures - time course.
Cultures were treated with 200ng/ml NGF for time periods of 4 days 
and 1 week. Control wells received culture medium alone.Cells were 
then processed for in situ hybridisation.
Results, obtained from emulsion-dipped slides, are expressed as mean 
number of pixels occupied by silver grains ± SEM.
Significance was measured using one-way ANOVA and post-hoc 
Dunnett’s test. * p<0.05.
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5.6 Effect o f NGF on NADPH diaphorase activity in neuronal
cultures.
To investigate the possible role of NGF in regulating NOS 
levels, we treated cells with 200ng/ml of NGF for time periods of 24 
hours, 30 hours and 4 days. The addition of NGF was as previously 
described. Cultures were then stained to detect NADPH diaphorase 
activity. Exposure to NGF resulted in an increase in NADPH 
diaphorase levels after 24 hours [Fig. 5.3.1, F(4, 100) = 40.17, 
p<0.001, p<0.05, n = 6  cultures]. The effect of NGF was maximum 
after 24 hours with no significant increase in NADPH diaphorase 
activity after longer exposure times [Fig. 5.3.1, by Tukey’s p>0.05].
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Figure 5.3.1 : Effect of NGF on NADPH diaphorase levels in
neuronal basal forebrain cultures.
Cultures were again treated with 200ng/ml NGF or vehicle. Treatment 
was for the following time periods: 24 hours, 30 hours and 4 days. 
Cells were then processed for NADPH diaphorase staining.
Results are expressed as a percentage of control optical density levels 
±SEM .
Statistical analysis was carried out using one-way ANOVA followed 
by post-hoc Dunnett’s, and post-hoc Tukey’s. *p<0.05.
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5.7 Effect o f NGF on cy to skeletal protein and glycolytic enzyme 
immunostaining.
To examine further the effects of NGF on cytoskeletal proteins 
and glycolytic enzymes, we pre-treated the cultures with 
dexamethasone at a concentration of IpM (Radomski et al 1990). 
Dexamethasone was made up in HBSS and 20% DMSO,and 
incorporated directly into the culture medium 24 hours prior to the 
NGF addition. Control wells recieved HBSS and 20% DMSO. NGF 
was added at 2 0 0 ng/ml, again made up in the culture medium. 
Immunostaining for tau, MAP2 and NSE followed. As shown 
previously, NGF dramatically increased MAF2 immuostaining [Fig, 
5.4.1, F(3, 82) = 21.15, p<0.001, p<0.001, p<0.05, n = 6  cultures]. 
NGF also increased NSE immunostaining [Fig. 5.4.1, F(3,81) = 25.24, 
p<0.001, p<0.05, n = 6  cultures]. No change in tau immunostaining 
occurred. Pretreatment with l}iM dexamethasone alone did not alter 
immunostaining. The NGF-induced increase in MAP2 immunostaining 
was reduced to near control levels by Pretreatment with 
dexamethasone [Fig. 5.4.1].
As the actions of dexamethasone are varied, and involve more 
than iNOS inhibition alone, we repeated this experiment using the 
nitric oxide scavenger haemoglobin (Hb). 20|iM of Hb was added to 
the cultures in HBSS (Martin et a l ., 1985). NGF was again used at a 
concentration of 200ng/ml added directly to the culture medium. Hb 
reduced the NGF-induced increase in MAP2 immunostaining to near 
control value [Fig. 5.4.2, F(4, 110) ™ 21.16, p<0.001, p<0.05, n = 6  
cultures].
The calmodulin antagonist W7 was then used to investigate the 
possible type of NOS involved in the increase in MAP2 
immunoreactivity. Cultures were again exposed to 200ng/ml NGF for 
24 hours. W7 (400|i.M) was applied to the cells 4 hours prior to 
fixation. All compounds were made up in culture medium, and control 
wells received medium alone. W7 reduced the NGF-induced increase 
in MAP2 immunoreactivity to near control levels [Fig. 5.4.3, F(4, 
161)= 111.17, p<0.001, p<0.05, n= 4 cultures].
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Figure 5.4.1 : Effect of NGF and dexamethasone on MAP2. tau and
NSE immunoreactivity in neuronal basal forebrain cultures.
Cultures were pretreated for 24 hours with 1|XM dexamthasone in 
HBSS or vehicle (HBSS alone). Addition of either 200ng/ml NGF to 
dexamethasone and vehicle pretreated wells, or vehicle, for 24 hours 
followed. Cells were then processed for MAP2 immuonstaining.
Results are expressed as a percentage of control optical density levels 
+ SEM.
Significance was analysed byone-way ANOVA followed by post-hoc 
Dunnett’s test. *p<0.05.
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Figure 5.4.2 : Effect of NGF. dexamethasone and Hb on MAP2
immunoreactivity in neuronal basal forebrain cultures.
Cultures were pretreated for 24 hours with l|iM  dexamethasone in 
HBSS or vehicle (HBSS alone). Pretreated wells then recieved 
vehicle, 200ng/ml NGF, 20|aM Hb or coadministration for 24 hours 
followed. Compounds were administered in HBSS, vehicle received 
HBSS alone. Cells were then processed for MAP2 immunostaining.
Results are expressed as a percentage of control optical density levels 
±SEM .
One-way ANOVA, followed by post-hoc Dunnett’s test and post-hoc 
Tukey’s pairwise test, was carried out. *p<0.05.
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Figure 5.4.3: Effect of NGF. dexamethasone and W7 on MAP2 
immunoreactivity in neuronal basal forebrain cultures.
Cultures were pretreated for 24 hours with l|iM  dexamethasone in 
HBSS or vehicle (HBSS alone). Pretreated wells then received 
vehicle, 200ng/ml NGF for 24 hours followed. W7 (400jiM) 
treatment was for 4 hours prior to cell fixation. Compounds were 
administered in HBSS, vehicle recieved HBSS alone. Cells were then 
processed for MAP2 immunostaining.
Results are expressed as a percentage of control optical density levels 
+ SEM.
One-way ANOVA, followed by post-hoc Dunnett’s test and post-hoc 
Tukey’s pairwise test, was carried out. *p<0.05.
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5.8 Effect o f glutamate on NADPH diaphorase activity.
Cells were exposed to 50pM glutamate for a time period of 24 
hours. The compound was made up in HBSS and incorporated into 
the culture medium. Vehicle recieved HBSS alone. Glutamate caused 
a dramatic increase in NADPH diaphorase activity as illustrated in Fig. S
5.5.1 [F(3, 63) = 20.19, p<0.001, p<0.05, n = 7 cultures]. Cultures 
were also treated with 50|iM glutamate for 24 hours and 400}xM W7, 
added 4 hours prior to tissue fixation. Exposure to glutamate and W7 
did not alter the increase caused by glutamate alone, [p >0.05 by 
Tukey’s pairwise test].
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Figure 5.5.1 : Effect of glutamate and W7 on NADPH diaphorase
levels in neuronal basal forebrain cultures.
Cultures were treated with 50fxM glutamate in HBSS or vehicle 
(HBSS alone) for 24 hours. 4 hours prior to fixation, cultures were 
exposed to 400|U.M W7 or vehicle.
Results are expressed as a percentage of control optical density levels 
±SEM .
Significance was analysed by one-way ANOVA followed by post-hoc 
Dunnett’s test. *p<0.05.
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5.9 Effect o f excitatory amino acid agonists on cytoskeletal protein
expression.
Cells were exposed to the non-NMDA agonist kainate (IfxM 
and lOjiM) for 24 hours. The metabotropic receptor agonist ACPD 
was added at concentrations of lOjiM and 50p,M, also for a time 
period of 24 hours. Exposure to kainate significantly increased MAP2 
immunostaining at both concentrations [Fig. 5.6.1a, F(2, 60), 
p<0.001, p<0.Q5, n = 6  cultures]. However, no further increase in 
MAP2 immunostaining was seen at the higher concentration of 10|LiM 
of the compound, [p>0.05 by Tukey’s pairwise test]. No changes in 
MAP2 immunoreactivity occurred after exposure to ACPD [Fig. 
5.6.1b]. Neither kainate or ACPD altered tau immunoreactivity [Fig. 
5.6.2a and b].
The effect of kainate was further investigated by in situ 
hybridisation using an oligonucleotide probe specific for MAP2 
mRNA. Kainate significantly increased MAP2 gene expression, again 
with no further increase seen at the higher concentration of lOpM 
[Fig. 5.6.3, F( 2, 60) = 60,17, p<0.001, p<0.05 ], p>0.05 by Tukey’s 
pairwise test.
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Figure 5.6.1 : Effect of ACPD and kainate on MAP2
immunoreactivity in neuronal basal forebrain cultures.
a\ Cultures were exposed to IpM  and 10|xM kainate in HBSS or 
vehicle (HBSS alone) for a time period of 24 hours.
Results are expressed as a percentage of control optical density levels 
±SEM .
Significance was analysed by one-way ANOVA followed by Dunnett's 
post hoc test.. * p<0.05,
b\ Cultures were exposed to lOjiM and 50|iM ACPD in HBSS or 
vehicle (HBSS alone) for a time period of 24 hours.
Results are expressed as a percentage of control optical density levels 
+ SEM.
By one-way ANOVA, no statistically significant difference occured 
between drug and vehicle treated wells.
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Figure 5.6.2 : Effect of ACPD and kainate on tau immunoreactivity in
neuronal basal forebrain cultures.
a\ Cultures were exposed to lp.M and lOjiiM kainate in HBSS or 
vehicle (HBSS alone) for a time period of 24 hours.
Results are expressed as a percentage of control optical density levels 
+ SEM.
By one-way ANOVA, no statistically significant difference occured 
between drug and vehicle treated wells.
b\ Cultures were exposed to lOjiM and 50}xM ACPD in HBSS or 
vehicle (HBSS alone) for a time period of 24 hours.
Results are expressed as a percentage of control optical density levels 
±SEM .
By one-way ANOVA, no statistically significant difference occured 
between drug and vehicle treated wells.
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Figure 5.6.3 : Effect of kainate on MAP2 mRNA levels in neuronal
basal forebrain cultures.
Cultures were exposed to IjxM and 10|xM kainate in HBSS or vehicle 
(HBSS alone) for a time period of 24 hours. Cells were then 
processed for in situ hybridisaiton.
Results, obtained form emulsion-dipped slides, are expressed as mean 
number of pixels occupied by silver grains ± SEM.
Significance was analysed by one-way ANOVA and post hoc 
Dunnett's test. * p<0.05.
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5.10 Effect o f nitric oxide releasing compounds on cytoskeletal
protein expression.
To investigate the effects of NO on cytoskeletal protein 
expression, cultures were exposed to the NO-releasers SNP, SNAP 
and SIN-1 for 24 hours. The compounds were made up in HBSS and 
incorporated directly into the medium. Care was taken to make up the 
compounds immediately prior to use, and to protect them from 
excessive light, as they aie light-sensitive. Control wells received 
HBSS alone. As shown in Fig. 5.7.1, by ANOVA, 50|iM SNP, SOpM 
SNAP and SOpM SIN-1 all significantly increased MAP2 
immunostaining after 24 hours [F(5, 120) = 79.81, p<0.001, p<0.05, n 
= 6  cultures]. Treatment for 24 hours with 20|xM of the NO 
scavenger Hb plus 50|iM SNAP reduced the SNAP-induced increase 
in MAP2 immunoreactivity to near control levels [Fig. 5.7.1]. None of 
the NO-releasing compounds caused a change in either tau or NSE 
immunostaining [Fig. 5.7.1].
Treatment with the cyclicGMP analogue 8 bromocyclicGMP 
resulted in an increase in MAP2 immunostaining. 8 bromocyclicGMP 
was again made up in HBSS and added directly to the medium. 
Control wells recieved HBSS alone. By analysis of variance, it can be 
seen that the concentrations of 20[iM and 200|iM significantly 
increased MAP2 immunoreactivity [Fig. 5.7.2, F(5, 120)= 79.81, 
p<0.001, p<0.05, n = 6  cultures]. There was no significant rise in 
MAP2 levels after exposure to the higher concentration relative to the 
lower concentration of SbromocyclicGMP, [p>0.05 by Tukey’s 
pairwise test].
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Figure 5.7.1 : Effect of nitric oxide releasers on MAP2. NSE and tau
immunoreactivity in neuronal basal forebrain cultures.
Cultures were treated with 50|iM SNP, 50|xM SNAP, 50|liM SIN-1, 
20|xM Hb or vehicle for 24 hours. Cultures were also treated with 
coadministration of 20)iM Hb together with SOfxM SNAP for 24 
hours. Cultures were then taken for immunostaining to MAP2 , NSE 
and tau.
Results are expressed as a percentage of control optical density ± 
SEM.
Significance was analysed using one-way ANOVA followed by post- 
hoc Dunnett’s test and post-hoc Tukey’s pairwise test. *p<0.05.
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Figure 5.7.2 : Effect of SNP and SbromocyclicGMP on MAP2
immunoreactivity in neuronal basal forebrain cultures.
Cultures were treated with lOpM and 50)iM SNP, or 20fiM and 200p 
M SbromocyclicGMP or vehicle (HBSS alone) for 24 hours.
Results are expressed as a percentage of control optical density level ± 
SEM.
Statistical analysis was by one-way ANOVA followed by post-hoc 
Dunnett’s test, *p<0.05.
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5.11 Effect o f NGF and NO-releasers on neurite morphology.
In order to obtain the most accurate assessment of neurite 
moiphology in the neuronal cultures, cells were grown at a further 
dilution of 20 X 10  ^ in order to obtain accurate measurements of the 
neurite characteristics. Neurites with clear cell origin and length were 
measured. Cultures were exposed to 50fxM SNP, 50jxM SNAP and 
200 ng/ml NGF for a time period of 24 hours. The NO-releasers were 
made up in HBSS and incorporated into the medium, vehicle receiving 
HBSS only. NGF was added directly in the culture medium., vehicle 
receiving medium only. None of the compounds had an effect on 
primary neurite length or neurite staining intensity [Figs 5.8.1.and 
5.8.2].
98
Figure 5.8.1 : Effect of nitric oxide releasers on neurite characteristics
in neuronal basal forebrain cultures.
Cultures were treated with SOjxM SNP, 50|liM SNAP, or vehicle, for 
24 hours. Cultures were then processed for immunostaining to MAP2, 
tau and NSE.
The measurements of primary neurite growths were taken from single 
neurites with clearly defined lengths and cell origin. Due to the lesser 
cell number in these experiments, the result of a more dilute cell 
suspension, single neurites were clearly visible. Results are expressed 
as a percentage of control optical density or neurite outgrowth 
measurement ± SEM.
Statistical analysis was by one-way ANOVA: no significant changes 
were observed.
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Figure 5.8.2 : Effect of NGF on neurite characteristics in neuronal
basal forebrain cultures.
Cultures were treated with 200ng/ml NGF or vehicle for 4 days. 
Cultures were then processed for immunostaining to NSE.
Results are expressed as a percentage of control optical density or 
neurite outgrowth measurement ± SEM.
Statistical analysis was by one-way ANOVA: no significant changes 
were observed.
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5,12 Effect o f EPS and IL-1 on APP and C0X2 immunostaining in
neuronal cultures.
Cultures were exposed to lOOjLig/ml LPS and 0.25ng/ml IL-1, or 
coadministration for 24 hours. No significant changes occurred in 
either APP or COX2 immunostaining [Figs 5.9.1 and 5.9.3 
respectively]. Following in situ hybridisation, no changes in APP gene 
expression occurred after exposure to IL-1 or LPS [Fig. 5.9.2]. 
PGE2 also did not induce a significant change in APP or COX2 
immunostaining levels as shown in Fig. 5.9.4.
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Figure 5.9.1 : Effect of LPS and IL-1 on APP immunoreactivitv in
neuronal basal forebrain cultures.
Cultures were treated with 100|Xg/ml LPS, 0.25ng/ml IL-1, vehicle 
(HESS alone), or coadministration of lOOjig/ml LPS with 0.25ng/ml 
IL-1. All treatments were for a time period of 24 hours, cultures were 
then taken for immunostaining to APP.
Results are expressed as a percentage of control optical density ± 
SEM.
Statistical analysis was carried out by ANOVA followed by post-hoc 
DunnetPs test. No significant differences were observed.
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Figure 5.9.2 : Effect of LPS and IL-1 on APP mRNA levels in
neuronal basal forebrain cultures.
Cultures were treated with 100)ag/ml LPS, 0.25ng/ml IL-1, vehicle 
(HBSS alone), or coadministration of 100|Lig/ml LPS with 0.25ng/ml 
IL-1. All treatments were for a time period of 24 hours. Cultures were 
then taken for in situ hybridisation.
Results are expressed as mean number of pixels pccupied by silver 
grains ± SEM.
Statistical analysis was carried out by ANOVA followed by post-hoc 
Dunnett’s test. No significant differences were observed.
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Figure 5.9.3 : Effect of LPS and IL-1 on COX 2 immunoreactivitv in
neuronal basal forebrain cultures.
Cultures were treated with lOOjig/ml LPS, 0.25ng/ml IL-1, vehicle 
(HBSS alone), or coadministration of 100|ig/ml LPS with 0.25ng/ml 
IL-1. All treatments were for a time period of 24 hours. Cultures were 
then taken for immunostaining.
Results are expressed as a percentage of control optical density ± 
SEM.
Statistical analysis was carried out by ANOVA followed by post-hoc 
Dunnett’s test. No significant differences were observed.
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Figure 5.9.4 : Effect of PGE2 on COX 2 and APP immunoreactivitv
in neuronal basal forebrain cultures.
Cultures were treated with four different concentrations of PGE2: 
lOpM, 20)iM, lOOpm and 200)iM, or vehicle. All treatments were for 
a time period of 24 hours. Cultures were then taken for 
immunostaining.
Results are expressed as a percentage of control optical density ± 
SEM.
Statistical analysis was carried out by ANOVA followed by post-hoc 
Dunnett’s test. No significant differences were observed.
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Discussion
S,13a Characterisation o f basal forebrain neuronal cultures.
The cells cultured from the basal forebrain region of embryonic 
rats can be cleaiiy characterised as cholinergic neuronal cells. The 
cells were typically around 25 pm in diameter with many extensive and 
branching neurites. The average neurite length was 10-15 pm. Cells 
showed positive immunostaining for ChaT; a marker for cholinergic 
cells. Positive immunostaining was also seen with MAP2, which is 
only found in neuronal cell types, and NSE, the glycolytic enzyme 
specific to neuronal cell populations.
It is important at this stage to consider whether the cells grown 
in culture show any of the phenotypes present in the adult brain basal 
forebrain. Basal forebrain neurons located in the medial septum, the 
diagonal band of Broca and nucleus basalis magnocellulaiis are the 
main source of cholinergic innervation to the hippocampal formation, 
cortex and olfactory bulb and have been implicated in cognitive 
decline associated with Alzheimer’s Disease and ageing (Gibbs et 
al., 1994). The adult basal forebrain shows well documented positive 
immunoreactivity for ChaT, NSE and MAP2 ( Cavicchioli et al., 1991; 
Gibbs et a l, 1989). Thus, the cultured cells used in the present study 
have a similar phenotype to those cells in the adult basal forebrain in 
terms of ChaT, NSE, and MAP2 immunoreactivity. However, it 
should be noted that numerous other properties of the fully intact 
cholinergic system have not been classified in the cultured cells.
5.13b Cell culture as an experimental model.
Cell cultures have many advantages as experimental models; 
they provide easily observable systems that often retain biological 
properties parallel to those observed in vivo. At present, the greatest 
source of culture model systems to investigate CNS function and 
dysfunction is fetal brain material from experimental animals, typically 
rodents. For studies of human CNS disorders these models have two 
disadvantages; their fetal origin and their source from another species. 
Also, the experimental animal from which the cultures develop may 
have little or no natural susceptibility to the disorder being studied.
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Also, isolated cells in culture may have many functional differences 
from the fully intact in vivo situation.
The use of immunohistochemistry and in situ hybridisation to 
monitor any changes in expression has the advantage that the cell 
types where any change has occurred can be identified. All of the 
changes observed occurred in the same population of cells that 
displayed positive MAP2, ChaT and NSE immunoreactivity, and 
therefore occurred in the cholinergic neuronal cells.
5.14 Ejfects o f nerve growth factor on ChaT, tau and MAP2 
expression in neuronal cultures.
The development and maintenance of the cholinergic neurons 
innervating the cortex is dependent on the trophic support provided by 
NGF (Hefti et al., 1985). NGF clearly increases the expression of 
ChaT and MAP2, but not tau, in the cholinergic cultures after 4 days 
treatment. Time course treatment with NGF showed a maximal effect 
on MAP2 immunostaining after 4 days, with no further change after 1 
week exposure to NGF. MAP2 gene expression continued to increase 
after 4 days and 1 week exposure to NGF. A great many experiments 
document the ability of NGF to support survival, neurite outgrowth 
and protection of a variety of CNS neurons, most notably the 
magnocellular cholinergic neurons of the basal forebrain (Gage et 
al., 1991; Springer., 1988; Wilcock et ah, 1995). NGF has been shown 
to enhance cholinergic function in vitro and in vivo (Higgins and 
Mufson., 1989; Hefti et al., 1989). Present results agree with past 
literature demonstrating NGF to selectively increase chohnergic 
markers in rat basal forebrain in culture (Martinez et al., 1987; 
Haitikka and Hefti., 1988). The time courses of induction of MAP2 
mRNA and protein expression provided curious results. A predicted 
result would have seen the time course of mRNA increase to be faster 
than that of the increase in protein expression. However, the mRNA 
levels for MAP2 continue to rise after 1 week, the protein levels 
remaining unchanged. It is possible that an increase in mRNA levels 
precedes the increase in protein levels, or that a regulatory mechanism 
within the cells may prevent a further rise in MAP2 protein levels, 
despite the continued increase in gene expression. It would be of
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interest to study MAP2 mRNA levels at an early time point of 8  hours 
and also at a later time point greater than 24 hours.
5.15 Ejfect o f nerve growth factor on NADPH diaphorase levels in 
neuronal cultures.
NGF causes PC I2 cell growth and differentiation. This response 
to NGF involves a proliferative phase that is followed by growth 
arrest and differentiation (Greene and Tischler.,1976). The cytostatic 
effect has recently been shown to be mediated by NO (Peunova et 
al., 1995). The exposure of neuronal cultures to NGF resulted in an 
increase in NADPH diaphorase staining after 24 hours. This affect 
was maximal after 24 hours, with no further increase following 30 
hours, or 4days exposure. The NADPH diaphorase stained cells were 
moiphologically of the same population as those positive for MAP2, 
ChaT and NSE indicating that the cholinergic neuronal cells possess 
NO activity, although whether this indicates the presence of NOS or, 
the possible type of NOS involved can not be defined. NOS has been 
shown to be localised in the same neuronal population as NADPH 
diaphorase in vivo (Bredt et al., 1991). NADPH diaphorase 
immunostaining has shown eolocalisation with the cholinergic basal 
forebrain (Pasqualotto and Vincent.,1991), and, colocalisation of 
NOS and the low affinity nerve growth factor has been demonstrated 
in the medial septum and diagonal band nuclei (Peng et al., 1994), 
Neuronal NOS immunoreactivity has been clearly demonstrated in 
basal forebrain sections (Bredt and Snyder 1991).
The time course of the effect of NGF on NADPH diaphorase 
immunostaining is similar to that seen previously (Peunova et 
al., 1995), with a maximal effect seen after 24 hours. Peunova and 
coworkers suggested that a large proportion of the NGF-induced 
NOS activity in PC 12 cells is calcium-independent especially at the 
early stages of NGF action (within 24 hours), and may be due to 
iNOS (Peunova et a l, 1995). Different types of NOS may be activated 
during the different stages of NGF's action on the cell line, starting 
with induction of a calcium-independent inducible form (Peunova et 
a l, 1995). Whether a similar pattern occurs in neuronal cells involving 
inducible and neuronal NOS, where basal levels of neuronal NOS rise 
in the presence of NGF together with the induction of iNOS, can not
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be elucidated from the present results. The present results do provide, 
evidence that NGF induces a form (s) of NOS in neuronal cells. 
Holtzman and colleagues recently showed that the expression of 
neuronal NOS in developing basal forebrain cholinergic neurons is 
regulated by NGF (Holtzman et al., 1996). They raised the possibility 
that endogenous NGF may regulate regulate neuronal NOS 
expression in developing basal forebrain cholinergic neurons, and that 
NGF may act through NO to affect differentiation and maturation of 
cholinergic neurons. The high affinity nerve growth factor receptor, 
the p^ "^ *^ trkA tyrosine kinase receptor, is thought to be essential and 
sufficient to elicit NGF responses (Kahle et al., 1994). This receptor 
has intrinsic tyrosine kinase activity and is capable of evoking cellular 
neurotrophic responses in the absence of the p^  ^ low affinity receptor 
(Loeb and Greene., 1993). As has been discussed previously, LPS 
induction of iNOS is thought to be via tyrosine kinase activation 
(Kitamura et al., 1996). As the actions of NGF are through the high 
affinity tyrosine kinase receptor, this would argue in favour of the 
presence of iNOS in the neuronal cells. Further experiments using 
radiolabelled oligonucleotide probes to nNOS and iNOS would clarify 
the possible type (s) of NOS present in the neuronal cells, and whether 
a similar pattern to that seen in PC 12 cells where iNOS is induced in 
the beginning stages of NGF’s action (Peunova et al., 1995).
5,16 Ejfect o f nerve growth factor on cytoskeletal proteins and 
glycolytic enzyme immunostaining in neuronal cultures.
The NGF-induced increase in MAP2 and NSE immunostaining 
was reduced to near baseline levels following pre-treatment of the 
cultures with dexamethasone. Dexamethasome is not primarily an 
inducible NOS inhibitor, the synthetic glucocorticoid is used clinically 
to suppress the immune response and the processes of inflammation 
(Pai'illo and Fauci., 1979). iNOS transcription has recently been 
shown to be regulated by activation of the immune system regulator 
nuclear faetor kappa B (NFkB) (Goldring et al., 1995). It is thought 
that inhibition of iNOS gene expression may be due to a decreased 
availability of NFkB (Colasanti et al., 1995), and dexamethasone may 
inhibit iNOS gene expression by affecting NFkB activation (Colasanti 
et al., 1995). As the actions of dexamethasone are varied, a similar
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1experiment was earried out using the NO scavenger haemoglobin 
(Hb), focusing on MAP2 immunoreactivity.
Exposure of the cultures to Hb and NGF resulted in MAP2 
immunostaining reducing to baseline levels. The results obtained with 
Hb and dexamethasone suggest that the effeet of NGF on MAP2 
immunoreactivity may involve NO activity, and may involve iNOS. 
Further experiments discussed in section 5.19 also provide further 
evidence for the involvement of NO; the results obtained with NGF 
are mimicked by the NO-releasers SNP and SNAP. Inducible NOS 
activity has been demonstrated in other neuronal cell types: LPS- 
activated granule neurons express iNOS activity (Sato et al., 1996), 
and an increase in iNOS immunoreactivity is thought to accompany 
regenerative processes in peripheral ganglia (Magnusson et al., 1996). 
It has also recently been shown that direct intracerebellar injection of 
LPS induces in vivo nemonal expression of the iNOS gene 
(Mincgolomb et a l ,1996). Thus, it is possible that the present 
neuronal cells possess iNOS activity.A further experiment using the 
calmodulin antagonist W7 suggests that the NGF-induced increase in 
MAP2 immunoreactivity involves a calmodulin-dependent NOS; 
exposure of the cells to W7 reduced the NGF-induced increase in 
MAP2 immunoreactivity to near control values. This agrees with the 
fact that the neuronal form of NOS is a calmodulin-dependent enzyme 
(Schmidt et a l, 1991; Bredt and Snyder., 1990). However, as has been 
discussed previously, W7 can not be used as a distinguishing 
compound as both neuronal and inducible NOS are calmodulin- 
dependent. Recent data shows that glial cells may possess a calcium- 
insensitive but calmodulin coupling NOS, and that iNOS induced from 
glial cells is coupled tightly with endogenous calmodulin even in the 
absence of calcium (Kitamura et a l, 1996). The calmodulin-binding 
region of iNOS has been shown to account for its calcium 
independence (Ruan et al., 1996). In the present work, inhibition of 
the NGF-induced increase in MAP2 immunostaining by 
dexamethasone indicates the presence of an inducible form of NOS in 
the neuronal cultures, while inhibition with W7 indicates the presence 
of a calmodulin-dependent form of NOS. As it is more than likely that 
the neuronal cells contain basal levels of neuronal NOS, it is possible 
that they also possess inducible NOS activity.
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As has been mentioned previously, the conclusive way to
elucidate the type (s) of NOS involved in the neuronal and glial cells
would be to use specific oligonucleotide probes. Also, calcium
involvement has not been investigated in the present work. iNOS is
now though to be calcium-independent, thus removal of calcium by
using chelators such as EOT A would decrease neuronal NOS activity.
Induction of astroglial iNOS has been shown to involve tyrosine
.kinase activity (Feinstein et al., 1994; Kitamura et al., 1996). A further 
neuronal culture experiment using the tyrosine kinase inhibitors 
genistein and herbimycin A would enable any involvement of tyrosine 
kinase activation in NOS activity to be studied.
An important question unanswered at the present time is 
whether the differential expression of the iNOS gene reported by 
Park et al (1996) is due to differences in the calmodulin binding site. 
As discussed in Chapter 4, the cultured ghal cells may possess 
different types of NOS enzyme differing in calmodulin dependency, 
and this may also be tme of the neuronal cholinergic cells.
5.17 Ejfect o f glutamate on NADPH diaphorase levels in neuronal 
culture.
One process speculatively linked to the pathogenesis of 
Alzheimer's Disease has been the neurotoxicity of glutamate (Choi et 
al.,1988). NMDA and NO have been shown to increase MAP2 gene 
expression in hippocampal granule cells (Johnston and Morris., 1994).
In light of this evidence, the effect of excitatory amino acids on 
NADPH diaphorase and cytoskeletal immunostaining was 
investigated. Exposure of the basal forebrain cell cultures to 
glutamate resulted in a significant increase in NADPH diaphorase 
staining. Treatment with W7 and glutamate resulted in no change in 
the glutamate-induced rise in NADPH diaphorase staining. This result 
is similar to that seen in the ghal cultures, where an LPS induced 
increase in NADPH diaphorase levels appeared to involve a 
calmodulin-independent NOS; NADPH diaphorase immunostaining 
remaining unaltered after W7 exposure (Chapter 4). As has been 
discussed, it is possible that the neuronal cultures, as well as the glial
.•cells, possess various forms of NOS. It may be that the cultured
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neuronal cells possess neuronal NOS, iNOS and, differential 
expression of iNOS with valions forms differing in calmodulin 
dependency. As discussed at the end of section 5.16, experiments to 
further investigate the different forms of NOS are necessary.
It is important to also discuss discrepancies in NADPH 
diaphorase immunostaining reported. NADPH-diaphorase 
histochemistry has been widely used to identify neurons that produce 
NO (Valtschanoff et al.,1993; Dawson et al., 1992). However, it 
should be noted that recent studies have noted discrepancies regarding 
the correlation between NADPH-diaphorase activity and NOS 
immunoreactivity. Whereas some authors report a complete overlap of 
both (Decker and Reuss.,1994; Hashikawa et al., 1994; Valtschanoff et 'al., 1993), others report that NADPH diaphorase histochemistxy and 
nNOS immunohistochemistry do not necessarily label the same 
neuronal population (Kharazia et al.,1994; Vizzard et al., 1994). These 
differences may be due to the sensitivity of NADPH diaphorase to 
paraformaldehyde as a fixative (Spesser and Layes.,1994), or to the 
existence of enzymes other than NOS displaying NADPH diaphorase 
activity (Hope et al., 1991). In the present study, great care was taken 
to ensure identical staining conditions throughout each set of 
experiments.
5.18 Ejfect o f excitatory amino acids on cytoskeletal protein 
expression.
Basal forebrain cholinergic neurons have been shown to be 
selectively vulnerable to non-NMDA receptor mediated neurotoxicity 
(Weiss et al.,1994). Glutamate has been shown to induce a dose- 
dependent increase in tau immunoreactivity in primary neuronal 
cultures (Sindou et al.,1992; Sautiere et al.,1992). In light of this 
evidence, cultured cells were exposed to the non-NMDA receptor 
agonist kainate, and the metabotropic receptor agonist ACPD. 
Kainate significantly increased MAP2 immunoreactivity, with no 
significant effect on tau immunoreactivity. ACPD had no significant 
effect on the immunoreactivities of either cytoskeletal protein. This 
result suggest that the cultures may be sensitive to non-NMDA 
receptor activated increase in MAP2 immunoreactivity, and an
1 0 6
absence of metabotropic receptor involvement in cytoskeletal protein 
immunoreactivity. The induction of MAP2 but not tau may indicate a 
preferential action of kainate on dendritic as opposed to axonal 
morphology. However, as is discussed in Section 5.20, the NGF- 
induced increase in MAP2 is not linked to detectable changes in 
dendritic morphology.
5.19 Ejfect o f NO releasers on cytoskeletal protein expression.
The NO-releasing compounds SNP, SNAP and SIN-1 
breakdown in solution releasing NO. All three of these compounds 
caused an increase in MAP2 immunoreactivity with no effect on tau or 
NSE levels. This increase in MAP2 levels was reduced to neai' 
baseline levels following combined exposure to SNAP and the NO 
scavenger Hb. The membrane-permeable cyclicGMP analogue, 
SbromocyclicGMP, also increased MAP2 immunoreactivity. As 
discussed previously, NO is released by cells containing NOS 
following an increase in intracellulai' calcium levels. NO can then 
diffuse to affect neighbouring cells, where many of its actions involve 
the activation of guanylate cyclase which results in increases in 
intracellular cGMP levels and stimulation of cGMP-dependent protein 
kinase (Garthwaite et al., 1988; Knowles et ah, 1989). Recently, it has 
been shown that NO stimulates expression of the immediate eaiiy 
genes c-fos and zif/268 in PC 12 cells (Haby et al.,1994; Peunova et 
al.,1993). NO has also been shown to alter proenkephalin, 
prodynorphin and MAP2 gene expression in hippocampal granule cells 
(Johnston et al., 1994a; Johnston et al.,1994b). Thus, it is possible that 
NO may regulate gene expression in those areas of the brain 
containing NOS activity. As shown in Section 5.15, the neuronal 
cholinergic cultures contain NOS activity.
Recent evidence has shown that certain drugs which cause NO 
release in solution can also give rise to non-specific effects unrelated 
to the release of NO (Butler et al.,1995). Therefore a number of NO- 
releasing compounds from different structural classes were used. All 
three compounds increased MAP2 immunoreactivity, and their only 
common feature is NO release. This, together with the fact that the 
NO scavenger Hb redueed the increase in MAP2 immunoreaetivity
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strongly implicates NO in this affect. NO-induced increases in c-fos 
and zif/268 mRNA levels in PC I2 cells have been shown in one case 
to involve the activation of guanylate cyclase and cGMP-dependent 
protein kinase (PKG), as mimicked by SbromocGMP (Haby et 
al.,1994). Other results implicated synergism with calcium influx 
following treatment with the calcium ionophore A23187 (Peunova et 
al.,1993). The present results suggest that NO may exert an induction 
in MAP2 immunoreactivity through a pathway that involves guanylate 
cyclase and cGMP-dependent protein kinase, corresponding with the 
results seen in the cell line. However, further experiments using the 
cGMP phosphodiesterase inhibitor MY5445 and the selective PKG 
inhibitor KT5823 would strengthen this theory.
It is important at this stage to discuss the main antibodies used 
in the experiments. As has been discussed, tau immunoreactivity has 
remained unaltered, with dramatic effects being observed in MAP2 
immunoreactivity. The tau antibody is a mouse monoclonal antibody 
which reacts with all isoforms of tau in both the phosphorylated a’hd 
unphosphorylated states. It recognises tau along the microtubules, in 
axons, somata and ribosomes. The fact that no immunoreactivity 
changes have occurred, and no alterations in mRNA levels have 
occurred, indicate no change in synthesis of any isoform. Also any 
changes in phosphorylation that may have occurred will not have 
affected the results. The MAP2 antibody is also monoclonal and reacts 
with all known forms of MAP2: MAP2a, 2b and 2c. It is also a 
phosphorylation-independent antibody.
5.20 Ejfect o f NGF and NO releasers on neurite morphology.
In view of the fact that NGF and the NO releasing compounds 
had such a dramatic effect on MAP2 immunoreactivity, and of the 
well documented effect of NGF on neuronal cell survival and neurite 
outgrowth, an investigation of neurite morphology was carried out'. 
The use of a more dilute cell suspension in this set of experiments 
enabled clear measurements of the neurites. Surprisingly NGF did not 
induce any change in primary neurite length or neurite staining 
intensity. It had been expected that NGF may cause some change in 
neurite morphology. It is possible that an undetected change occurred.
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and it is worth considering that there may have been a morphological 
change to the dendritic spines or neurite branching points. Perhaps it 
was an oversight to have focused on the primary neurite length given 
that this remains unaltered. A  look at further branching points may 
have given clearer results.
Growth of nerve fibres occurs under three conditions: during" 
development, as regeneration of neurites after lesion and in the 
differentiated nervous system as a prerequisite of structural plasticity. 
Neurite growth is regulated on two levels of the neuron: in the œil 
body, and at the growing tip of axons or dendrites. A  variety of 
factors-have been described which influence neurite growth on-these 
different levels, the most extensively studied molecule being NGF 
(Thoenen and Barde .,1980; Teng and Greene., 1994). The reasons 
why NGF failed to cause any change in neurite growth in the present 
study remain unclear.
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5.21 Effect o f LPS and IL-1 on APP and COX2 immunostaining id  
neuronal cultures. ' -
Recent studies have suggested a neuroprotective influenœ for 
non-steroidal anti-inflammatory drugs (NSAIDS), and a beneficial 
association between concurrent NSAID use and cognitive functioning 
in Alzheimer’s Disease (Rich et al., 1995). IL-1 is thought to be 
involved in the neuronal mechanisms underlying Ap deposition in AD 
(Forlini et al.,1992). As with NOS, COX2 possesses distinct cytokine- 
inducible isoforms (iNOS and Cox2 respectively). In the present 
study, the effect of LPS and IL-1 on APP and COX2 
immunoreactivity was investigated. Neither compound or combined 
exposure to both altered APP or COX2 immunoreactivity. Exposure 
of the cultures to the prostaglandin PGE2 did not alter COX2 or APP 
immunoreactivity. Thus it appears that the compounds at the 
concentrations and time points used have no effect on APP or COX2 
expression. Evidence suggests that induction of COX2 by LPS can 
occur in bovine aortic endothelial cells (Akarasereenont et al.,1994). 
A similar system does not appear to occur in neuronal cells at the 
concentrations used. It has recently been shown that induction of 
COX2 mRNA may involve activation of NMDA receptors in vivô
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(Miettinen et al., 1997). In light of this evidence, perhaps more 
conclusive results would have been obtained using excitatory amino 
acid agonists and antagonists. Further investigations into the possible 
function (s) of APP have been cairied out using two transgenic APP 
models, and this is discussed in chapter 6 .
Summary:
In the present section of work, cholinergic neuronal cultures 
have been characterised by positive immunostaining to ChaT, MAP2 
and NSE. Using these cultured cells, the distribution and expression of 
cytoskeletal proteins, and NADPH diaphorase immunostaining have 
been investigated as summarised below:
1\ Exposure of the cells over a 24 hour period to NGF resulted in a 
dramatic increases in ChaT, MAP2 and tau immunoreactivity.
2\ The cultured cells appear to possess a type of NOS that is 
regulated by NGF.
3\ NGF induced an increase in MAP2 and NSE immunoreactivity. 
This induction of MAP2 expression may be through a neuronal 
calmodulin-dependent form of NOS.
4\ Exposure of the cells over a 24 hour period to glutamate resulted in 
the induction of a calmodulin-independent form of NOS.
5\ It is possible that the neuronal cells possess various types of NOS 
enzyme differing in their calmodulin-dependency.
6 \ Exposure of the cells to NO-releasing compounds over a 24 hour 
period resulted in a dramatic increase in MAP2 expression. It is 
possible that NO may regulate MAP2 expression through a pathway 
involving guanylate cyclase and cGMP-dependent protein kinase. The
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induction of MAP2 expression by NGF and NO-releasers was not 
accompanied by any detectable morphological changes.
The next stage of work has focused on APP function. An 
investigation into the distribution and regulation of cytoskeletal and 
other proteins in response to APP removal and mutation has been 
carried out.
I l l
Chapter 6
Immunohistochemical study of 
morphological and synaptic 
markers in two mutant 
mouse models.
INTRODUCTION
This section of work made use of two transgenic mice models. 
The aims were as follows: to investigate glial fibrillaiy acidic protein 
(GFAP), synaptophysin, MAP2, the calcium binding protein calbindin 
D28k, and presenilin immunoreactivity in two transgenic mice models: 
one with deleted amyloid precursor protein (APP-null), and another 
with a mutated a-secretase cleavage site on the APP gene (APP/RK). 
Changes in immunostaining observed have been discussed in relation 
to possible physiological role (s) of APP.
6.1 Transgenic Models
The lack of a suitable animal model for Alzheimer’s Disease has 
slowed our understanding of the pathogical mechanisms that occur in 
the development of Alzheimer’s Disease. Many research groups have 
been attempting to generate transgenic rodent models of Alzheimer’s 
Disease to determine if these mice show the neuropathological 
hallmarks of the disease and demonstrate memoiy and learning 
deficiencies. The neuropathological hallmarks of Alzheimer’s Disease 
include proteinaceous deposits known as plaques and neurofibrillaiy 
tangles, as well as neuronal and synaptic loss. The related processes of 
neurodegeneration and synaptic loss are the key substrates of 
Alzheimer’s Disease. An ideal animal model of the disease would 
develop each of the pathological symptoms of the disease as a 
function of age.
The majority of animal models for Alzheimer’s Disease have 
focused on manipulation of the APP gene. Prior to 1995, animals 
transgenic for APP had failed to show extensive Alzheimer’s Disease- 
type neuropathology (Quon et al ., 1991, Pearson et al ., 1993). 
Transgenic mice have been produced that express various forms of the 
human APP gene (Price and Sisodia, 1994). Recently, Games et al 
reported the production of transgenic mice that express high levels of 
human mutant APP, ( with valine at residue 717 substituted by 
phenyalanine), and progressively develop many of the pathological 
hallmarks of the disease including numerous thioflavin-positive 
amyloid deposits, neuritic plaques, synaptic loss and reactive gliosis 
(Games et al., 1995).
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The present study has focused on the following two transgenic 
models:
1\ APP-null mice:
A complete deficiency of APP in mice was generated by 
homologous recombination in embryonic stem cells (Zheng et 
ah,1995), The homozygous APP-deficient mice weighed 15-20% less 
than age-matched wild type controls, and demonstrated premature 
mortality, seizures and behavioural abnormalities such as aggression 
and hostility. At 14 weeks of age, four out of six animals showed 
reactive gliosis in the hippocampus, striatum and cortex (Zheng et a l ., 
1995). Synaptic loss was observed especially in the dentate gyrus and 
LTP impairment has also been reported.
A complete removal of the APP gene may allow insight into the 
function of APP in AD, and serve as a valuable strain for the possible 
insertion of the human APP gene. In the present study, brain sections 
taken from the APP-null mice have been compared with sections from 
age-matched wildtype animals, focusing on the following: reactive 
gliosis levels have been investigated by quantification of GFAP 
immunoreactivity, quantification of calbindin immunoreactivity has 
been measured using both immunohistochemistry and radiolabelling, 
and, a comparison of MAP2 and synaptophysin immunoreactivity has 
also been carried out.
2\ APP/RK mutant mice
The proteolysis step of APP secretion, mediated by an as yet 
unknown proteinase named a  secretase, is an intrinsic and essential 
step in the mechanism of APP secretion. Whereas the known clinical 
mutations in APP affect the (3 and y secretase sites, no natural 
mutations have been described at the a  secretase site. The functional 
importance of the a-secretase processing of APP was examined by 
Moechars and coworkers (Moechars et al.,1996). Introducing a 
double mutation in the a  secretase region by replacing two basic 
residues with two acidic residues gave a APP/RK mutant. This mutant 
was secreted at a reduced rate from three different cell types: COS 
cells, MDCK cells and primary neurons (De Strooper et al.,1993). 
Expression of this a-secretase mutant in the brain of transgenic mice
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resulted in behavioural disturbances, seizures and premature death. 
The neuropathological changes observed included apoptosis, necrosis 
and reactive gliosis in the hippocampus, cortex and amygdala 
(Moechars et al.,1996). The results demonstrated the severe 
neurotoxicity resulting from incorrect a  secretase processing of APP 
in the CNS.
In the present study, it was fortunate to obtain brain sections 
from these transgenic mice and examine GFAP immunostaining in 
APP/RK and age matched wildtype animals.
6.2 Calcium binding proteins
An uncontrolled sustained elevation of free calcium ions is toxic 
to neurons and may eventually lead to cell death (Siesjo et a l ., 1985). 
Neurons possess several control mechanisms that prevent such an 
overload of calcium. Besides storage in cellular granules and extrusion 
of calcium by pumps and ionic exchange (Rasmussen et al ., 1990), 
neurons contain specific proteins such as paiwalbumin and calbindin 
D-28k which transiently bind calcium ions (Celio et al ., 1990). 
Evidence suggests that dysfunction of calcium homeostasis occurs 
during ageing. An increased calcium concentration in whole brain 
homogenates (Michaelis et al ., 1992), and an elevated concentration 
of free calcium ions in synaptosomes and dorsal root ganglion cells 
have been demonstrated in aged rats (Kirischuk et al ., 1992). 
Calbindin D-28k plays an important role in the buffering system which 
protects tissue from calcium-induced cellular injury (Tao et al .,1996a) 
and calbindin D-28k has been shown to be expressed in the 
hippocampus of AD brains (Tao et a l ., 1996b). The protein has also 
been shown to be expressed in a number of forebrain areas implicated 
in learning and memoiy (Persechini et al., 1989, Baimbridge et al ., 
1992, Heizmann et al ., 1992). Calbindin D-28k levels have been 
shown to be reduced in the hippocampus and cerebral cortex of AD 
patients (Ichimiya et al., 1988). The influx of calcium into the 
postsynaptic neuron is likely to be an important event in memory 
formation, and it is thought that calbindin D28k may have a role in 
the activation of calcium-dependent intracellular signaling pathways 
underlying memoiy function. Transgenic mice deficient in calbindin
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D28k show impairments in learning pai'adigms and fail to maintain 
long term potentiation (Molinari et al.,1996).
In the present study, calbindin immunoreactivity levels were 
quantified by immunohistochemistry and radiolabelling in order to 
establish any effect removal of the APP gene has on caleium binding 
protein levels.
6.3 Presenilins
As discussed in Chapter 1 section 1.9.1, two novel genes, 
presenilins 1 and 2 , have been linked to the development of early 
onset Alzheimer's Disease. The presence of six to nine hydrophobic 
domains indicates that presenilins 1 and 2 (PS-1, PS-2) share a 
serpentine topology which produces one large and several small 
hydrophobic loops (Kovacs et al.,1996). The mechanism by wliich the 
early onset familial Alzheimer’s Disease (FAD)-associated mutations 
exert their effect is unknown. Around two separate causative 
mutations in 52 individual pedigrees linked to chromosome 14 have 
been identified on PSl (S182), and two mutations have been detected 
in PS2 (Wasco et al.,1995; Sorbi et al.,1995; Tanahashi et al.,1995; 
Cruts et al.,1995).
PSl and PS2 proteins show 67% identity and have homology to 
Caenorhabiditis elegans, indicating that the PS genes aie conserved 
during evolution (Levitan and Greenwald.,1995). Although the role(s) 
of the presenilins have not been discovered, several predictions have 
been made as to their biological role based on their structures. These 
include possible roles as receptor molecules, ion channel or membrane 
structural proteins or protein transporters (Levitan and 
Greenwald.,1995; Sherrington et al.,1995). PS2 has also recently been 
implicated in apoptosis (Vito et al.,1996).
PS 1 immunostaining has been found intracellulaiiy in the 
perikarya of cells, mostly neurons, appearing as thick granules 
resembling large vesicles (Moussaoui et al.,1996). The gene product 
for PS 1 has been found in neurons in human, rat and mouse CNS as a 
membrane bound protein of 48kDa, with dendritic staining stronger 
than axonal staining (Elder et al.,1996). PSl mRNA has also been 
seen to be widely expressed in non-neural tissues including the heart, 
liver and lung (Sherrington et al.,1995). PSl expression has been
■f
found to be predominant in the hippocampus and cerebral, i.e. in those 
areas of the brain that are most susceptible to plaque formation 
(Cribbs et al.,1996).
The present work has examined the effect of APP deletion on 
PS-1 expression in various areas of the brain. Using antibodies 
directed against the N and C termini of PS-1, the pattern of 
immunostaining in APP-null and age matched control animals has 
been investigated.
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Results
6.4 GFAP immunoreactivity in brain sections o f APP-null and wild 
type animals.
GFAP-immunostained coronal sections through the 
hippocampus, corpus callosum and cortex from wildtype (wt) and f
APP-null mice (-/-) at 13 months of age were examined for reactive 
gliosis, (all antibodies used in this section of work are described in the |
Materials section p52). As can be clearly seen in Figs 6.1.1 and 6 .1.2, 
a larger degree of GFAP immunoreactivity occurred in the wt animals.
The wt animals show marked GFAP immunoreactivity: astrocytes '
with enlarged cell bodies and thicker processes staining heavily for 
GFAP. In the hippocampus, extensive GFAP immunoreactivity was 
observed in the CAl region, and dentate gyrus especially the granule 
cell layer. GFAP immunoreactivity was seen throughout the cortical 
layers. Surprisingly, the APP-null animals displayed a low level of 
GFAP immunoreactivity principally localised in the hippocampus, 
corpus callosum and outer cortical layer. GFAP immunoreactivity was 
investigated quantitatively, and the numbers confirmed the 
photographic observations, as shown in Fig. 6.1.3. By the Mann- 
Whitney U-test, the wt animals show a dramatically higher GFAP 
optical density [Fig.6.1.3, p<0.001, n = 4 animals]. GFAP 
immunostaining was also significantly higher in the corpus callosum of 
the wt animals [Fig. 6.1.4, p<0.001 by Mann Whitney U test, n = 4].
Cell counts for cortical layers 2-3 were also significantly higher for the 
wt animals [Fig. 6.1.5, p<0.001 by Mann Whitney U test, n = 4].
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Figure 6.1.1 (top photographs): GFAP immunostaining in the cortex
of APP-null and wildtvpe mice.
Photomicrographs illustrate cortical sections from the brains of : 
a\ APP-null mice and
b\ wildtype mice processed for immunohistochemistry using an 
antibody against glial fibrillary acidic protein (GFAP).
Scale bar represents 25pm.
Figure 6.1.2 (bottom) : GFAP immunostaining in the hippocampus of 
APP-null and wild type mice.
Photomicrographs illustrate hippocampal sections from the brains of 
a\ APP-null mice and
b\ wildtype mice processed for immunohistochemistry using an 
antibody against glial fibrillary acidic protein (GFAP).
The photomicrographs show the granule cell layer, dentate gyrus and 
hilus.
Scale bar represents 25pm.
arrow indicate reactive GFAP positive glial cells
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Figure 6.1.3 : Quantification of GFAP immunostaining in APP-null
and wild type mice in the hippocampus.
Following processing for immunohistochemistry using antisera against 
GFAP in the hippocampal region, mean optical density levels of 
GFAP staining intensity were quantified.
Results are expressed as mean optical density levels per mm^ ± SEM.
Statistical analysis was by Mann Whitney U test. *** p<0.001.
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Figure 6.1.4 : Quantification of GFAP immunostaining in APP-null 
and wild type mice in the corpus callosum.
Following processing for immunohistochemistry using antisera against 
GFAP, mean optical density levels of GFAP staining intensity were 
quantified.
Results are expressed as mean optical density levels per mm^ ± SEM.
Statistical analysis was by Mann Whitney U test. *** p<0.001.
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Figure 6.1.5 : Reactive astrocyte cell count of the outer cortical laver 
(layer D in APP-null and wild type mice.
Cell counts were taken in the outer cortical layers following 
immunohistochemistry of cortical sections using antisera against 
GFAP.
Results are expressed as an average reactive astrocyte cell count ± 
SEM.
Statistical analysis was carried out using the Mann Whitney U test.
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6. 5 Calbindin D28k immunoreactivity in brain sections o f APP-null
and wild type animais.
As clearly illustrated in Figs. 6.2.1 and 6.2.2, calbindin D28k 
immunoreactivity is higher in the APP-null mice compared to the wt 
animals in the entorhinal and cerebral cortices. These observations 
were confinned by immunoradiolabelling, as described in Chapter 2 
section 2.10, of coronal and cerebellar sections [Figs.6.2.3 and 6.2.4 
respectively]. The highest level of calbindin D28k labelling can be seen 
in the corpus callosum. Immunoreactivity was quantitatively measured 
in three regions: the entorhinal cortex, CAl pyramidal cells and frontal 
cortex. Calbindin D28k immunoradiolabelling was significantly higher 
in the APP-null animals compared to wt mice in all three regions [Fig. 
6.2.5, p<0.05, n = 4 for all three regions]. An important consideration 
at this stage is whether the increased immunolabelling and 
radiolabelling represents an increase in immunoreactivity, an increase 
in the number of pyramidal cells containing calbindin D28k protein, or 
both. From the photographs in Figs. 6.2.1 and 6.2.42 it appears that 
an increase in the number of pyramidal cells containing calbindin has 
occurred in the APP-null animals. However, a more accurate 
assessment would have been obtained by cell counts.
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Figure 6.2.1 : Calbindin D28k immunostaining in cortical sections 
from APP-null and wild type mice.
Cortical sections from 
a\ APP-null mice and
b\ wildtype mice were processed for immunohistochemistry using 
antisera against calbindin.
The photomicrographs show cortical layers I-in.
Scale bar represent 100pm.
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Figure 6.2.2 : Calbindin D28k immunostaining in entorhinal cortical
sections from APP-null and wild type mice.
Entorhinal cortical sections from 
a\ APP-null mice and
b\ wildtype mice were processed for immunohistochemistry using 
antisera against calbindin.
The photomicrographs show cortical layers I-in.
Scale bar represent 100pm.
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Figure 6.2.3 : Calbindin D28k radioimmunolahening of coronal
sections from APP-null and wildtvpe mice.
Radiolabelling was carried out using a polyclonal primary antibody to 
calbindin, and a labelled secondary antibody. Photomicrographs 
illustrate labelling intensities in APP-null and wildtype animals.
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Figure 6.2.4: Calbindin radioimmunolabelling of cerebellar sections 
from APP-null mice at 6  months of age . and wildtype mice.
Radiolabelling was carried out using a polyclonal primary antibody to 
calbindin, and a labelled secondaiy antibody. Photomicrographs 
illustrate labelling intensities in APP-null and wildtype animals.
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Figure 6.2.5 : Quantification of calbindin D28k radioimmunolabelled
sections from APP-null and wildtype mice.
Radiolabelled sections were quantified in the following areas: 
a \C A l
b\ entorhinal cortex 
c\ frontal cortex.
Results are expressed as relative optical density values ± SEM. 
Statistical analysis was carried out using Mann Whitney U test. ***
p<0 .0 0 1 .
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6 . 6  MAP2 and synaptophysin immunoreactivity in brain sections o f 
APP-null and wild type animals.
As can be seen in Fig. 6.3.1, an initial observation of 
synaptophysin immunostaining in the cortex reveals no difference in 
synaptophysin immunostaining between APP-null and wt animals.
MAP2 immunostaining was also no different in APP-null and wt 
animals (data not shown).
Figure 6.3.1 : Synaptophysin immunostaining in cortex of APP-null
and wildtype mice.
Photomicrographs illustrate synaptophysin immunostaining in 
a\ APP-null mice and 
b\ wildtype mice cortical sections.
The photomicrographs show cortical layers I-III.
Scale bar represents 50|Lim.
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6.7 PS-1 (SI82) immunoreactivity in brain sections o f APP-null and
wild type animals.
:
The pattern of distribution of S182 N-19 and S I82 C-20 was 
investigated in tissue sections from the brains of APP-null and wt 
mice. The pattern of distribution was similar to that described for APP 
in rats (Mita et a l ., 1989-to get). Interestingly, S I82 antibody staining 
was observed not only in those regions of the brain that display 
Alzheimer’s Disease pathology such as the cortex and hippocampus, 
but also in the striatum and cerebellum. The N-terminal S 182 antibody 
staining appealed to be more abundant than the C-terminal and had a 
membrane-bound distribution. The C-terminal S I82 appeared to be 
mostly cytoplasmic [Figs. 6.4.1 and 6.4.2]. This initial observation 
illustrated no difference in PS-1 immunoreactivity between APP-null 
and wild type animals.
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Figure 6.4.1 (top photographs): S182-N19 immunostaining in the 
cortex of APP-null and wild type mice.
Photomicrographs illustrate cortical sections from 
a\ APP-null mice and
b\ wild type mice processed for immunohistochemistry using an 
antibody against SI82-N-19.
Scale bar represents 25p,m.
Figure 6.4.2 (bottom photographs): S182-C-20 immunostaining in 
the cortex of APP-null and wild type mice.
Photomicrographs illustrate cortical sections from 
a\ APP-null mice and
b\ wild type mice processed for irnmunohistochemistry using an 
antibody against S182-C-20.
Scale bar represents 25pm.
arrows indicate S I82 positive neurons
" /mm S 6»
« % -
6 . 8  GFAP immunoreactivity in brain sections o f APP/RK and wild 
type animals.
GFAP immunoreactivity was markedly higher in the 6  month 
old APP/RK mice compared to age matched wild type animals. As 
seen in the APP-null and wt mice, the reactive astrocytes had enlarged 
processes and reactive cell bodies. Reactive astrocytes were observed 
throughout the cortical layers and hippocampal region. The coipus 
callosum was also very reactive. Figs. 6.5.1 and 6.5.2 illustrate the 
dramatic increase in reactive gliosis in the APP/RK mice in the cortical 
and hippocampal regions. The observations were analysed 
quantitatively, and GFAP immunostaining was proved to be 
significantly higher in the hippocampus and corpus callosum [Figs. 
6.5.3 and 6.5.4, p<0.001 by Mann Whitney U test, n = 4 for both 
regions]. Cell counting in the cortical layers revealed a higher count 
throughout layers 2-3 in the APP/RK mice compared to wt animals 
[Fig. 6.5.5, p<0.001 by Mann Whitney U test, n = 4].
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Figure 6.5.1 (top photographs) : GFAP immunostaining in the
hippocampal region of APP/RK and wildtype mice.
Sections from the hippocampal region of APP/RK and wildtype mice 
were processed for immunohistochemistry using antisera against 
GFAP.
Photomicrographs illustrate the reactive astrocytes in the dentate 
gyrus and hilus of:
a\ APP/RK mice 
b\ wildtype mice
Scale bar represents 25p,m.
Figure 6.5.2 (bottom): GFAP immunostaining in the cortex of 
APP/RK and wildtype mice.
Sections from the cortex of APP/RKand wildtype mice were 
processed for immuonhistochemistry using antisera against GFAP.
Photomicrographs illustrate the reactive astrocytes in:
a\ APP/RK mice 
b\ wildtype mice
Scale bar represents 25p.m.
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Figure 6.5.3 : Quantification of GFAP immunostaining in the
hippocampal region of APP/RK and wild type mice.
Following processing for immunohistochemistry using antisera against 
GFAP, mean optical density levels in the dentate gyrus were 
quantified.
Results are expressed as mean optical density levels of GFAP staining 
intensity per mm^ ± SEM.
Statistical analysis was by Mann Whitney U test. *** p<0.001.
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Figure 6.5.4 : Quantification of GFAP immunostaining in the corpus
callosum of APP/RK and wild type mice.
Following processing for immunohistochemistry using antisera against 
GFAP, mean optical density levels in the corpus callosum were 
quantified.
Results are expressed as mean optical density levels of GFAP staining 
intensity per mm^ ± SEM.
Statistical analysis was by Mann Whitney U test. *** p<0.001.
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Figure 6.5.5 : Reactive astrocyte cell count of the outer cortical laver 
(layer D in APP/RK and wild tvpe mice.
Cell counts were taken in the outer cortical layers following 
immunohistochemistry of cortical sections using antisera against 
GFAP.
Results are expressed as an average reactive astrocyte cell count ± 
SEM.
Statistical analysis was carried out using the Mann Whitney U test,
*** p<0 .0 0 1 .
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*** p < 0 .0 0 1  c o m p a r e d  t o  wild  t y p e  
b y  M an n  W h i tn e y  U t e s t .
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Discussion
6.9 GFAP immunoreactivity in APP-null and wild type brain 
sections, j
In view of the fact that four out of six APP-null mice displayed 
reactive gliosis at 14 weeks of age (Zheng et al., 1995), the results 
obtained in the present study for GFAP immunoreactivity were 
surprising. The wild type animals showed marked reactive gliosis: 
astrocytes with enlarged cell bodies and thicker processes stained 
heavily for GFAP in the hippocampus and through the superficial 
layers of the cortex. The intense astrocytic reaction was absent in the 
APP-null mice. Reactive gliosis occurs in many disease states, in 
response to neuronal injury (Eddleston and Mucke.,1993), and in 
normal ageing brains (Norton et ah, 1992; Dickson et al., 1993). Thus, 
the observed reactive gliosis seen in the wild type animals may be due 
to the normal ageing process. The mice were at 13 months of age, and 
taking into account the average longevity of mice to be 18-20 months,
13 months would classify as fairly aged. An interesting further study 
would be to compare GFAP immunoreactivity levels in 13 month and 
younger aged animals, to investigate the effect of ageing on GFAP 
levels. It is also possible that reactive gliosis may have peaked in the 
APP-null mice after 14 weeks, and somehow desensitised during the 
period between 14 weeks and 13 months. The mechanisms underlying 
reactive gliosis are still unclear*, although it is thought to be a tissue- 
based mechanism, with changes in eicosanoid and nitric oxide levels 
mechanisms by which ghal structure may be altered (Caggrano et 
al.,1996).
Abnormal regulation and processing of APP may contribute to 
Alzheimer's Disease. Five different mutations have been identified in 
the human APP gene, linking the gene to early onset familial 
Alzheimer's Disease (Mullan et al., 1993). By developing a transgenic 
model of complete removal of the APP gene, it is possible to 
investigate the possible physiological roles of APP in the brain and the 
relevance of this role in the mechanisms that lead to the development 
of Alzheimer’s Disease. Prior to this model, complete removal of the 
gene had not been examined. Muller and coworkers developed mice 
with a disrupted APP gene. These animals were severely impaired in
spatial learning and exploratory behaviour, and showed increased 
incidence of agenesis in the corpus callosum (Muller et al.,1994). No 
reactive gliosis was reported in these animals, so it is possible that a 
partial retention of function in the APP gene prevented the 
development of reactive gliosis. The fact that the APP-null animals 
showed marked reactive gliosis at 14 weeks but not at 13 months 
could be due to an accelerated process which had somehow stabilised 
by 13 months. Further work on these animals between the ages of 14 
weeks and 13 months is clearly necessary. There is the future 
possibility that these animals will be used for the insertion of a human 
APP FAD gene to generate a mouse model of Alzheimer’s Disease, 
and to investigate the effects of mutations in the FAD gene on protein 
expression and regulation.
6.10 Calbindin D28k immunoreactivity in APP-null and wild type 
brain sections.
Calbindin D28k plays an important role in the buffering system 
which protects tissue from calcium-induced cellular injury (Tao et 
al., 1996a). It is expressed in the hippocampus of Alzheimer's Disease 
brains (Tao et ah, 1996b). The results from the current study show an 
increase in calbindin D28k in the superficial frontal cortical layer, 
superficial entorhinal cortical layer and CAl in the APP-null mice 
compared to age matched control animals. Removal of the APP gene 
may have resulted in a potential calcium-induced toxicity which was 
controlled by increased levels of calbindin D-28k buffering system. 
This observation may suggest an interesting link between APP 
function and calbindin activity. It is important, however, to address 
the issue of whether the observed increase in calbindin 
immunoreactivity is the result in an increase in the number of cells, or 
an increase in the calbindin labelling intensity within the cells. An 
initial observation of the stained sections suggests an increase in cell 
number as well as cell staining intensity, although quantification by 
cell counting is necessary to verify this. An interesting possibility is the 
de novo synthesis of calbindin protein within pyramidal cells in 
response to removal of the APP gene.
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6.11 MAP2 and synaptophysin immunoreactivity in APP-null and
wild type brain sections.
Severe synaptic loss occurs throughout the brain in Alzheimer's 
Disease, and it has been sho’wn that the severity of synaptic loss 
correlates with the degree of cognitive impairment to a substantially 
better degree than either plaques or tangles (Terry et ah, 1991). 
Synaptophysin and MAP2 immunoreactivity remained unaltered in the 
APP-null animals compared to wildtype animals. It should be noted 
however that the synaptophysin and MAP2 studies were initial 
observations and no quantification was performed. No alteration in 
synaptophysin immunoreactivity levels could be due to the fact that 
the APP-null animals underwent régulai* and extensive behavioural 
testing throughout their 13 months. Regular stimuli may have helped 
to maintain synaptic function that may have been altered by removal 
of the APP gene. A further study to investigate in more detail the 
effect of removal of the APP gene on synaptic formation would use 
immunostaining for synaptosomal associated proteins such as SNAP- 
25. SNAP-25 is a 25kD synaptosomal associated protein that is 
highly expressed in murine hippocampus, being localised mainly in 
axons and axon terminals (Branks and Wilson., 1986; Oyler et 
al., 1989). Expression of this protein has been found to be strongly 
induced during late stages of axonal growth, and during the onset of 
synapse formation (Catsicas et al., 1991; Oyler et al., 1991; Osen-Sand 
et al., 1993).
MAP2 immunoreactivity remained unchanged in the APP-null 
animals compared to wild type animals. Thus, MAP2 may have no 
connection with APP and thus levels were no altered by removal of 
the APP gene.
As discussed in section 6.1, GFAP levels in the wildtype animals 
changed dramatically, and this could be due to the normal ageing 
process. It would be of interest to compare synaptophysin and MAP2 
immunoreactivity levels in 13 month and younger wildtype animus to 
see if the ageing processes alters either.
.;a
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6.12 Presenilin-1 immunoreactivity in APP null and wild type brain 
sections.
The pattern of distribution of PS-1 (SI82) in both APP-null and 
wild type animals was similai* to that seen in rats (Mita et al., 1989). 
PS-1 was observed not only in those regions of the brain that display 
Alzheimer’s Disease pathology, but also in the striatum and 
cerebellum. The cerebellum shows Ap plaques though of the diffuse 
type. N-terminal immunoreactivity was stronger than that of C- 
terminal PS-1, and had a membrane-bound distribution. The C- 
terminal PS-1 appeared to be mostly cytoplasmic. The PS-1 
immunoreactivity appeared to be present mostly in neurons, with a 
lack of immunoreactivity observed in blood vessels or white matter. 
The levels of N- and C-terminal PS-1 remained unchanged between 
APP-null and wildtype animals. However, an initial study of cerebellar 
tissue from the APP-null mice at 6  months of age indicated a possible 
increase of N- and C- terminal PS-1 compared to that observed in 
age-matched controls (photographs not shown). This preliminary 
study requires further investigation, and there is the interesting 
possibility that PS-1 may have a synaptic role and that an increase in 
expression may compensate for the lack of APP. Recent results 
suggest that alteration in the processing of APP may have 
considerable physiological effects on synaptic plasticity (Nalbantoglu 
et al., 1997). It is thought that PS-1 exists in small quantities as a fuU 
length protein of 43-47 kDa, but instead is rapidly processed into an 
endoproteolytic fragments. Proteolysis results in the generation of two 
fragments: a 25-3BkDa N terminal fragment, and a 16-19kDa C 
terminal fragment (Thunakaran et al.,1996; Podlisny et al.,1997). The 
significance of the two fragments remains to be elucidated, and it is 
not known whether one fragment has a more active role than the 
other.
The relationship between presenilins and APP metabolism is still 
uncleai'. Present evidence is as follows. In increased secretion of the 
amyloidogenic Ap 1-42 peptide in cultured fibroblasts from 
individuals in early onset familial Alzheimer's Disease (FAD) 
pedigrees with PS1/PS2 mutations has been observed (Scheuner et 
al., 1996; Lemere et al., 1996). Recent evidence has demonstrated that 
PS-1 mutations may alter the trafficking or processing of APP
1 2 6
stimulating the activity of y secretase thus resulting increased 
production of Ap ^ _ 4 2  (Citron et al., 1997). Increased Ap production 
has been reported in fibroblasts from an FAD patient who has a 
mutation in the PS-1 gene (Martins et al., 1995). Key current questions 
are whether the presenilins interact directly with APP, or whether the 
effects of the presenilin mutations ar e mediated through a unique and 
indirect pathway. Recent work has suggested the possibility that 
mutant PS-1 can directly induce changes in tau phosphorylation in 
neurons in vivo (Giannakopoulos et al., 1997). PS-1 is thought to have 
a neuroprotective role, and in Alzheimer’s Disease low cellulai* 
expression of the protein may be associated with increased neuronal 
loss and NFT formation (Giannakopoulos et al.,1997). The formation 
of stable complexes between PS-2 and APP has recently been 
observed in COS cells, suggesting a possible paiticipation of 
presenilins in intracellular processing of APP (Weidemann et 
al., 1997). It seems likely that a final common pathway in the 
pathogenesis of sporadic and genetic forms of Alzheimer’s Disease 
exists, and a central question is how the presenilins mutations cause 
the typical neuropathology. Recent evidence suggests that PS-1 is 
required for the correct formation of the axial skeleton, normal 
neurogenesis and neuronal survival (Shen et al., 1997).
The present study of brain sections from APP-null transgenic 
mice has enabled a preliminary investigation into the possible actions 
of APP, and a look at the pattern of distribution of N and C terminal 
PS-1 in mice brain sections. The search for possible roles of APP 
continues, and recent evidence has shown that human APP can 
protect neurons against chronic and acute excitotoxic insults in vivo, 
and that impairments of neuroprotective human APP could contribute 
to neurodegeneration (Masliah et al., 1997).
6.13 GFAP immunoreactivity in APP/RK and wild type brain 
sections.
The marked increase in GFAP immunoreactivity seen in the 
APP/RK animals at 6  months of age agrees with the reported data for 
Moechais (Moechars et al., 1995; Moechars et al., 1996). The 
astrocytes appealed strongly reactive with enlarged cell bodies and 
thicker processes. The 6  month wild type animals showed little
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reactive gliosis, unlike the more aged mice discussed in section 6.9 
that showed marked reactive gliosis.
The mutation of the APP gene at the a-secretase site appears to 
have resulted in the onset of reactive gliosis in these animals. This 
onset of reactive gliosis, along with the previously reported severe 
behavioural deficits, and neuropathological changes including necrosis 
and apoptosis, (Moechars et al., 1995; Moechars et al., 1996), 
demonstrate the severe cellular neurotoxicity resulting from incorrect 
a-secretase processing of APP in the CNS.
It is worth discussing the two transgenic animals investigated in 
this study, as well as other studies using transgenic models. LaFerla 
and coworkers developed a transgenic mice that overexpress the Ap 
peptide intracellularly (LaFerla et al., 1995). The phenotypic traits 
observed in these animals were similar to those seen by Moechars and 
colleagues. This suggests a possibility that cell bound APP/RK 
fragments could lead to intracellular Ap peptide , thus resulting in a 
situation similar to that seen in the LaFerla model where Ap peptide is 
produced intracellularly. This would then imply that Ap peptide 
produced intracellularly causes neurodegeneration. This in comparison 
with extracellularly produced Ap peptide requires further 
investigation. It has been suggested that the normal and pathological 
physiology of APP in the brain includes more than production of Ap 
peptide (Moechars et al., 1996). It is of interest that the APP-null mice 
at 14 weeks demonstrated several phenotypic characteristics in 
common with the APP/RK mice (Zheng et al., 1995). The absence or 
suppression of an unknown function of APP will explain this similarity 
and further research is necessary.
Summary
Studies of brain sections taken from two transgenic mice 
models has enabled a preliminary investigation into the possible 
actions of APP within the CNS. Complete removal of the APP gene 
has been previously shown to result in a dramatic onset of reactive 
gliosis at 14 weeks (Zheng et al.,1995) which, as shown in the present 
work, stabilises by 13 months by an as yet unloiown mechanism.
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Calbindin immunoreactivity increases in the 13 month APP-null 
animals, suggesting an interesting link between APP and calcium 
buffering. There is also the possibility of a link between APP and 
PS-1: an initial investigation of the APP-null mice at 6  months of age 
suggests an increase of cerebellai* PS-1 compared to age-matched 
controls animals. Mutation of the a-secretase site on APP results in 
severe neuronal degeneration.
Having investigated protein levels in the transgenic mice, it was 
of great interest to study the pattern of distribution of presenilin and 
GFAP in postmortem human Alzheimer’s Disease brain tissue.
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Chapter 7
Immunohistochemical study of 
presenilin-1 and glial fibrillary 
acidic protein expression in human
Alzheimer’s Disease postmortem 
brain tissue.
Introduction
The previous sections of work have focused on cytoskeletal 
protein immunoreactivity and gene expression, particularly of those 
proteins involved in the pathogenesis of Alzheimer’s Disease. As the 
theory behind the project has also focused on various aspects of the 
disease pathology, it was of great interest to be able to examine 
postmortem Alzheimer’s Disease brain tissue. While this was only a 
preliminary study, several interesting observations have been made.
The postmortem tissue was obtained from the Cambridge Brain Bank 
Laboratories. Immunostaining of the following was carried out on the 
diseased and age matched control tissue sections : GFAP, PS-1 and 
AT8 .
7.1 AT8 antibody:
Numerous antibodies have been developed which show selective 
specificity for Alzheimer’s Disease pathology, including AT3, ATS, 
ATIO (Novak et al.,1991; Mercken et al., 1992; Yen et al.,1987). The 
AT3 antibody recognises both pathological and normal structures, and 
has been shown to label NFTs in Alzheimer tissue as well as the 
normal axonal distribution of tau in non-diseased tissue (Novak et 
al., 1991). Similarly, the ATIO antibody reacts with normal tau as well 
as that in the diseased state (Yen et al.,1987). Perhaps the most 
commonly used monoclonal antibody is AT8  (Mercken et al., 1992). 
This antibody has been shown to positively stain for NFTs and senile 
plaques, recognising the PHF epitopes with no cross-reactivity with 
normal tau (Mercken et al., 1992). In the present study, sections of 
postmortem Alzheimer’s Disease brain tissue were stained using the 
AT8  antibody.
7.2 Presenilin-1:
As has been discussed in more detail in Chapter 6 , 
immunohistochemieal studies have revealed PS-1 to be present in 
neuritic plaques in sporadic Alzheimer’s Disease brains, suggesting 
that this protein may be involved in the development of the disease 
pathology (Wisniewski et al., 1995). In situ hybridisation studies
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revealed that both PS-1 and PS-2 are expressed at the highest levels in 
the hippocampus and cerebellum (Kovacs et al., 1996; Suzuki et al., 
1996; Cribbs et al., 1996). PS-1 and PS-2 mRNA levels have been 
found to be considerably higher in neurons, with lower levels in glial 
cells (Lee et al., 1996). The in situ hybridisation of Lee et al also 
revealed PS-1 to be expressed in somatodendritic and neuropil 
compartments of neurons in the neocortex and hippocampal 
formation. In the present study, it was of interest to carry out double 
immunolabelling of AT8  and PS-1 in postmortem Alzheimer’s Disease 
brain sections.
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7.3 Comparison o f Alzheimer’s Disease and age matched control 
brain sections.
The slide-mounted brain seetions from the Alzheimer’s Disease 
patients appear noticeably smaller than the age-matched control tissue 
seetions, with greatly enlarged ventricles. In the diseased tissue, the 
areas most affected by tissue loss are the entorhinal and frontal 
cortices. Perhaps the most striking initial observation was the degree 
of tissue loss between patients, some showing very little remaining 
entorhinal matter, and lai'ge portions of the cerebral cortex engulfed 
by expanded ventricles.
7.4 GFAP immunostaining in Alzheimer’s and control brain sections.
As with the transgenic models, GFAP immunostaining proved 
interesting in the human sections. A dramatic difference between 
patterns of immunoreactivity was observed. As can clearly be seen in 
Fig. 7.1a, reactive astrocytes occur throughout the cortical layers in 
Alzheimer’s tissue. While reactive cells are confined to the outer layer 
in the control tissue, (7.1b), in the diseased tissue, the reactive cells 
are more numerous and are present deep in the cortex. The outer layer 
is fiercely reactive, the cells having greatly thickened processes.
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Figure 7.1 : GFAP immunostaining in the cortex of Alzheimer’s
Disease and control postmortem tissue.
Sections from the cortex of postmortem Alzheimer's and control 
tissue were processed for immunohistochemistry using antisera against 
GFAP. Photomicrographs illustrate reactive gliosis in
a\ Alzheimer's tissue 
b\ control tissue.
Scale bar represents 100 |xm.
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7.5 ATS and S I82 (PS~1)~AT8 double labelling in Alzheimer's and 
control brain sections.
Figures 7.2 shows AT8  (a) and S182-AT8 (b and c) double 
labelling in the CA3, subiculum and CA2 regions of Alzheimer's 
Disease tissue respectively. AT8  immunoreactivity illustrates plaques, 
tangles and proteinaceous deposits throughout the three regions. In 
this particular patient, the most striking pathology is seen in the 
subiculum. Colocalisation of S I82 with plaques and tangles can 
clearly be seen in the subiculum and CA2 areas. SI 82 
immunoreactivity is strongest in the large hippocampal pyramidal 
cells.
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Figure 7.2 : S 182 N-19 and ATS labelling in Alzheimer's Disease 
postmortem tissue.
a\ Tissue sections processed for immunocytochemistry using antisera 
against AT8  in postmortem tissue from the CA3 region. Arrow 
indicates tangle, smaller proteinaceous deposits surround.
Tissue sections were processed for double labelhng using antisera 
against S I82 -N19 (purple staining) and AT8  (dark brown staining) in 
postmortem tissue from the following regions:
b\ subiculum, arrow indicates large plaque and proteinaceous deposit. 
Numerous flame shaped tangles surround.
c\ CA2, arrow indicates doubled labelled granule cell.
Scale bar represents 50 jxm.
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Discussion
Comparison of the brain sections from Alzheimer’s and age 
matched control tissue, reveals a dramatic atrophy in the diseased 
brain tissue. The lateral ventiicle is enlarged, and the hippocampus 
shrunken, with a large space between the hippocampus and the 
inferior horn of the temporal cortex.
7.6 Reactive gliosis in Alzheimer's Disease brain tissue.
As was expected, a marked increase in GFAP immunoreactivity 
was evident in the Alzheimer's Disease tissue where reactive gliosis is 
seen throughout all cortical layers. Reactive astrocytes are also seen in 
the control tissue but to a lesser extent. In both the Alzheimer's and 
control tissue, the most striking reactive gliosis was seen in the 
dentate gyrus, CAl and CA3 areas. As discussed previously, reactive 
gliosis occurs in non disease states as part of the ageing process 
(Nirton et al.,1992; Dickson et al.,1993).
7.7 AT8 and S182 immunostaining in Alzheimer's Disease tissue.
The AT8  antibody stains for Alzheimer's pathology. As 
expected, immunoreactivity was stronger in the diseased tissue, 
revealing positive NFTs and senile plaques. NFTs of 30|xm diameter 
are seen in the subiculum, entorhinal and cerebral cortices. Large 
plaques of around 60pm in diameter are seen in the subiculum, and 
small proteinaceous deposits are evident throughout the diseased 
tissue. Immunostaining of the senile plaques revealed negative amyloid 
cores surrounded by positive neurites.
PS-1 (SI82) distribution in the human sections was again similai* 
for N and C terminal antibodies. Both were widely distributed in the 
temporal lobe, entorhinal cortex and hippocampal regions, and 
predominant in the hippocampus and cerebral cortex, i.e, those areas 
most susceptible to plaque formation, as reported previously by 
Cribbs and coworkers (Cribbs et al., 1996). The observed PS-1 
immunostaining was consistent with previous evidence reporting PS-1 
immunostaining intracellularly in neurons appearing as thick granules 
resembling large vesicles (Moussaoui et al., 1996). N and C terminal
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immunoreactivity was possibly at a lower level in the dentate gyrus 
than in the CA fields although this initial observation is without 
quantification. PS-1 distribution appears to be essentially within the 
neuronal population of the brain, with a lack of immunoreactivity seen 
in the blood vessels and white matter glial cells. This contrasts with 
APP which has been shown to be expressed ubiquitously in all cell 
types of the human brain (Tanzi et al.,1993; Hyman et al.,1993), 
although other groups have observed lower but significant levels of 
PS-1 immunoreactivity in white matter glial cells (Lee et al., 1996).
Defining the cellular and subcellular localisation pattern of PS-1, 
determining whether it is present in the pathological hallmarks of 
Alzheimer’s Disease such as the neuiitic plaques or neurofibrillary 
tangles, is expected to provide insights into the pathophysiological 
function of this important protein. Double staining with S182 N-19 
and AT8  illustrated some colocalisation of PS-1 within plaques and 
tangles in the hippocampal and entorhinal cortical areas, however, 
other areas such as the cerebral cortex did not illustrate this 
colocalisation. The reason for this difference in areas showing 
colocalisation is unclear, although differences in severity of 
neurodegeneration between regions may account for the difference. 
Several similarities in the expression profile of PS-1 and APP have 
been described. First, both genes are ubiquitously expressed, and the 
pattern of expression of the two is similar (Cribbs et a l, 1996; Mita et 
al., 1989). It has been suggested that an overlapping PS-1 
immunoreactivity with Alzheimer’s Disease pathology and APP 
expression may be the result of altered levels of PS-1 expression 
within affected areas. Recent evidence has shown that PS-1 protein 
does not appear to be a primary constituent of amyloid plaques 
(Weber et al., 1997). However, PS-1 immunoreactivity has been found 
in the neuritic component of senile plaques as well as in neurofibrillai’y 
tangles (Levey et al.,1997). As discussed in section 6.12, the 
mechanism by which presenilin mutations cause typical Alzheimer’s 
Disease pathology remains to be elucidated. Recent evidence suggest 
that presenilins may be involved in the pathogenesis of sporadic as 
well as familial Alzheimer’s Disease (Takami et al., 1997). Localisation 
of PS-1 immunoreactivity in both familial and sporadic Alzheimer’s 
Disease suggests that genetically heterogenous forms of the disease
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share a common pathophysiology involving the PS-1 protein (Levey et 
al.,1997).
Summary
It was of great interest to perfoim an initial study of GFAP and 
presenilin immunoreactivity in human post mortem Alzheimer’s 
Disease tissue. The current study investigated pathology in brain 
sections from one patient, and clearer results would obviously be 
obtained by looking at tissue from several patients. As expected, a 
greater degree of GFAP immunoreactivity was observed in the 
diseased tissue, with numerous reactive astrocytes present. 
Colocalisation of PS-1 protein and plaques and tangles has been 
reported by some, but not all, research groups. In the present study, 
overlap of PS-1 within plaques and tangles was observed in some but 
not all areas. It is possible that intracellular PS-1 somehow becomes 
exti'acellularly bound to Ap and PHF tau. The mechanisms behind 
this, and the reasons why it occurs in shown but not all cases, remain 
to be elucidated.
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Chapter 8
GENERAL DISCUSSION
This work was undertaken to investigate the distribution and 
expression of proteins related to neuronal degeneration. Using cell 
culture models, we have focused on changes in cytoskeletal protein 
expression and cell morphology. In addition, two mutant mouse 
models have been used to study the distribution of morphological and 
synaptic markers.
Chapter 3 has dealt with tau gene expression in the basal 
forebrain and hippocampal regions of adult and neonatal rats 
(gestation day 17). A compaiison of Tau typel and Tau type 2 mRNA 
distiibution in adult and neonatal rat brain agrees with previous 
reports: Tau 1 mRNA levels are higher in the neonatal rat brain, Tau 2 
mRNA levels higher in the adult rat brain. Type 1 and type 2 tau 
proteins are thought to be developmentally regulated, with type 2  
transcripts being absent from the fetal brain but expressed in the adult 
brain (Goedert et al.,1988a; Goedert et al.,1989b). The transition from 
the simple type 1  to a more complex pattern of type 2  in the rat brain 
begins around postnatal day 15, and is completed by postnatal day 35 
(Couchie and Nunez., 1985). The present results are consistent with 
this: the neonates at gestation day 17 showed very little type 2 tau 
mRNA in the basal forebrain and hippocampal regions.
Intraperitoneal administration of the following compounds to 
adult rats did not alter Tau 1 or Tau 2 mRNA levels in either the basal 
forebrain or hippocampus after a 24 hour time period: ondansetron, 
MK801, GYKI52466, indomethacin, aniracetam. Thus, from these 
experiments it appears that expression of the tau gene does not show 
a great deal of plasticity. However, the compounds were administered 
at only one dose, and over a single time period. Future investigations 
into tau gene plasticity would involve several different drug 
concentrations and administration time points. In light of the fact that 
the in vitro experiments covered in chapter 5 illustiated dramatic 
induction of MAP2 protein and mRNA levels in response to a wide
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variety of compounds, it would be of interest to repeat these 
experiments to monitor MAP2 mRNA levels.
NADPH diaphorase has been shown to be a nitric oxide 
synthase (Hope et al., 1991), and nitiic oxide synthase (NOS) can be 
demonstrated conveniently by the histochemical technique for 
NADPH diaphorase immunostaining (Dawson et al.,1991). Chapters 4 
and 5 have looked at the distribution and regulation of NADPH 
diaphorase immunostaining in glial and neuronal primary cultures. The 
endotoxin LPS has previously been shown to cause induction of a 
calcium-dependent inducible NOS in primary glial cultures (Galea et 
al., 1992; Simmons and Murphy., 1992). The cytokine interleukin-1 has 
also been shown to cause induction of iNOS in glial cells (Lee et 
al., 1995). In agreement with this, the glial cultures in the present work 
illustrated increased NADPH diaphorase immunostaining in response 
to exposure to LPS, and also in response to interleukin-1. As there is 
a vast literature to support the induction of iNOS by LPS and 
interleukin-1, the increase in NADPH diaphorase immunostaining in 
the present work has been taken as an increase in NOS activity. Use 
of the calmodulin antagonist W7 illustrated that the type of NOS 
induced in response to LPS is a calmodulin-independent form. 
Inducible NOS (iNOS) in macrophages and hepatocytes has been 
shown to tightly bind calmodulin (Cho et al.,1992; Evans et al.,1992). 
Recent evidence suggests that a similar system occurs in glial cells: 
iNOS tightly binds calmodulin and produces NO even when calcium 
levels aie low or absent (Kitamura et al., 1996; Ruan et al., 1996). The 
enzyme induced in the present results in response to LPS is more than 
likely to be iNOS given that a vast number of studies have shown this, 
however, the NOS in the present work is calmodulin-independent. 
Recent work has suggested the presence of differential expression and 
/or structural diversities of the iNOS gene (Park et al.,1996). It is 
possible that the ghal cells possess several forms of iNOS differing in 
their calmodulin dependency. It would be of interest to discover
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whether the difference in the stmcture of the enzymes is in the 
calmodulin binding site. Exposure of the glial cells to glutamate 
resulted in the induction of a calmodulin-dependent NOS, further 
indication that the glial cells possess more than one type of NOS 
enzyme, and different forms of the enzyme could be activated in 
response to different compounds. Future work using radiolabelled 
oligonucleotide probes to monitor iNOS and neuronal NOS mRNA 
levels would give a clearer insight into the type (s) of NOS present in 
the glial cells.
The neuronal cells also appear to possess several different types 
of NOS again differing in their calmodulin dependency. Nerve growth 
factor (NGF) has been shown to induce a form of NOS in the 
neuronal cells. It has recently been suggested that the expression of 
neuronal NOS in developing basal forebrain cholinergie neurons is 
regulated by NGF (Holtzman et al., 1996). The high affinity NGF 
receptor, the pl40 trkA receptor, is thought to be essential and 
sufficient to elicit NGF responses (Kahle et al., 1994). LPS induction 
of iNOS is thought to be via tyrosine kinase activation (Kitamura et 
al., 1996). The NGF-induced increase in MAP2 protein levels in the 
neuronal cells has been shown to be through a calmodulin-dependent 
form of NOS. In contrast, glutamate exposure resulted in the 
induction of a calmodulin-independent form of NOS. Thus, it is 
possible that the neuronal cells possess both basal levels of neuronal 
NOS and form (s) of iNOS differing in calmodulin-dependency, 
similai- to the situation seen in the glial cells. It is likely that different 
forms of NOS are activated in response to different compounds acting 
through different pathways. As with the glial cells, future work using 
radiolabelled oligonucleotide probes to monitor iNOS and neuronal 
NOS mRNA levels would clarify the results presented.
Chapter also focused on the distribution and regulation of the 
cytoskeletal proteins MAP2 and tau in neuronal cultured cells. NO has 
been previously shown to stimulate the expression of the immediate
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early genes c-fos and zif/268 in PC12 cells (Haby et al.,1994). NO has 
also been shown to alter proenkephalin, prodynorphin and MAP2 
gene expression in hippocampal granule cells (Johnston et al., 1994a; 
Johnston et al., 1994b). Thus it is possible that NO may regulate gene 
expression in those areas of the brain that contain NOS activity. The 
present results suggest that NO may exert an induction in MAP2 
immunoreactivity through a pathway that involves guanylate cyclase 
and cGMP-dependent protein kinase, and the neuronal cells may thus 
respond to NO in a similar manner to hippocampal granule cells and 
PC 12 cells. Further work using specific inhibitors such as the cGMP 
phosphodiesterase inhibitor MY5445 and the cGMP dependent 
protein kinase inhibitor KT5823 would clarify the pathway involved in 
NO-stimulated MAP2 induction. Despite the dramatic effect of NO on 
MAP2 protein expression, no detectable effect of NO on neuronal cell 
moiphology was observed. However, it is possible that an alteration 
to the dendritic spines or neurite branching points may have occurred 
and had not been detected with the antibodies used.
Recent studies have suggested a neuroprotective influence for 
NSAIDS and a beneficial association between NSAID use and 
cognitive functioning in Alzheimer’s Disease (Rich et al., 1995). The 
target of the NSAIDS is cyclooxygenase (COX). Evidence suggests 
that induction of COX2 by LPS can occur in bovine aortic endothelial 
cells. In the neuronal cell however, exposure of the neuronal cells to 
interleukin-1 and LPS failed to alter COX protein or gene expression. 
Amyloid precursor protein (APP) protein and gene expression levels 
remained unaltered following exposure to LPS and interleukin-1. 
Chapter 6  covers a further investigation into the role (s) of APP.
The use of two transgenic mice models, one with the APP gene 
completely removed, the other with a mutated a-secretase site on the 
APP gene, has enabled a preliminary investigation into the possible 
actions of APP within the CNS. Complete removal of the APP gene 
results in a marked increase of reactive gliosis within most areas of the
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the brain at 6  months of age (Zheng et a l, 1995). The present work 
suggests that this induction of reactive gliosis nonnalises by 13 
months of age, by an as yet unknown mechanism. The age matched 
wildtype mice showed a marked induction of reactive gliosis, 
especially in the corpus callosum and hippocampus, compared to the 
APP-null mice. It is possible that this was due to the normal ageing 
process; as reactive gliosis has been shown to occur in normal ageing 
brains (Norton et a l, 1992; Dickson et a l, 1993). Calbindin 
immunoreactivity has been shown to increase in the APP null mice at 
13 months of age compared to age matched control animals. Thus 
suggests an interesting link between APP and calcium; it is possible 
that removal of the APP gene resulted in a potential calcium-induced 
toxicity which was controlled by increased levels of calbindin. The 
relationship between APP metabolism and presenilin function is 
uncleai'. The distribution of PS-1 in the mice was similar to that seen 
in rats (Mita et al., 1989), and no difference in pattern of distribution 
or immunoreactivity was observed in the APP-null mice in comparison 
to age matched control animals in the cortical and hippocampal 
regions. However, an initial study of cerebellai’ sections from the 
APP-null mice at 6  months of age suggest a possible increase of PS-1 
in the null animals compared to controls. There is the interesting 
possibility that PS-1 may have a synaptic role, and reeent results 
suggest that an alteration in the processing of APP may have 
considerable effects on synaptic plasticity (Nalbantoglu et a l, 1996). 
The distribution of N and C terminal PS-1 has been compared in the 
APP null and age matched control animals. N tenninal PS-1 has been 
shown to have a membrane-bound distribution, the C terminal appears 
to be mostly cytoplasmic. It is thought that PS-1 exists in small 
quantities as a full length protein, and is rapidly processed into an 
array of stable N and C terminal endoproteolytie fragments 
(Thunakaian et a l, 1996; Podlisny et al.,1997). Further studies on the 
APP-null mice, especially between the ages of 6  and 13 months would
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enable a further understanding of the roles of APP within the CNS. 
The mutation of the a-secretase site appears to have resulted in the 
onset of reactive gliosis, agreeing whit the initial report of Moechars 
(Moechars et al.,1996). This onset of reactive gliosis, along with the 
previously reported severe behavioural deficits and neuropathological 
changes demonstrate the severe cellular neurotoxicity resulting from 
incorrect a-secretase processing.
Chapter 7 has looked at neuropathology of Alzheimer’s Disease 
in human postmortem brain tissue. A large degree of reactive gliosis 
was evident in the diseased brain throughout the cortical layers, 
corpus callosum and hippocampus. PS-1 distribution was throughout 
the temporal lobe, entorhinal cortex and hippocampus, and was 
consistent whit previous reports of PS-1 immunostaining 
intracellularly in neurons appearing as thick granules (Moussaoui et 
al., 1996). Defining the cellular and subcellular localisation pattern of 
PS-1 is expected to provide insights into pathophysiological function 
of the protein. Differing evidence exists regarding the presence of PS- 
1 in the pathological hallmarks of Alzheimer’s Disease such as neuritic 
plaques and neurofibrillaiy tangles. Colocalisation of PS-1 protein 
with some plaques and tangles was observed in some but not all 
regions in the present study. A further study looking at several 
different patients would enable a clearer picture to be observed. The 
mechanism by which presenilin mutations cause Alzheimer’s Disease 
pathology and their link to APP is of current research importance.
It seems likely that for the future, the development of further 
transgenic models will enable the relationship between presenilins, the 
amyloid generation pathway, the development of plaques and tangles 
and synaptic loss to claiified. It is hoped that transgenic models may 
provide a preclinical model for testing therapeutic drugs.
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